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ABSTRACT 
Enzymatic treatment of biomass is an environmentally friendly method to obtain a range 
of products, such as biofuels, animal feed or food ingredients. The objective of this PhD 
study was to produce functional food ingredients – oligosaccharides and 
polysaccharides by means of enzymatic catalysis from biomass: casein 
glycomacropeptide (cGMP) and potato pulp. These saccharides should possess prebiotic 
properties, i.e., they should be non-digestable, selectively fermented and allow specific 
changes, both in the composition and/or activity of the gastrointestinal microbiota that 
confers benefits upon host well-being. Therefore the obtained compounds were 
incubated with single bacterial cultures to examine their prebiotic potential. 
Different types of oligosaccharides were produced in the present study. The first group 
of compounds was human milk oligosaccharides (HMOs) containing sialic acid in their 
structures. These were synthesized from cGMP (a donor of sialic acid) and appropriate 
glycan in trans-glycosylation reaction catalysed by mutant sialidase from Trypanosama 
rangeli expressed in Pichia pastoris, Tr6. Production of the model HMO, sialyllactose 
was enlarged to 5 L scale. 
The second type of sialylated oligosaccharides was obtained with the same donor of 
sialic acid – cGMP and different glycans with a new Trypanosoma rangeli trans-
sialidase, Tr13. Well-documented prebiotics galactooligosaccharides (GOS), iso-
maltooligosaccharides (IMO) and lactulose, and three other compounds, i.e., melibiose, 
maltose, and fucose were sialylated with this enzyme resulting in creating novel human 
milk- like oligosaccharides. Both HMO and human milk- like oligosaccharides were 
purified by filtration and chromatography. 
The last compounds produced during this study were GOS and some 
galactopolysaccharides. They were generated from isolated galactan and galactan 
contained in solubilised potato pulp polysaccharides (SPPP). An endo-1,4-β-galactanase 
from Emericella nidulans was produced in a recombinant P. pastoris strain to catalyse 
hydrolysis of galactan and SPPP. This enzyme was purified, characterized and its 
crystal structure was determined. The products of enzymatic hydrolysis were 
fractionated according to their molecular weight using membrane filtration. 
The results of this work pave the way for development of new functional food 
ingredients from industrial side-streams and generate value-added products with 
valuable biological properties and great market potential. 
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DANSK SAMMENFATNING 
Behandling af biomasse med enzymer er en bæredygtig grøn metode hvorved mange 
produkter, såsom biobrændstof, foder og fødevare ingredienser kan fremstilles. Målet 
med dette PhD studie var at producere funktionelle fødevare ingredienser – oligo-
sakkarider og poly-sakkarider ved hjælp af enzymatisk katalyse af forskellige 
biomasser; casein glycomacropeptide (cGMP) og kartoffel pulp. Disse sakkarider har et 
prebiotisk potentiale, dvs. de er svære at nedbryde af mave/tarm floraen, de kan fremme 
eller hæmme mikroorganismerne og give en helbredsmæssig effekt. De forskellige 
produkter blev derfor testede i vækstforsøg med enkelt celle kulturer fra mave/tarm 
systemet. 
I dette PhD studie blev der fremstillet en række af forskellige oligo-sakkarider.  Den 
første gruppe var Humane Mælke Oligo-sakkarider (HMOs), der indeholder sialinsyre. 
Disse stoffer blev fremstillet ud fra cGMP (doner til sialinsyre) og forskellige acceptor 
molekyler (glycaner). Katalysen var Tr6, der er en muteret sialidase fra Trypanosomas 
rangeli, der har 6 mutanter og har en rimelig trans-sialidase aktivitet. Tr6 blev 
produceret i Pichia pastoris. Produktionen af sialyl-laktose blev udført i 5-L skala. 
Den anden gruppe af sialylerede oligo-sakkarider blev fremstillet med den samme 
donor, cGMP, men med Tr13, et mutant enzym med 13 mutationer, og en meget høj 
trans-sialidase aktivitet. Ved rationel mutagenese fik vi vendt hydrolyse (sialidase) til en 
Transferase (trans-sialidase). Nogle af de godkendte prebiotiske oligo-sakkarider, 
Galacto-oligosakkarid (GOS), og isomalto-oligosakkarid (IMO), samt andre glycaner 
såsom melibiose, maltose og fucose blev sialyleret ved hjælp af dette Tr13 enzym. Alle 
produkterne blev oprenset vha. membran-filtrering og anion-kromatografi og deres 
struktur blev bestemt ved LC-MS og NMR. De nye sialylerede oligo-sakkarider blev 
navngivet som HMO-lignende molekyler. 
Den tredje kategori af prebiotiske molekyler var galactooligo-sakkarider, der blev 
fremstillet ved enzymatisk katalyse fra kartoffel pulp galactaner også kaldet SPPP 
(”solubilized potato pulp polysaccharides”). Det anvendte enzym, en endo-1,4-β-
galactanase fra Emericella nidulans blev produceret i en rekombinant P. pastoris 
stamme, og blev oprenset ved søjle kromatografi, karakteriseret, hvorefter 3-D 
strukturen blev bestemt. 
Resultaterne in denne PhD Tese viser en ny vej til fremstilling af nye funktionelle 
fødevare ingredienser fra industrielle side-strømme og værdiskabende nye produkter 
med stor marked potentiale. 
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1 HYPOTHESES AND OBJECTIVES 
This PhD study was focused on enzymatic synthesis of oligo- and polysaccharides from 
side-streams from the food industry. The produced compounds are potential functional 
food ingredients. They were fractionated or purified by membrane filtration and/or 
column chromatography. Their biological properties were examined by measuring 
growth stimulation of gut bacteria in prebiotic tests. 
General hypotheses of this work: 
- It is possible to use side-streams from dairy and agriculture to generate value-
added products, i.e. food fibers, like oligosaccharides and polysaccharides. 
- Saccharides of different structures may be purified by column chromatography 
or separated into different molecular weight fractions by membrane technology. 
- Oligosaccharides produced from side-streams possess prebiotic properties. 
Objectives of this work: 
- To produce and characterize enzymes for optimal catalysis of oligo- and 
polysaccharides production. 
- To produce value-added products from industrial side-streams. 
- To fractionate or purify oligo- and polysaccharides. 
- To examine prebiotic potential of obtained products. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
2 THEORETICAL INTRODUCTION 
2.1 FUNCTIONAL FOOD INGREDIENTS 
The concept of functional foods was introduced in Japan in middle 1980s. Its objective 
was to improve the health of the population and thereby reduce the health-care expenses 
of the society. In 1991 this type of food was legislated in Japan as “foods for specified 
health use” (FOSHU). In the same year oligosaccharides as fructo-, galacto-, soybean 
and palatinose oligosaccharides were listed as FOSHU. Until 1996 FOSHU status 
embraced also lactulose, lactosucrose, xylo- and isomaltooligosaccharides. The term 
“functional foods” first appeared in 1993 in the “Nature” magazine under the heading 
“Japan explores the boundary between food and medicine” (Henry, 2010).  
Functional food is generally not recognized by law, besides Japan. It is essentially a 
marketing term. The Food and Drug Administration (FDA) regulates claims that 
manufacturers make about foods' nutrient content and effects on disease, health or body 
function. The FDA regulates these types of foods according to whether a food is 
considered to be a conventional food, a food additive, a dietary supplement, a medical 
food or a food for special dietary use. 
There are several definitions of functional food which are presented in Table 1. 
Functional food can be: (1) natural food, (2) a food to which a component is added, both 
by increasing concentration of a component naturally occurring and by adding a 
component that is not naturally present (e.g. fructooligosaccharides), (3) a food from 
which a component is removed (e.g. allergenic protein), (4) a food where one or more 
components are modified, (5) a food in which the bioavailability is modified and (6) any 
combinations of mentioned above (Henry, 2010). 
The functional food defined by different institutions and Japanese food for specific 
health use define the same criteria that should be met: (1) this type of food should be a 
part of usual diet, (2) it should be in food form, (3) it should contain an ingredient which 
provides health benefit (Duncan et al., 2012; Farr, 1997). The Japanese Ministry of 
Health, Labour and Welfare mentions also more features of FOSHU: the health benefit 
of the food or relevant components should have a medical or/and nutritional basis, the 
appropriate level of consumption should be definable based on medical or nutritional 
knowledge, the food or relevant components should be safe and well defined in terms of 
physicochemical properties and methods of determination, it should not be the 
components exclusively used in medicaments, the composition of the product should 
not be notably defective in comparison with the composition of nutritive components 
that are normally contained in similar types of food (Farr, 1997). 
 
 
 3 
organization definition 
Japanese Ministry of 
Health, Labour and 
Welfare - Foods for 
Specified Health Uses 
(FOSHU) 
Foods for Specified Health Uses (FOSHU) refer to foods 
containing ingredient with functions for health and officially 
approved to claim its physiological effects on the human body. 
FOSHU is intended to be consumed for the maintenance or 
promotion of health or special health uses by people who wish to 
control health conditions. 
Health Canada A functional food is similar in appearance to, or may be a 
conventional food, consumed as part of a usual diet, and is 
demonstrated to have physiological benefits and/or reduce risk of 
chronic disease beyond basic nutritional functions. 
Food and Agricultural 
Organization (FAO) of 
the United Nations 
Functional foods should be a food similar in appearance to a 
conventional food (beverage, food matrix), consumed as part of the 
usual diet which contains biologically active components with 
demonstrated physiological benefits and offers the potential of 
reducing the risk of chronic disease beyond basic nutritional 
functions. 
Academy of Nutrition 
and Dietetics (formerly 
the American Dietetic 
Association) 
All foods provide some level of physiological function, but the term 
functional food is defined as whole foods along with fortified, 
enriched, or enhanced foods that have a potentially beneficial effect 
on health when consumed as part of a varied diet on a regular basis, 
at effective levels. 
Dieticians of 
Canada (DC) 
Functional foods are foods that offer unique health benefits that go 
beyond simply meeting basic nutrient needs. Many also help to 
reduce chronic disease risk. Functional foods contain “bioactive 
compounds,” or naturally occurring chemicals that act on our 
bodies. It is these bioactive compounds that offer the health and 
wellness benefits that have been linked to functional foods. 
International Food 
Information Council 
(IFIC) 
Functional foods are foods or dietary components that may provide 
a health benefit beyond basic nutrition. 
International Life 
Sciences Institute of 
North America (ILSI) 
Functional foods are foods that by virtue of physiologically active 
food components provide health benefits beyond basic nutrition. 
Ministry of Agriculture, 
Fisheries and Food in 
United Kingdom 
Functional food is a food that has a component incorporated into it 
to give a specific medical or physiological benefit, other than a 
purely nutritional effect. 
Table 1. Functional food definitions, adapted from Duncan et al., 2012; Henry, 2010; Farr, 
1997. 
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The assessment of safety of the potential functional food is proposed to be based, in 
some cases, on comparison with traditional acceptable reference food. When the 
functional food is substantially equivalent or similar to the known traditional food, the 
nutritional and toxicological studies may be reduced (Farr, 1997). 
Among the functional food ingredients many different types of compounds are 
mentioned: phytosterols lowering the blood cholesterol level by preventing its 
absorption from the intestine, antioxidants playing fundamental role in prevention of 
cancer by neutralization of free radicals, polyunsaturated fatty acids showing an activity 
in prevention of cardiovascular diseases, as well as oligosaccharides, dietary fibers, 
probiotics, prebiotics and synbiotics.  
 
2.2 OLIGOSACCHARIDES 
Oligosaccharides are used in food for different purposes. They are often used as 
prebiotics. However, some oligosaccharides are susceptible to hydrolysis in small 
intestine and therefore they do not exhibit prebiotic properties. That does not exclude 
them from application in food. Maltooligosaccharides are, for example, susceptible to 
hydrolysis but they still demonstrate ability to reduce levels of harmful bacteria in the 
gut. Maltooligosaccharides are produced from starch by debranching with pullulanase 
and isoamylase and then by hydrolysis catalysed by α-amylase (Crittenden and Playne, 
1996). Cyclodextrins are another group of oligosaccharides used as functional food but 
not exhibiting prebiotic activity. They are cyclic maltooligosaccharides consisting of 6-
12 glucose monomers. They are obtained from starch in the reaction catalysed by 
cyclomaltodextrin glucanotransferase. They can form inclusion complexes with various 
compounds by incorporating them into their structure. Cyclodextrins may therefore be 
used in stabilization of compounds, especially volatile ones, in protection of unstable 
compounds and in masking the substances causing bitterness in foods and medicines 
(Crittenden and Playne, 1996). They are also applied in water treatment to encapsulate 
and adsorb contaminants and in cosmetics, like toothpaste, fabric softeners, tissues to 
control the release of fragrances (Mussatto and Mancilla, 2007).  
Most of the food-grade oligosaccharides may be used as sweeteners, like for example, 
glucosyl sucrose produced from maltose and sucrose by glucanotransferase. It does not 
cause tooth decay and suppress crystal formation and browning reactions which make it 
a good replacement of sugar (Crittenden and Playne, 1996). 
 
2.3 FIBERS 
The following definition of dietary fiber was proposed by AACC Dietary Fiber 
Definition Committee in 2001: “Dietary fiber is the edible parts of plants or analogous 
carbohydrates that are resistant to digestion and absorption in the human small intestine 
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with complete or partial fermentation in the large intestine. Dietary fiber includes 
polysaccharides, oligosaccharides, lignin, and associated plant substances. Dietary 
fibers promote beneficial physiological effects, including laxation, and/or blood glucose 
attenuation”.  
Some specific examples of dietary fibers are pectin and their derivatives, cellulose, β-
glucans, hemicelluloses and resistant starch. Cellulose can be found in general in plants. 
Hemicellulose is obtained mainly from oat, rye, wheat or barley. Pectin is extracted 
from fruit (e.g. citrus fruit) or vegetables (e.g. sugar beet). Different dietary fibers may 
be classified according to solubility in water, viscosity in aqueous solutions, gel-
forming capabilities, and fermentation rate by the gut microflora. For example, pectin is 
known for its gelling properties and is widely used in many foods to modify the texture 
of the products. 
Dietary fibers are associated with improvements of bowel function, reduced risk of 
gastrointestinal disorders, as well as reduced risk of colon cancer. They also decrease 
risk of cardiovascular diseases and type 2 diabetes, improve glycemic control, and 
reduce inflammations. Moreover, dietary fibers are associated with lowering lipid levels 
and increase of satiety, and therefore are recommended to help with weight loss. 
There is just one step from dietary fibers to prebiotics and that is a selective stimulation 
of the growth or activity of health-promoting bacteria. The fibers do not stimulate 
selectively prebiotic bacteria in the colon, whereas prebiotics do. The majority of 
dietary fibers is constituted by polysaccharides, whereas prebiotics are mainly 
represented by oligosaccharides. 
 
2.4 PROBIOTICS 
Probiotics are defined as “live microorganisms which, when administered in adequate 
amounts, confer a health benefit to the host”. The microorganisms must meet safety, 
functional and technological criteria in order to be applied as probiotics. They must not 
be pathogenic, should not have any connection with diarrheagenic bacteria and no 
ability to transfer antibiotic resistance genes. They should also maintain genetic stability 
and should not produce any toxic compounds. Furthermore, the microorganisms must 
survive the acidity, the bile and the digestive enzymes. Another attribute they should 
posses is antagonistic activity towards pathogens. From the technological point of view 
probiotic microorganisms should survive such processes as freeze-drying, spray-drying, 
stirring which causes hydrostatic pressure and mechanical stress to the cells. Moreover, 
in a bioreactor, bacterial growth is connected with quick nutrient depletion and 
accumulation of harmful metabolites in the bacterial culture. This has to be overcome 
by the cells and the bacteria should keep their viability. The probiotics should keep their 
properties during long shelf-storage and have good sensory properties (Grajek et al., 
2005). 
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The most common probiotics include strains of Lactobacillus and Bifidobacterium. 
They are mainly used to produce yoghurts and capsules containing dried probiotic 
cultures. Use of probiotcs is associated with stimulation of immune system, treatment of 
gastrointestinal disorders, like constipation, diarrhoea and inflammatory bowel disease. 
Furthermore, some investigations indicate that probiotics may have effect against 
infection with Helicobacter pylori and prevent allergies, reduce risk of colon cancer, 
lower serum cholesterol and levels of faecal enzymes, which are potential mutagens and 
may induce tumors (Ziemer and Gibson, 1998). An article by Ouwehand et al., 1999 
adds to this long list of health benefits also improvement of bioavailability of food 
compounds and production of vitamins. In publication by Chauhan and Chorawala, 
2012 probiotics are ascribed even more beneficial properties. These are: alleviation of 
lactose intolerance, treatment of food allergies and prevention of necrotizing 
enterocolitis, which is a relatively often disease in premature infants. 
Prebiotics are compounds that are non-digestable by human and selectively stimulate 
the growth of health-beneficial bacteria in the gut (more detailed description of these 
ingredients will follow in the chapter 2.5). The action of pro- and prebiotics can be 
combined and the food additive containing these two ingredients is called synbiotic. 
Combining pro- and prebiotics should result in an improved survival and implantation 
of healthy microorganisms in the host. One of the most obvious choices to create a 
symbiotic is to combine fructo- or galactooligosaccharides with a strain of 
Bifidobacterium, which is able to grow well on these substrates. Obviously, application 
of synbiotics should show the same effects as particular pro- and prebiotics applied. It 
could be also expected that combining these two functional food ingredients could 
enhance the health-beneficial effect. The literature reports that synbiotics have 
anticancer activity (Gibson et al., 2004), anti-pathogenic activity (Sheela and Suganya, 
2012) and many others characteristic for probiotics and prebiotics. An effect that is not 
mentioned so often in case of pro- and prebiotics used alone is prevention of infections 
in people who underwent surgeries (Chauhan and Chorawala, 2012). 
 
2.5 PREBIOTICS 
2.5.1 Definition and determination 
The most recent definition of prebiotics describes them as “selectively fermented 
ingredients that allow specific changes, both in the composition and/or activity in the 
gastrointestinal microbiota that confers benefits upon host well-being and health”. 
The International Scientific Association for Probiotics and Prebiotics (ISAPP) describes 
the requirements for prebiotic effect as follows: 
1) resistance to gastric acid, hydrolysis by mammalian enzymes and 
gastrointestinal absorption 
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2) fermentation by intestinal microorganisms 
3) selective stimulation of the growth and/or the activity of intestinal microbiota 
associated with health and well-being. 
Besides these three official requirements to be fulfilled in order to call compounds 
prebiotics, ISAPP mentions two additional ones, i.e., testing in human trials and 
administering in sufficient amounts to confer a measurable benefit. 
Prebiotics target the microbiota which is already present in the host’s ecosystem. 
Whereas probiotics deliver microbial supplements, which positively influence the host 
health by improvement of the composition of the colonic microbiota. This effect may, 
however, not be a long-term, since the probiotic bacteria need to compete against 
established microbial community in the gut. On the other hand, if there is a deficiency 
of the health-promoting microbiota in the large intestine, which may be caused by the 
disease or antibiotic treatment, then there is no point in administering prebiotics, 
because they cannot work effectively in such an environment. 
In the publication by Gibson et al., 2004 the methods of determination of prebiotic 
properties of compounds are summarized. Testing non-digestibility comprises of in 
vitro testing resistance to gastric acidity, hydrolysis by mammalian enzymes and 
gastrointestinal absorption. In vivo experiments are performed by measurement of the 
recovery in faeces of an oral dosage. These tests are done either in human or in germ-
free rats. 
Testing if a carbohydrate can be fermented by intestinal microflora is also performed by 
in vitro or in vivo methods. The in vitro methods are performed in batch or continuous 
culture fermentation systems. Batch systems are inoculated with pure culture or cultures 
or with faecal slurry. Continuous systems are multi-chamber and reproduce 
characteristics of different gastrointestinal fragments. In vivo methods can be studied in 
humans or animals by addition of investigated substances to food. Then the 
measurement of the recovery of carbohydrate is done in case of humans. The animals 
are killed and the content of the gastrointestinal fragments is analyzed. Human studies 
may also be performed by measurement of exhaled air and the concentration of gases, in 
particular H2, after oral application of single dose of the carbohydrate. The H2 is 
produced by the bacteria present in the human colon. 
Selective stimulation of growth of bacteria in the colon is assessed, for example, by use 
of pure culture studies, fluorescence in situ hybridisation (FISH), and direct community 
analysis (Gibson et al., 2004). Pure culture studies are rapid and straightforward but do 
not include cross-feeding effect between different strains. FISH can be used for 
culturable and non-culturable bacteria. The direct community analysis by PCR enables 
investigation of diversity of the entire sample.  
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2.5.2 Structures and production methods 
Most of food-grade oligosaccharides are manufactured using enzyme-catalysed 
processes. They are either produced in trans-glycosylation reactions, e.g. lactosucrose, 
or as a result of hydrolysis of polysaccharide, e.g. fructooligosaccharides. Only soybean 
oligosaccharides are produced by direct extraction from plant. Lactulose is produced 
chemically from lactose in an alkali isomerization process. 
The most extensively tested and confirmed prebiotics are lactulose, inulin, FOS and 
GOS (also called trans-galactooligosaccharides: transGOS). According to publication 
by Gibson et al., 2004 only these compounds deserve prebiotic status. The other 
sources, e.g. Charalampopoulos and Rastall, 2009 mention also xylooligosaccharides, 
mannan-derived compounds, arabinogalactans, resistant starch, iso-
maltooligosaccharides, soybean oligosaccharides, lactosucrose, pectin and pectin-
derived products as prebiotics. There is an increasing list of potential prebiotics which 
have not been as extensively studied as GOS or inulin, such as glucooligosaccharides, 
gentiooligosaccharides, palatinose oligosaccharides, raffinose, and lactitol. The 
structures and production methods of some established and potential prebiotics will be 
described in this chapter. 
Lactulose (ß-D-Gal-(1,4)-ß-D-Fru) is manufactured from lactose (ß-D-Gal-(1,4)-α-D-
Glc) in the process of isomerization in alkali solution. The glucose moiety in lactose is 
converted to fructose (Figure 1). Another compound with potential prebiotic activity 
produced from lactose is lactosucrose (ß-D-Gal-(1,4)-α-D-Glc-(1,2)-ß-D-Fru). It is 
produced in an enzymatic process involving ß-fructofuranosidase catalysing trans-
fructosylation of lactose at its glucose residue at position C1, creating a non-reducing 
oligosaccharide (Figure1). The co-substrate in enzymatic synthesis of lactosucrose is 
sucrose (α-D-Glc-(1,2)-ß-D-Fru) (Crittenden and Playne, 1996). The third product 
generated from lactose by transglycosylation with ß-galactosidase is a mixture of 
galactooligosaccharides (Figure 1). The structures, detailed production methods and 
prebiotic properties of galactooligosaccharides will be described in chapter 2.6.  
 
Figure 1. Oligosaccharides produced from lactose, adapted from Crittenden and Playne, 1996. 
Sucrose, in similar manner to lactose, is a substrate for synthesis of prebiotic 
oligosaccharides. One of them was mentioned above: lactosucrose. Transfructosylation 
of sucrose with ß-fructofuranosidase (e.g. from Aspergillus niger) leads to creation of 
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mixture of fructooligosaccharides with DP from 2 to 4 (Figure 2). Glucose, fructose and 
un-reacted sucrose are removed from the product by chromatography. The action of 
dextran sucrase on sucrose and maltose results in synthesis of glucooligosaccharides 
(Gibson et al., 2004) (Figure 2). 
Raffinose is a trisaccharide built of galactose, fructose and glucose (α-D-Gal-1,6-α-D-
Glc-(1,2)-β-D-Fru). It can be found in beans, cabbage, brussels sprouts, broccoli, 
asparagus and some other vegetables. It can be synthesized from galactose and sucrose 
by means of α-galactosidase (Nakata et al., 2013) (Figure 2). 
 
Figure 2. Prebiotic and potentially prebiotic oligosaccharides manufactured from sucrose. 
Chicory inulin is composed of a mixture of oligo- and polysaccharides in which DP 
varies from 2 to 60 and the average DP is 12. By applying separation technologies a 
long-chain inulin may be produced with DP from 10 to 60 and average DP of 25. The 
partial hydrolysis of inulin by means of an endo-inulinase produces mixture of 
fructooligosaccharides in which DP varies from 2 to 7. Both inulin and 
fructooligosaccharides contain fragments consisting of α-D-glucopyranosyl-(β-D-
fructofuranosyl)n-β-D-fructofuranoside and β-D-fructopyranosyl-(β-D-
fructofuranosyl)n-β-D-fructofuranoside. Different industrial products vary in DP and 
properties (Gibson et al., 2004). As mentioned above fructooligosaccharides can also be 
generated from sucrose by action of β-fructosidase. 
Gentiooligosaccharides ((ß-D-Glc-1,6)n) are produced from glucose by enzymatic 
transglucosylation. Substrate for this reaction – glucose is obtained by enzymatic or acid 
hydrolysis of starch. Starch is also a substrate for generation of iso-
maltooligosaccharides (Figure 3). Starch is liquefied by α-amylase and ß-amylase (both 
α- and ß-amylases act on α-1,4 bonds) to produce maltose. Maltose is subsequently used 
by α-glucosidase to produce iso-maltooligosaccharides by transglucosylation and 
converting α-1,4 bond to α-1,6 (Crittenden and Playne, 1996). The final product consists 
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of a mixture of oligosaccharides of DP from to 2 to 5, and different types of linkages, α-
1,6 and α-1,4. 
 
Figure 3. Oligosaccharides manufactured from starch, adapted from Crittenden and Playne, 
1996. 
Soybean oligosaccharides are directly extracted from the raw material, which is a 
soybean whey, a side-product from the production of soy protein. The saccharides 
extracted from this material comprise of raffinose (α-D-Gal-1,6-α-D-Glc-(1,2)-β-D-
Fru), stachyose (α–D-Gal-1,6-α-D–Gal-1,6-α-D-Glc-1,2-β-D-Fru), sucrose, glucose and 
fructose. Raffinose and stachyose are not digestable and they can stimulate growth of 
bifidobacteria in the colon (Crittenden and Playne, 1996). 
Pectins are complex heteropolysaccharides with gelling, thickening and emulsifying 
properties, which promote human health as dietary fibers (Gulfi et al., 2007). They are 
widely used in the food industry, in products such as jams, jellies, yoghurts and 
desserts. Almost all plants contain pectin in their cell walls. Especially citrus peels and 
sugar beet pulp are used as sources to extract pectin. The main component of pectin is 
homogalacturonan, which is built of α-1,4-linked galacturonic acid. The other 
component is xylogalacturonan, which is homogalacturonan substituted with single 
xylose residues at position C3. Rhamnogalacturonan I (RGI) is the third pectic 
polysaccharide and its structure is very complex. The backbone of RGI is built of 
repeating disaccharide [ →4)- α-GalA- (1,2)- α-Rha-(1→ ]. The rhamnose residues of 
RGI can be substituted at O4 with neutral sugar side chains, composed mainly of 
galactosyl and/or arabinosyl moieties (galactan, arabinan, arabinogalactan). The side 
chains may vary from a single residue to more than 50. The last component of pectin is 
rhamnogalcturonan II, which has a backbone as homogalacturonan and complex side 
chains attached to the galacturonic acid residues. The side chains contain such rare 
moieties as, for example, apiose and aceric acid (Seveno et al., 2010). Mild acid 
hydrolysis of pectin leads to depolymerization of homogalacturonan. Alkaline 
conditions result in the removal of methyl and acetyl groups, as well as β-elimination 
reaction. Hydrothermal treatment leads to production of oligomers of galacturonic acid 
(Charalampopoulos and Rastall, 2009). There is a wide range of enzymes applied in 
modification of pectin. They are: pectin methyl esterase, pectin acetyl esterase, pectin 
lyase, pectate lyase, endo-polygalacturonase, exo-polygalacturonase, RGI lyase, RGI 
hydrolase, endo-xylogalacturonan hydrolase, RGI rhamnohydrolase, RGI 
galacturonohydrolase. An example of oligosaccharides generated from pectin are 
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homogalacturonides and rhamnogalacturonides, which were successfully produced by 
use of a sequence of monocomponent enzymes and separated by anion exchange 
chromatography, as described by Holck et al., 2011. There are many enzymes able to 
produce oligosaccharides from RGI side chains, e.g. endo-1,4-β-galactanase from 
Emericella nidulans, which action will be thoroughly described in chapters 6 and 7. 
Xylooligosaccharides are produced by enzymatic hydrolysis or chemical treatment of 
xylan contained in different raw materials, like corn and sunflower hulls, olive pulp, 
straws, bagasses and bran. Xylan is a ubiquitous polysaccharide present in plant cell 
walls. Usually it is made up of a main backbone of β-1,4 xylose which is often 
substituted at positions C2 and C3 with arabinose, 4-O-methylglucuronic acid, acetyl or 
phenolic groups. The hydrothermal treatment of raw material results mainly in the 
products of DP between 9 and 25. Xylooligosaccharides of low DP can be obtained by 
application of endo-β-1,4-xylanases. In order to produce food-grade 
xylooligosaccharides, xylose and polysaccharides are removed by ultrafiltration, 
nanofiltration and precipitation with ethanol, acetone or 2-propanol (Charalampopoulos 
and Rastall, 2009). 
2.5.3 Biological activities 
The human gastrointestinal system consists of mouth, oral cavity, esophagus, stomach, 
small intestine and large intestine (colon). Biological functions of the large intestine are 
absorption, secretion of electrolytes and water, storage and excretion of waste materials. 
The functions that affect the health and well-being are connected, to some extent, to the 
gut microbiota (Gibson and Reberfroid, 1995), especially that large intestine is the most 
colonized part of digestive tract. To reach the large intestine compounds cannot be 
digested in any of the previous part of the digestive system. When the food ingredient 
reaches the colon it is fermented by the large intestinal microbiota. 
Bacteria present in the colon are able to produce a wide range of compounds, which 
may have health-beneficial or negative effect on the host. The negative influence may 
be caused by, for example, production of cancerogenic compounds and toxins, such as 
ammonia, amines and phenols, which are products of peptides degradation (Brownawell 
et al., 2012). The compounds that may affect the host in a positive manner are, for 
example, short-chain fatty acids (SCFA). 
Majority of human large intestinal microorganisms is strict anaerobes, and facultative 
anaerobes are many magnitudes lower. The dominant anaerobes are Bacteroides (Gram-
negative rods) which may constitute up to 30% of the total faecal flora and have 
significant impact on processes in the colon. The other important groups are 
bifidobacteria, eubacteria, clostridia, and lactobacilli which are all Gram-positive rods. 
Bacteroides may exhibit health-promoting properties, such as stimulation of immune 
functions, promotion of minerals absorption, synthesis of vitamins, but also pathogenic 
effect, i.e. production of carcinogens. Eubacteria are associated with inhibition of 
pathogen growth. Bifidobacteria and lactobacilli are associated only with health-
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beneficial effects, whereas clostridia are seen only as producing toxins pathogens 
(Gibson and Roberfroid, 1995). 
Present prebiotics, fulfilling the requirement of selective stimulation of the growth of 
health-beneficial bacteria, are directed towards bifidobacteria and (to a lesser extend) 
lactobacilli. Lactobacilli may inhibit the growth of harmful bacteria, stimulate immune 
functions and enhance absorption of minerals (Gibson and Roberfroid, 1995). 
Bifidobacteria produce SCFA, acetate and lactate as metabolic end products. They 
lower the pH of the environment and thus exert an antibacterial activity towards 
pathogens (Kawase, 1982). Moreover, bifidobacteria contribute to lowering of blood 
cholesterol and ammonia levels and help to absorb minerals. They produce vitamins of 
group B and act as immunomodulators, e.g. by promoting attack against malignant cells 
(Gibson and Roberfroid, 1995). 
The ability to stimulate production of short-chain fatty acids by prebiotics is evaluated 
very positively. Increased SCFA production is associated with improvement of 
immunity system and cancer prevention. For example, an intravenous administration of 
acetate increases peripheral blood antibody production and natural killer cells (a type of 
lymphocyte) activity in cancer patients compared to controls (Ishizaka et al., 1993). 
Butyrate stimulates apoptosis and may be a protective factor in carcinogenesis 
(Macfarlane et al., 2008). Almost all prebiotics or potential prebiotics were tested in 
relation to the immunological and anti-cancer effect (e.g. FOS, GOS, 
xylooligosaccharides, different pectin derived oligosaccharides) and all exhibited 
promising results. For example, propionate produced from GOS showed anti-
inflammatory effect in respect to cancer cells (Nurmi et al., 2005). Furthermore, SCFA 
are an important source of energy for the host and they play a role in colonic epithelial 
cell transport processes, hepatic control of lipid and carbohydrate metabolism 
(Charalampopoulos and Rastall 2009). Modulation of immune system takes place, as 
stimulation of SCFA production, by stimulation of the growth of immunomodulatory 
bacteria (bifidobacteria and lactobacilli). In numerous investigations a mixture of GOS 
and FOS revealed the ability to stimulate the amount of faecal bifidobacteria and reduce 
the incidences of diseases in infants and children.  
Experimental investigations in animals, and a few human studies, have shown 
interesting cholesterol and/or triglycerides lowering effects by applying prebiotics. 
Different mechanisms of influence on lipid metabolism are postulated. One involves 
lower capacity to synthesize lipoprotein in the liver, another decreasing fat digestibility. 
The ability to modulate lipid metabolism was mainly studied with FOS, but xylo- and 
manooligosaccharides demonstrate activity against triglycerides, phospholipids and 
cholesterol, too (Charalampopoulos and Rastall 2009). However, these effects may be 
also induced by selective growth of bacteria in the colon. Some studies report that 
relative proportions of Bacteroidetes to Firmicutes present in the large intestine are 
lower in obese than in lean people. Following the appropriate diet results in reduction in 
a group of butyrate-producing Firmicutes and increased relative abundance of 
Bacteroidetes (Brownawell et al., 2012; Duncan et al., 2012). 
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Another significant health effect of prebiotics on mammalian physiology is the ability to 
improve calcium, zinc, iron and magnesium absorption, which can be beneficial in 
preventing osteoporosis and avoiding diet-related anaemia (Charalampopoulos and 
Rastall 2009). Mineral absorption is connected to degradation of phytic acid, and for 
that prebiotics are responsible as well. Phytic acid molecule may posses up to six 
phosphate groups, which may bind mineral ions making them unavailable for absorption 
in the body. Therefore phytate is associated with reduced zinc and iron uptake. Studies 
in rat indicated that prebiotic consumption enhanced degradation of phytic acid, because 
SCFA produced in bacterial fermentation induce phytases. Moreover, SCFA form 
soluble ligands with cations, which prevent their binding to phytic acid 
(Charalampopoulos and Rastall, 2009). On the other hand, degradation of phytic acid 
may not be so beneficial because it possesses anti-carcinogenic activity (Shamsuddin, 
2002).  
Other often mentioned health benefits associated with prebiotics are: increase of 
numbers of epithelial cells and the intensity of their secretory functions 
(Charalampopoulos and Rastall, 2009), laxative effect (Macfarlane et al., 2007), 
reduction of rheumatoid arthritis by altering inflammatory joint symptoms 
(Charalampopoulos and Rastall, 2009), antihypertensive and lowering blood glucose 
effects (Chauhan and Chorawala, 2012). Prebiotics are also widely tested against 
inflammatory bowel disease (IBD), a multifactorial disorder associated with reduced 
levels of bifidobacteria and increased levels of putatively pathogenic microorganisms. 
Prebiotic action in IBD includes the bifidogenic effect and immunomodulation 
(Charalampopoulos and Rastall, 2009). 
Properties of prebiotics were extensively tested in the context of infants health. Studies 
in allergic infants show reduction in the incidence of atopic dermatitis, which is 
associated with increased numbers of bifidobacteria (Moro et al., 2006). Furthermore, 
bifidobacterial colonization stimulated by prebiotics reduces a risk of necrotizing 
enterocolitis which is one of the most common causes of morbidity in premature infants 
(Charalampopoulos and Rastall, 2009). The bifidobacteria and SCFA patterns in infants 
fed with formula containing prebiotics are similar to these that are breast-fed. The 
prebiotic-containing formulas have also favourable effect on stool consistency. 
However, there are still questions to be answered, e.g. prebiotics may reduce the risk of 
disease but should they be used in case of illness? Moreover, the optimal composition of 
prebiotics and their dosage should still be studied further, and more studies in vivo 
should be done (Veerneman-Wauters, 2005). More information is needed concerning 
the growth, body composition, nutrient availability and water balance in infants fed with 
prebiotics (Macfarlane et al., 2007). 
The consumption of prebiotics has a variety of metabolic consequences. Many of 
physiological traits attributed to prebiotics are related to the effects of gut microbiota 
and its biochemical activities. The majority of investigations looked at only a few 
bacterial groups. The growth effects seen in these studies may not be replicated in the 
gut, where many different carbon sources are available for the bacteria. In summary: in 
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order to confirm prebiotic effects, well conducted human trials are required. That is the 
most reliable way to properly evaluate the properties of these ingredients, since only the 
human body offers the very complex in vivo conditions which enable occurrence of 
numerous processes, like bacterial cross-feeding effect, SCFA release and absorption at 
the same time, decrease in toxins release, expression of different enzymes, minerals 
absorption, changes in mucosal structures, altered lipid metabolism, rise in 
bifidobacteria or lactobacilli amount, decrease of pathogens growth and stimulation of 
the immunity. 
2.5.4 Applications and market 
Some prebiotics occur naturally in foods, for example, in artichoke, leek, chicory, 
asparagus, garlic, onion, oat, tomatoes and soybean. Unfortunately their content is low 
and it would require large amount of these vegetables to evoke a prebiotic effect. More 
practical method of observing prebiotics effects is to enrich food products with defined 
amount of prebiotics. Currently prebiotic compounds are added to products such as 
cereals, yoghurts, breads, biscuits, jellies, ice-creams, spreads (such as jams and 
marmalades), drinks and infant formulas. They can also be applied in non-food products 
e.g. as drug delivery basis. Moreover, there are advantages provided to product formulas 
by the physicochemical properties of prebiotic oligosaccharides, such as increased 
viscosity or protection from dryness. For example, xylooligosaccharides are applied in 
cosmetics as moisturizing agents (Charalampopoulos and Rastall 2009). They may also 
be applied as bulking agents because of their reduced sweetness (usually 0.3-0.6 times 
as sweet as sucrose) or in low-caloric food because of their indigestibility and high 
viscosity in the solutions. Additionally, prebiotic oligosaccharides can be used to 
control the amount of browning due to the Maillard reactions in heat-processed foods. 
Furthermore, future prebiotics may promote growth of other than Bifidobacterium and 
Lactobacillus beneficial gut bacteria, for example, Eubacterium, Propionibacterium, 
and Roseburia. All these features ensure that production of prebiotics will continue to 
expand in the future. 
Prebiotics are added to infant formulas in an attempt to conserve or restore high 
bifidobacteria content in the microflora, since high bifidobacteria content prevents from 
infections and allergies. The prebiotics used in infant formulas are usually GOS and 
inulin (sometimes FOS). They are applied at concentrations up to 0.8 g/dl, since the 
Scientific Committee on Food of the European Commission stated that addition of the 
prebiotic mixture at a concentration of 0.8 g/dl to infant formula is considered safe 
(Veerneman-Wauters, 2005). 
The regulatory status for carbohydrate prebiotics on the market today is Generally 
Recognized As Safe (GRAS). The European Union regulates prebiotics as Novel Foods. 
Prebiotics, including inulin and FOS, were submitted for approval of a health claim but 
were rejected. Therefore, it is unlikely that the European Food Safety Authority (EFSA) 
will permit any health claim for prebiotics in the near future, just as it has disallowed 
any health claims for probiotics (Sloan and Hutt, 2013). 
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Nutrition Business Journal estimated the gastrointestinal supplement market at $1.5 
billion in 2012, +13% vs. 2011. After cholesterol lowering effect, digestive health was 
the second most purchased condition-specific food/beverage category in 2011 (Sloan 
and Hutt, 2013). Therefore, new and novel prebiotics will likely be the future drivers of 
the market. Especially that new food and beverages with prebiotics are growing quickly 
in the global market (291 in 2012 vs. 195 in 2011). 
In general, food-grade prebiotic oligosaccharides are mixtures of oligosaccharides of 
different degree of polymerization. Often the substrate, i.e. polysaccharide or 
monosaccharide is present as well. Most manufacturers produce different classes of 
products with different purity level. The production of food-grade oligosaccharides 
except lactulose was 35000 t in 1991 and increased to 65000 t in 1995. Lactulose 
production in 1995 was estimated to be about 20000 t, whereas GOS production was 
15000 t and FOS 12000 t (Crittenden and Playne, 1996). 
The manufacturers of animal feed and pet food started to show interest in prebiotics as 
well. The main aim of application of prebiotics in these products is the reduction of 
infections and decrease of faecal putrefactive compounds. In case of animal feed the 
intension to introduce prebiotics, concerns outbreak of food-borne diseases, which has 
mainly been caused by prohibition of antibiotics as growth promoters (Gaggia et al., 
2010). Including prebiotics in the chickens and cattle diet does not have a strong health-
improving effect. Application of synbiotics is more beneficial for both groups of 
animals. It improves gut health and control pathogen release in the environment, 
decreasing the risk of food-borne infections in humans. (Gaggia et al., 2010). 
Incorporating fructooligosaccharides into dogs’ diet resulted in the increase of number 
of bifidobacteria and increase in concentration of short chain fatty acids. The other 
outcome of supplementing dogs with FOS was decrease in faecal concentration of 
ammonia and phenols which, among other compounds, are responsible for the malodour 
of dog faeces (Hussein et al., 1999). Introducing FOS to canine diet induced only to a 
low extent increase in bifidobacteria, but glucose-based oligosaccharides caused a 
significant increase (Gibson et al., 2004). As can be seen, the nutrition research for 
companion animals generates broad perspectives for prebiotics use. 
It can be concluded that the prebiotics production will continuously increase and more 
applications and forms for these food ingredients will appear in the future. The scientific 
investigation towards new prebiotic compounds, as well as better understanding of their 
mode of action will definitely accompany the trends in the industry and the market.  
 
2.6 GALACTOOLIGOSACCHARIDES 
2.6.1 Methods of production 
Galactooligosaccharides (GOS) are prebiotic food ingredients. The commercial method 
of production of galactooligosaccharides involves lactose as substrate, as both, donor 
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and acceptor in the reaction. Lactose is relatively cheap and moreover it may be a side-
product from production of, e.g. lactose-free milk. The conversion of lactose to GOS is 
performed in enzyme-catalysed reaction. The enzymes employed for this purpose are 
bacterial and fungal galactosidases – glycoside hydrolases, which act as glycoside 
transferases, e.g. β-galactosidase from Bacillus circulans used in production of GOS by 
Friesland Campina or Aspergillus oryzae and Streptococcus thermophillus β-
galactosidases used by Yakult Honsha. The literature reports broad range of enzymes 
producing galactooligosaccharides from lactose, e.g. α-galactosidase from Aspergillus 
nidulans (Emericella nidulans) (Nakai et al., 2010), β-galactosidases from different 
strains of Bifidobacterium: B. angulatum, B. bifidum, B. adolescentis, B. infantis and B. 
pseudolongum (Rabiu et al., 2001), β-galactosidase from Lactobaciulls reuteri 
(Maischberger et al., 2007), β-galactosidase from Kluveromyces lactis 
(Chockchaisawasdee et al., 2005) and many others. 
GOS are produced as mixtures of oligosaccharides of different DP, usually from 1 to 9, 
since the mixture contains also un-reacted lactose and free glucose and galactose. This 
happens because GOS are simultaneously synthesized and degraded by β-galactosidase. 
The degree of polymerization depends on microbial origin of enzyme, substrate 
concentration and reaction conditions. A. oryzae β-galactosidase shows optimal product 
formation at pH 3.5, whereas yeast and bacterial enzymes have pH optima around 6-7.5 
(Charalampopoulos and Rastall, 2009). Furthermore, by pH manipulation, the trans-
galactosylation can be promoted and hydrolysis can be kept low. Higher temperature 
speeds up the reaction. Moreover, high temperature is preferred because of better 
lactose solubility and prevention of its crystallization, as well as reduction of reaction 
mixture viscosity when high substrate concentrations are used. High substrate 
concentration is favoured because it results in decrease of water activity and thus in 
decreased hydrolysis and production of GOS of higher DP. Therefore the thermostable 
β-galactosidases are getting more attention (Onishi and Tanaka, 1995; Park et al., 2008; 
Nakao et al, 1994; Ji et al., 2005; Petzelbauer et al., 2000). Another factor influencing 
the DP of galactooligosaccharides is the reaction time. It often happens that prolonged 
incubation with the enzyme leads to hydrolysis of the products and therefore to decrease 
in the average DP. On the other hand, short reaction time results in higher DP, but also 
in lower conversion of the substrate.  
 
Depending on the enzymes used in the production process there appear different 
glycosidic linkages in the structures of galactooligosaccharides, which influences, of 
course, the prebiotic and physicochemical properties of the product. For example β-
galactosidases from B. circulans and Cryptococcus laurentii form mainly 4’-galactosyl 
lactose, whereas enzyme from S. thermophilus and B. bifidum 3’-galactosyl lactose. 
Fungal β-galactosidase from A. oryzae generates 3’- and 6’-galactosyl lactose and yeast 
enzyme from K. lactis 6’-galactosyl lactose (Charalampopoulos and Rastall, 2009). 
Moreover, depending on the enzyme applied in the process of GOS production, the 
monosaccharide composition of the products may vary. Usually GOS have a structure 
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of Galn-Glc, but there can be also structures Galn-Gal (where n means the degree of 
polymerization) or even branched structures (Torres et al., 2010).  
The yields of GOS production are usually lower than 50%. In Table 2 the maximum 
GOS concentrations produced with different enzymes and different reaction conditions 
are presented. The yields of GOS have been found to be higher when using organic 
solvents which lower the water activity. The toxicity of organic solvents limits however 
their use in food production (Gosling et al., 2010). 
Reaction conditions 
Enzyme source Initial lactose 
concentration 
[g/L] 
T (ºC) pH 
Lactose 
conversion 
(%) 
Maximum 
GOS yield 
(% w/w) 
Sulfolobus 
solfataricus 600 80 6.0 70 52.5 
Sulfolobus 
solfataricus 270 70 5.5 72 26 
Aspergillus oryzae 500 40 4.5 56 52 
Bullera singularis 180 50 6.0 72 50 
Saccharopolyspora 
rectivirgula 600 70 7.0 75 41 
Sterigmatomyces 
elviae 200 60 5.0 63 39 
Lactobacillus reuteri 205 37 6.5 80 38 
Pyrococcus furiosus 270 70 5.5 80 33 
Bifidobacterium 
longum 400 45 6.8 60 32.5 
Kluveromyces lactis 400 40 7 92 24.8 
Thermotoga maritima 500 80 6 50 19 
Table 2. The maximum GOS concentrations; adapted from Gosling et al., 2010. 
There are two types of reactors used for production of GOS. These are batch and 
continuous stirred reactors. In the continuous reactor, filtration happens at the same time 
as the reaction. In the batch process the enzyme applied in the reaction is usually lost 
after the termination of the reaction, whereas in the continuous process it may be reused 
and therefore decrease the product cost. Furthermore, the mode of operation influences 
the composition of produced GOS. In the batch system, the composition and 
concentration of galactosyl acceptors are changing constantly, while in the steady state 
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of a continuous system the concentration of acceptors stay constant (Charalampopoulos 
and Rastall, 2009). This leads to more defined GOS mixtures in case of continuous 
reactor (Splechtna et al., 2007), since it provides continuous removal of products and 
prevent their hydrolysis. Furthermore, the continuous process provides removal of 
glucose and galactose, which are known inhibitors of β-galactosidases (Gosling et al., 
2010). The removal of monosaccharides increases therefore the yield of GOS 
production. 
Another way of producing GOS involves whole cells. In that case there is no need to 
isolate the enzymatic catalyst. GOS yields up to 43% (w/w) have been achieved using 
this method and that makes it comparable with production using isolated enzymes 
(Gosling et al., 2010). Using whole cells have an advantage of removal of 
monosacchrides from the product, since growing microorganisms consume them in the 
process of growth. An example of employing the whole cells for production of 
galactooligosaccharides is use of mixture of B. bifidum and Saccharomyces cerevisiae. 
S.cerevisiae consumed 92% of glucose present in the reaction mixture and therefore 
purified the product (Gosling et al., 2010). The disadvantage of application of the whole 
cells is the presence of the metabolic end products, like ethanol or lactic acid. 
When the reaction is conducted with isolated enzyme, the purification of GOS from 
substrate – lactose and monomers generated during the progress of the reaction is not an 
easy step. None of the methods used for that purpose provides complete separation of 
the desired GOS from side-products and lactose. It is however important for some 
applications of GOS to produce them in high purity. At first because many people are 
nowadays lactose intolerant and secondly because presence of monosaccharides limits 
applications in diabetic food. Removal of mono- and disaccharides produced from 
lactose has been attempted by different techniques. Comparison of them is described by 
Hernandez et al., 2009. Diafiltration with cellulose acetate membranes of cut off 500 
and 1000 Da did not show any selectivity between mono-, di- and oligosaccharides. 
Activated charcoal treatment showed different selectivity in GOS recovery depending 
on the ethanol concentration in the solution in which Vivinal GOS were dissolved. The 
best results were obtained with 8 and 10% of ethanol. Applying the first concentration 
resulted in 90% recovery of GOS, but 20% of disaccharides were also recovered from 
active charcoal. 10% ethanol led to almost complete removal of disaccharides, but loss 
of about 47% of GOS. Another fractionation technique employed yeast. The 
commercial mixture of GOS was incubated with Saccharomyces cerevisiae, which 
removed monosaccharides selectively and converted them to ethanol and CO2. The 
yeast did not, however, degrade the disaccharides. Another disadvantage of this method 
could be presence of the yeast’s metabolites in the GOS solution. The most effective 
method of GOS fractionation was size exclusion chromatography. It separated almost 
completely mono-, di-, tri-, tetra- and pentasaccharides, and hexa-, hepta- and 
octasaccharides were obtained in high purity. Furthermore, the GOS recovery was high, 
i.e. between 81 and 92%.  
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Besides trans-galactosylation of lactose GOS may also be obtained by enzymatic 
hydrolysis of galactan (polymeric side chain of pectin rhamnogalacturonan I). Since 
galactan is built mainly of galactose monomers connected with 1,4-β, 1,6-β and 1,3-β 
linkages, the enzymes employed in its hydrolysis are endo-β-galactanases. 
Commercially available galactan contains besides galactose arabinose, galacturonic acid 
and rhamnose. Moreover, galactan is sometimes called arabinogalactan, usually in cases 
when the arabinose content is relatively high. The method of production of GOS 
(usually 1,4-β-GOS) from galactan is not applied in the industry. Until now it concerns 
mainly production of oligosaccharides in laboratory scale. However, due to the 
abundance of plant material, which is so far considered a waste stream from agriculture, 
this method has a potential for application in the big-scale production. The enzymes 
available for this purpose are getting more attention. There are fungal galactanases, e.g. 
from Aspergillus aculeatus (Luonteri et al., 2003) and Aspergillus niger (Yamaguchi et 
al., 1995; de Vries et al., 2002; Luonteri et al., 2003), as well as bacterial ones, e.g. from 
Bifidobacterium longum (Hinz et al., 2005), Streptomyces avermitilis (Ichinose et al., 
2008) or Thermotoga maritima (Yang et al., 2006). 
The endo-galactanases have different specificities and preferences towards different 
substrates. The endogalactanase from B. longum degrades 1,4-β and 1,3-β bonds 
between galactose units and it is hindered by the presence of arabinose in the substrate 
(Hinz et al., 2005). The β-1,4-endogalactanase from A. niger is able to produce 
galactooligosaccharides containing arabinose from soy arabinogalactan. The endo-β-
1,6-galactanase from A. aculeatus was able to produce galactose and 1,6-β-galactobiose 
from 1,3/6-arabinogalactan, and moreover exhibited promiscuitism by liberating 
arabinose from arabinan (Luonteri et al., 2003). The endo-β-1,6-galactanase from S. 
avermitilis catalysed hydrolysis of β-1,6-linked galactosyl linkages of oligosaccharides 
and polysaccharides, as well as degradation of tomato and radish arabinogalactan 
protein (Ichinose et al., 2008). 
The enzymatic hydrolysis of galactan, as transglycosylation of lactose, is not devoid of 
drawbacks. The main one is the presence of monomer in the product. Galactobiose is an 
important, if not the most abundant one, component of the products mixture too 
(Yamaguchi et al., 1995; Ichinose et al., 2008; Luonteri et al., 2003; de Vries et al., 
2002). The content of galactose and galactobiose usually increases with the incubation 
time. For example, the endogalactanase from B. longum produces mainly galactotriose 
at the beginning of incubation with potato arabinogalactan and then degrades this 
trisaccharide to dimer and monomer (Hinz et al., 2005). Thus the composition of the 
GOS mixture may be influenced by choosing an appropriate reaction time. Application 
of another endo-1,4,-β-galactanase - from Emericella nidulans to obtain 
galactooligosaccharides and influence of time on product composition is described in 
the publication attached in chapter 9.3. 
There is also a group of glycosyltransferases which can synthesize GOS. Although they 
are highly efficient, regio- and streoselective they are not used in industry due to their 
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poor availability and very high prices, as well as need of specific sugar nucleotides as 
substrates (Gosling et al., 2010). 
Besides enzymatic reactions, GOS may be obtained by chemical methods, like acid 
hydrolysis of polysaccharides. An example of such a treatment is preparation of 
galactooligosaccharides exhibiting anti-angiogenesis activity from polysaccharides of 
Nerium indicum (Hu et al., 2009). Also sulfated galactooligosaccharides are often 
obtained by acid hydrolysis (Käsbaueret al., 2001), since it is troublesome to find 
enzymes active on sulfated polysaccharides.  
2.6.2 Biological properties 
The biological properties of GOS are the same as associated with prebiotics in general. 
Especially that the most investigated prebiotics are FOS and GOS. The most obvious 
biological activity of galactooligosaccharides as prebiotics is stimulation of probiotic 
bacteria. The probiotic strains which growth is usually tested are bifidobacteria and 
lactobacilli. GOS produced by enzymes of different microbial origin stimulate these 
bacterial strains to different extent. The best stimulation of bifidobacteria could be 
expected in case of GOS produced by bifidobacteria itself. In publication by Rabiu et 
al., 2001 β-galactosidases from different species of Bifidobacterium were used to 
produce GOS, which were subsequently tested on the same strains, as well as on 
Lactobacillus acidophilus. The highest single culture growth was achieved when the 
strains utilized GOS produced by their β-galactosidases. However, the mixed culture 
test revealed that the growth of probiotics was stimulated in some cases to the same 
extent by the commercially available product obtained by means of galactosidase from 
A. oryzae. On the other hand, it was demonstrated in human trials that GOS produced by 
β-galactosidase from B. bifidum had higher prebiotic potential than commercial GOS 
produced with β-galactosidase from A. oryzae (Gosling et al., 2010). 
With stimulation of bifidobacteria are associated beneficial effects on human health, 
such as reduced amount of toxic metabolites, prevention of diarrhoea and growth of 
pathogens – mainly by induction of production of short chain fatty acids, and 
stimulation of the immune system (de Sousa et al., 2011). Moreover, many 
mineralization studies have been done with GOS. The galactooligosaccharides have 
been reported to stimulate the absorption of calcium and magnesium (Macfarlane et al., 
2008; Weaver et al., 2011). Other positive influence of galactooligosaccharides on 
human body is demonstrated by ability to reduce incidence of allergies or alleviate joint 
inflammation (Macfarlane et al., 2008), as well as by the potential to protect from 
development of colorectal cancer (Charalampopoulos and Rastall, 2009). 
GOS are nowadays often used in infant formulas in Europe. Their task in these products 
is to stimulate the growth of probiotic microorganisms, especially bifidobacteria and 
thus provide microflora similar to that possessed by breast-fed infants. The other effects 
that are supposed to be delivered by GOS are prevention of diseases and atopy, and 
stimulation of immune response. 
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2.6.3 Applications and market 
Galactooligosaccharides have been manufactured and commercialized since 1980s. In 
2007 the global market size was estimated to be about 20000 tones (Torres et al., 2010). 
The mixtures of GOS are produced, among others, by Yakult Honsha, Nissin Sugar 
Manufacturing Co. and Friesland Foods Domo. The commercial names of GOS 
mixtures produced by different companies and enzymes used for this purpose are 
presented in Table 3. The composition of GOS in different products is presented in 
Table 4.  
company product 
name 
product 
form 
enzyme source 
Nissin Sugar 
Manufacturing Co. 
Cup-Oligo syrup or 
powder 
Cryptococcus laurentii 
Yakult Honsha Oligomate 
55 
syrup or 
powder 
Aspergillus oryzae, Streptococcus 
thermophilus 
Friesland Foods Domo Vivinal GOS syrup or 
powder 
Bacillus circulans 
Clasado Ltd. Bimuno syrup or 
powder 
Bifidobacterium bifidum 
Corn Products Intl. Purimune powder Bacillus circulans 
Table 3. Commercial GOS available in the market; adapted from Torres et al., 2010. 
As can be seen from Table 4 there are differences in the purity amongst the 
commercially offered GOS. The differences appear also in the linkages between 
monosaccharides and they are caused by application of different enzymes in the 
production process. The Oligomate GOS mixture contains mainly β1→6 linkages, 
Bimuno mainly β1→3 linkages, whereas Cup-Oligo, Vivinal GOS, and Purimune 
contain mainly β1→4 linkages (Torres et al, 2010). 
The combination of GOS and inulin in a ratio of 9:1 is used in infant formulas. The 
concentrations up to 0.8 g/dL of these prebiotics may be used (Veereman-Wauters, 
2005). Products such as Allomin by Semper, Nan by Nestle or Baby & Me Organic by 
Arla Foods contain GOS. Some of the infant formulas contain also probiotics, e.g. Nan 
by Nestle. 
Besides infant milk formulas, GOS may be incorporated in other food products, such as 
beverages (e.g. fruit juices), flavoured milks, ice-creams, jams, confectionery products, 
and baked products. The physicochemical properties of GOS, like heat stability or 
moisture-binding capacity, make them desired food ingredients. For example, because 
of the physicochemical properties, bread is a suitable food for galactooligosaccharides 
inclusion. During the yeast fermentation and baking of bread, GOS are not broken and 
render bread excellent in taste and texture (Mussatto and Mancilla, 2007). Another 
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property of galactooligosaccharides is reduced sweetness comparing to sucrose. It is 
typically between 0.3 and 0.6 times less sweet than sucrose. They can be then added in 
relatively high amounts to food, which is required to exhibit prebiotic properties, and at 
the same time they may be applied in food for people with diabetes or overweight.  
product glucose galactose lactose total 
GOS 
DP of GOS 
Cup-Oligo 25-30 70 - 
Oligomate 
55 
18-39 10-22 50-60 DP2: 15-17; DP3: 18-24; DP4:10-16; 
DP>4: 205.4 
Vivinal 
GOS 
19-22 0.8-1.3 10-23 57-59 DP2: 19-27; DP3: 22-23; DP4: 11; 
DP>4: 6-7.6 
Bimuno 18 12 22 48-55 DP2:25-29; DP3: 12-14; DP4: 6.7-7.7; 
DP>4: 3.8-4.4 
Purimune 0-1 0-0.5 7-10 90-92 DP2: 16-21; DP3: 38-51; DP≥4: 25-29 
Table 4. Composition of GOS products; adapted from Torres et al., 2010. Composition of GOS 
is given in % of w/w of dry matter. 
Another interesting application of GOS is in cosmetics. As in food, their prebiotic 
properties may be used to stimulate growth of beneficial bacteria – this time on human 
skin (Torres et al., 2010). Moreover, GOS can be used in livestock feed, for example for 
the poultry, pigs or fish, as well as in the pet food (Torres et al., 2010). 
 
2.7 HUMAN MILK OLIGOSACCHARIDES 
2.7.1 Structures and methods of synthesis 
Oligosaccharides are the third largest fraction of human milk, after lactose and lipids. 
The oligosaccharide content of human milk varies with the duration of lactation, 
diurnally and with the genetic makeup of the mother (Miller and McVeagh, 1999). The 
content of oligosaccharides in the milk is approximately 20 g/L in colostrum and 5 g/L 
in mature milk (Donovan, 2009). About 200 structures of human milk oligosaccharides 
(HMOs) have been identified (Ninonuevo et al., 2007). All HMOs have lactose core in 
their structures. Lactose is placed at the reducing end and it is elongated with N-acetyl-
glucosamine units by different types of glycosidic linkages. Fucose and sialic acid are 
placed at the non-reducing end of HMOs molecules. The HMOs vary in size (from three 
to thirty two) and may be linear (designated as para-HMO) or branched (designated as 
iso-HMO). The majority of the HMOs is neutral and contains fucose (Macrobal et al., 
2010). Some selected HMO structures are presented in Figure 4. 
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Figure 4. Selected HMO structures; adapted from Bode, 2012. A. HMOs blueprint; B. Lactose 
can be elongated by addition of either lacto-N-biose (type 1 chains) or N-acetyllactosamine 
(type 2 chains); C. Lactose can be fucosylated or sialylated; D. Elongated type 1 and 2 chains 
can be fucosylated; E. Elongated type 1 and 2 chains can be sialylated; monosaccharide key is 
shown at the bottom of the figure. 
The HMO composition mirrors blood group characteristics, which depends on the 
expression of certain glycosyltransferases (Bode, 2012). Four milk groups can be 
determined by the activity of two gene loci encoding for the α-1,2-fucosyltransferase 
FUT2 (encoded by Se gene) and the α-1,3/4-fucosyltransferase FUT3 (encoded by the 
Le gene). Individuals with an active Se locus are classified as Secretors. Their milk is 
abundant in 2′-fucosyllactose, LNFP I and otherα-1,2-fucosylated HMOs. The non-
Secretor lack a functional FUT2 enzyme and their milk does not contain α-1,2-
fucosylated HMO. Individuals with an active Le locus are classified as Le positive. 
They express FUT3, which transfers fucose in the α-1,4 linkages to subterminal 
GlcNAc on type 1 chains. In contrast, the milk of Le negative women lacks these 
specific α-1,4-fucosylated HMOs (Bode, 2012). 
According to publication by Bode, 2012 it is likely that HMOs biosynthesis is an 
extension of lactose synthesis, which occurs in the Golgi and starts with glucose. 
Moreover, there is a hypothesis that lactose core is extended by actions of N-
acetylglucosaminyl-transferases and galactosyltransferases (Bode, 2012). Fucosylation 
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of HMOs occurs because enzyme FUT2 adds fucose in an α-1,2-linkage to terminal 
galactose, and FUT3 adds fucose in an α-1,4-linkage to internal N-acetylglucosamine. 
An additional unknown FUT enzyme adds fucose in an α-1,3-linkage to the reducing 
end glucose or internal N-acetylglucosamine (Bode, 2012). Thanks to that, even the 
milk of Le negative non-Secretor contains fucosylated HMOs. The biosynthesis of 
sialylated HMOs remains poorly understood (Bode, 2012).  
The bovine milk which is a base for infant formulas contains very low amounts of the 
oligosaccharides present in human milk, less than 1 g/L (Jeong et al., 2012). The only 
known milk which is quite abundant in oligosaccharides of the same structures as 
human milk oligosaccharides, is milk of elephant. It is speculated that this occurs due to 
the fact that both man and elephant show similar patterns of postnatal ontogeny, i.e. 
they grow slowly, have highly developed nervous systems and show high degree of 
intelligence and learnt behaviour, as well as they are fed with the mother’s milk for 
relatively long period (Osthoff et al., 2008). 
The literature about synthesis of fucosylated oligosaccharides is quite limited. It reports 
that the synthesis of fucooligosaccharides can be catalysed by enzymes. The enzymes 
are often fucohydrolases which are genetically modified to exhibit trans-fucosidase 
activity (Osanjo et al., 2007; Wang, 2009). There are some microorganisms possessing 
α-fucosidases able to catalyse transfer of fucosyl moiety, for example Alcaligenes sp. 
(Zeng et al., 2003), Corynebacterium sp and Aspergillus niger (Ajisaka and Shirakabe, 
1992). There are fucosidases of non-microorganism origin too, for example from canine 
and mollusc (Berteau et al., 2004). However, the enzymatic methods of producing 
fucosylated oligosaccharides are applied to obtain a very limited numbers and quantities 
of fucooligosaccharides. The enzymes are also often applied to catalyse reaction with a 
synthetic donor or/and acceptor of fucose, like para-nitrophenyl glycosides (Osanjo et 
al., 2007, Zeng et al., 2003). There are also general chemical methods of synthesis of 
different oligosaccharides. They require many protection and deprotection steps and 
may result in the presence of some harmful chemicals in the product. Therefore none of 
the mentioned methods may not be used in a large scale production of HMOs enabling 
incorporating these valuable compounds into infant formulas. 
Sialylated oligosaccharides may be synthesized in vitro by chemical methods and 
enzymatic catalysis using sialyltransferases, trans-sialidases or sialidases. Chemical 
sialylation is usually complicated and time-consuming, since it requires multiple 
protection and de-protection steps (Yamamoto, 2010). Sialyltransferases transfer sialic 
acid (N-acetylneuraminic acid) from cytidine monophospho-sialic acid (CMP- sialic 
acid) to an acceptor. In this way they can synthesize sialyloligosaccharides, sialyl-
glycoproteins and sialyl-glycolipids (Yamamoto, 2010). The disadvantage of 
sialyltransferases is the high price of the substrate. Sialidases hydrolyse sialylated 
glycans to sialic acid and glycan moiety. Their modification by mutagenesis may 
decrease the hydrolytic activity and rise their trans-sialidase activity. The transferase 
activity may be enhanced by application of proper reaction conditions, like in case of 
many lipases. Trans-sialidases catalyse the transfer of sialic acid from a donor to an 
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acceptor. Usually the donors of sialic acid are sialoglycoconjugates and the sialic acid is 
transferred to β-galactosyl groups in the acceptor molecules (Amaya et al., 2004). One 
of the widely-investigated trans-sialidases is Trypanosoma cruzi trans-sialidase 
(E.C.3.2.1.18). It is an enzyme naturally produced by the parasite responsible for 
Chagas disease (Augusti et al., 2007). It transfers α-2,3-bound sialic acid from the donor 
to terminal β-galactosyl moiety of an acceptor (Lee et al., 2002). The T. cruzi trans-
sialidase expressed in E. coli is able to catalyse the transfer of sialic acid from fetuin, a 
glycoprotein from fetal calf serum, to lactose resulting in sialyllactose (Lee et al., 2002). 
Singh et al., 2000 reported that this enzyme also catalyses synthesis of sialylated 
oligosaccharides, including di-sialylated compounds. Moreover, Pelletier et al., 2001 
employed T. cruzi trans-sialidase in production of sialyllactose from lactose and isolated 
κ-casein, as well as from lactose and 2,3-sialosides (such as κ-casein and gangliosides) 
contained in skim milk, mozzarella and Swiss cheese whey.  
As mentioned above, sialidases can catalyse trans-sialidation. A patent by McJarrow et 
al., 2003 reported synthesis of sialylated saccharide from glycomacropeptide (GMP) 
and lactose by sialidases from Arthrobacter ureafaciens and Bifidobacterium infantis. 
Sialidases from Vibrio cholera, Clostridium perfringens and Salmonella typhimurium 
were applied to synthesize a series of sialyloligosaccharides using pNP-NeuAc as a 
donor, as reported by Schmidt et al., 2000. The examples of mutated sialidases 
exhibiting trans-sialidase activity are mutated Trypanosoma rangeli sialidases which 
contain five or six mutations (Paris et al., 2005). The T. rangeli sialidase is in 70% 
identical to T. cruzi trans-sialidase at the amino acid level. T. rangeli is not a pathogenic 
microorganism and therefore, from the commercial point of view, application of T. 
rangeli enzyme in potential production of sialylated compounds is more appealing than 
use of T. cruzi trans-sialidase. The applications of mutated T. rangeli sialidases in 
production of sialylated glycans are described in chapters 4 and 5, and in publications 
attached in chapters 10.1 and 10.2.  
2.7.2 Biological properties 
Infants digest a minor portion of HMOs present in the breast milk (Macrobal et al., 
2010), because the glycosidic bounds between monosaccharides constituting HMOs 
cannot be hydrolyzed by lactase and other enzymes produced in human gastrointestinal 
tract. Lactase is not able to hydrolyze the lactose moiety of trisaccharides or longer 
oligosaccharides (Miller and McVeagh, 1999). Thus, most of the HMOs are delivered to 
the colon in an intact state and are treated as a carbon source by the colon bacteria. The 
HMOs are substrates for the probiotic bacteria, especially bifidobacteria. The presence 
of N-acetylglucosamine in the HMOs structures is necessary for the growth of 
Bifidobacterium bifidum in the large intestine (Miller and McVeagh, 1999). Two strains 
of B. bifidum (JCM1254 and JCM7004) are reported to possess exo-α-sialidase activity 
(EC 3.2.1.18) (Kiyohara et al., 2011). By the end of the first week of life bifidobacteria 
constitute 95% of the bacteria population in the faeces of breast-fed infants, whereas in 
the formula-fed infants they represent less than 70% (Miller and McVeagh, 1999). 
Bifidobacterium longum subsp. infantis (ATCC15697) is considered an “archetypical 
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HMO-utilizing bacterium” (Sela et al., 2008). Macrobal et al., 2010 reports that B. 
longum subsp. infantis metabolizes HMOs with high efficiency and have specific 
preferences for fucosylated oligosaccharides. 
The bifidobacteria produce short chain fatty acids which decrease pH in the colon and 
thus prevent growth of pathogens. Through this mechanism the HMOs decrease the 
incidence of diseases in newborns. For example, three fucosylated oligosaccharides 
representing the structures of HMOs: 2’-fucosyllactose, 3-fucosyllactose, and 
lactodifucotetraose stimulated the growth of two B. longum strains in mixed infant 
faecal bacterial communities. At the same time these bacteria produced lactate and 
short-chain fatty acids, which decreased the pH. Escherichia coli and Clostridium 
perfringens did not utilize the fucosylated oligosaccharides and the SCFA inhibited 
their growth (Yu et al., 2013). Moreover, the SCFA produced by the bifidobacteria are 
absorbed in the large bowel and therefore provide nutrition for the body. Therefore, 
most of the energy contained in the human milk oligosaccharides is finally available for 
the body of the infant (Miller and McVeagh, 1999). The stimulation of the growth of 
bifidobacteria by HMOs is beneficial also for another reason than production of SCFA. 
That is the production of vitamins, mainly of B group, by bifidobacteria (Gibson and 
Roberfroid, 1995). An interesting aspect of the HMOs is that their positive effect may 
also occur in the lactating mothers, since there was observed a “leakage” of the HMOs 
into their circulation (Bode, 2012). 
Besides exhibiting the prebiotic properties, HMOs can stimulate bacterial growth in 
other manners according to Hunt et al., 2012. HMOs support the growth of 
Staphylococcus aureus and Staphylococcus epidermis without being consumed by these 
bacteria. The presence of HMOs stimulates bacterial growth and utilization of amino 
acids present in the medium. The HMOs may therefore promote the growth of 
Staphylococcus species in the lactating mammary gland and interact with the bacterial 
communities of lactating mother, and therefore extend their influence to the health of 
the lactating mother. On the other hand, Staphylococcus can also cause the breast 
inflammation (Bode, 2012). Since the Staphylococcus is present in mammary glands, it 
is also present in the human milk. Therefore, the bacteria in the breast milk can be 
regarded as natural probiotics, as well as commensals and pathogens.  
HMOs modulate intestinal cell proliferation and maturation, which means that the 
mucosal barrier of the intestine can be affected by these compounds (Macrobal et al., 
2010). HMOs may change the glycome of intestinal epithelial cells. 3’-sialyllactose 
reduces the expression of various glycosyltransferases, which diminishes the content of 
cell surface sialic acid, fucose and galactose (Bode, 2006). These modifications 
influence the biding ability of range of pathogens.  
HMOs are perceived as elements playing a crucial role in the pathogen decoy 
mechanism. The mucosal surface in the human body contains receptors recognized by 
the pathogens. Since the HMOs structures are similar to the receptors in the epithelial 
cells, the bacteria may attach to HMOs instead. This prevents the infection, because the 
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bacteria are then “flushed out” from their potential host. The HMOs can by such a 
matter of action prevent diseases caused by dangerous pathogens like Campylobacter 
jejuni or E. coli, as well as viruses such as HIV and hepatitis C (Bode, 2006; Morrow et 
al., 2005). Sialyllactose, being one of the simplest structures of HMOs, inhibits binding 
of cholera toxin in vitro (Idota et al., 1995). Its exposure to Caco-2 cells reduces the 
adhesion of enteropathogenic E. coli by 50%, which is correlated with reduced cell 
surface sialic acid and lactosamine, which are key glycans for adhesion of 
enteropathogenic E. coli (Bode, 2006). Moreover, a disaccharide moiety of lactose or 
lactosamine most likely represents the core HMO recognition element for exotoxins 
expressed by Clostridium difficile (El-Hawiet et al., 2011). The similarities between 
oligosaccharidic ligands naturally occurring in human milk and the receptors for 
pathogens are listed in Table 5.  
receptors microorganisms 
mannose-containing glycoproteins Escherichia coli (type 1 fimbriae) 
fucosylated oligosaccharides E. coli (heat-stable enterotoxin) 
fucosylated tetra- and pentasaccharides E. coli 
3’-sialyllactose, glycoproteins and sialyl-α-2,3-
galactosides in mucins 
E. coli (S-fimbriae) 
neutral oligosaccharides (LNT, LNnT) Streptococcus pneumoniae 
gal-β-1,4-GlcNAc or Gal-β-1,3-GlcNAc Pseudomonas aeruginosa 
fuc-α-1,2-Gal epitopes Candida albicans 
sialyllactose Helicobacter pylori, Streptococcus sanguis 
sialyllactose and sialylated glycoproteins H. pylori 
sialylated glycoproteins (α-2,3-linked) Mycoplasma pneumonia 
sialylated poly-N-acetyllactosamine M. pneumonia 
sialylated α-2,3-poly-N-acetyllactosaminoglycans Streptococcus suis 
6’-sialyllactose Influenza virus A 
3’-sialyllactose Influenza virus B 
9-O-Ac of NeuAc-α-2,3-R Influenza virus C 
Table 5. HMOs as receptors for pathogenic microorganisms; adapted from Kunz et al., 2000. 
The presence of sialic acid in the structures of many HMOs received also wide 
attention. The sialic acid-containing HMOs constitute about 20% of total HMOs (Wu et 
al., 2011). The sialic acid is a component of brain gangliosides. It is thought to play an 
essential role in nerve cell transmission, cell-to-cell communication and memory 
 28 
formation (Miller and McVeagh, 1999). Thus, its availability in the infant food is an 
important factor in the postnatal brain development. The sialic acid is present not only 
in the brain but can also be detected in the saliva. The saliva was compared between 
breast-fed and formula-fed infants. This comparison resulted in detection of about 50% 
more sialic acid in the saliva of breast-fed neonates (Miller and McVeagh, 1999) 
indicating that the breast-fed neonates have higher content of sialic acid in their bodies. 
Sialic acid is also supposed to play a role in regulating immune response by serving as 
ligand for lectins (carbohydrate-binding proteins) binding (Wu et al., 2011). 
Furthermore, the sialylated oligosaccharides decrease leukocyte adhesion. The question 
arises: do HMOs compromise the infant’s immune defence and harm the breast-fed 
infant or do HMOs keep the immune system in check and protect the breast-fed infant 
against overshooting immune response such as necrotizing enterocolitis (NEC) (Bode, 
2006). Since the incidence of NEC is 85% lower in breast-fed infants than in formula-
fed ones, it seems that the infant’s own leukocytes and their excessive production of 
reactive oxygen species propagate NEC. Therefore, because the HMOs inhibit 
leukocyte adhesion at sites of inflammation, they may contribute to the protection 
against NEC (Bode, 2006).  
The brain development requires, besides sialic acid as a component of gangliosides, also 
galactose which is a main saccharide in glycolipids in myelin. The liver may not be 
capable of providing all the galactose needed by the newborn mammals for the brain 
development and myelination. Therefore, a possible role of milk oligosaccharides in 
which galactose is a main component, is ensuring that galactose level in the infant do 
not become limiting during the brain development period (Kunz et al, 2000). A 
prerequisite for that is absorbtion of HMOs in the digestive tract without being digested. 
This phenomenon was confirmed in the study by Kunz et al., 2000. In that study 13C- 
labelled galactose was administered orally to lactating mothers. That led to labelling of 
milk lactose and oligosaccharides in mammary gland, which enabled to follow 
metabolic pathways of labelled HMOs in the infants. The 13C enrichment of milk was 
analysed by isotope ratio mass spectrometry (IR-MS). The highest content of 13C was 
found in lactose, followed by neutral and, to a lesser extent, acidic oligosaccharides. 
Then the urine samples were collected from the infants fed with labelled milk. The urine 
contained 13C and its highest content was found for lactose, followed by fucosyllactose, 
LNT, Fuc-LNT and Fuc2-LNT. The presence of the HMOs in the urine indirectly proves 
their presence in the systemic circulation. The fact that some HMOs are absorbed 
without being digested in the gastrointestinal tract means that a variety of physiological 
effects of HMOs may be possible not only locally, but also after being absorbed. 
2.7.3 Potential commercial applications 
The potential commercial application of human milk oligosaccharides is obviously the 
infant formula. The fact that the compounds in the formula would be identical to the 
natural ones would make it an unbeatable product. Nowadays, the infant formulas 
contain galacto- and fructooligosaccharides, which do not naturally occur in human 
milk. The fructose monomer does not occur in human milk at all. GOS and FOS are not 
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sialylated or fucosylated, and presence of fucose and sialic acid is an important feature 
of HMOs. Addition of GOS and FOS to infant formulas stimulates the growth of 
bifidobacteria and provides some other benefits, but the long-term health benefits and 
risks of providing infants with significant amounts of these non-human milk glycans 
still need to be further investigated (Bode, 2012). 
There could be more than one product created from HMOs. Depending on the dosage, 
for example, the product could be a food ingredient with disease preventive properties 
or a therapeutic medicine. Moreover, if the production of different types of HMOs 
would not be limited, the composition of the products containing HMOs could be 
differentiated. For example, the milk desired for newborns whose mothers are Le 
positive would contain oligosaccharides with fucose attached by α-1,4 linkage, whereas 
milk for newborns whose mothers are Le negative individuals would not contain such 
oligosaccharides. In such a manner the milk formula would be as similar as possible to 
the natural ones and “personalized”. This last property could make it even more desired 
product for potential customers. Moreover, the HMOs could be used in combination 
with probiotics. The possibility to apply them in functional food for adults could be 
considered as well.  
Until now, however, the possibilities of producing HMOs are quite limited. The milk of 
farm animals is not as complex as human milk. Therefore there are not any natural 
resources that could be used to obtain HMOs in the large amounts. To perform synthesis 
of different HMOs, there are several enzymes needed to catalyse this process, such as 
trans-sialidases and trans-fucosidases. The enzymes capable of attaching N-
acetylglucosamine to oligosaccharide core would be useful as well. The β-
galactosidases could also be employed in creation of HMOs. These enzymes are 
relatively well characterized, especially for the purpose of production of 
galactooligosaccharides used in infant formulas as HMOs substitutes. All the enzymes 
used for HMOs production should have food grade status which means that they should 
not have a pathogenic origin. The advantage of enzyme catalysis is that it is an 
environmentally friendly method, on the contrary to chemical methods. The chemical 
methods are, moreover, time-consuming and require multistep reactions. Furthermore, 
the application of enzymes enables utilization of side-products from food industry and 
that would provide double benefit by generating a product and, at the same time, 
avoiding the disposal of biomass. The use of the enzymes in the production process 
would ensure that no harsh chemicals are engaged and make the products safer for 
infants. Finally, the application of HMOs as the infant formulas ingredients requires, 
regardless of used production method, exhaustive clinical trials. 
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3 METHODOLOGY 
This chapter describes experimental methods used in this PhD project. 
 
PRODUCTION OF ENZYMES IN P. PASTORIS AND THEIR PURIFICATION 
A 5 L Sartorius Biostat Aplus fermentor was inoculated with P. pastoris cells grown for 
20 hours at 30°C, at 150 rpm in shaking flasks with minimal glycerol medium as 
detailed by Stratton et al., 1999. The 5 L scale production of recombinant protein in P. 
pastoris was done essentially as described by Stratton et al., 1999 and as detailed by 
Silva et al., 2011, except that the temperature for the Glycerol Batch and Glycerol Fed-
Batch phases was 30 °C and then adjusted to 25 °C for the Methanol Fed-Batch phase in 
order to improve the stability of the enzyme. Agitation was specifically controlled 
below 750 rpm to avoid excessive cell debris from the P. pastoris cells and to limit the 
downstream purification process. Additional oxygen was added automatically to 
accommodate optimal growth and enzyme expression.  
At the end of the fermentation process the Pichia cells were collected by centrifugation 
at 5300 g, 5°C for 1 hour. The supernatant was subjected to sterile filtration, followed 
by concentration by ultrafiltration using a cross-flow bioreactor system. The enzyme 
preparations containing 25% (w/v) glycerol were stored at -80°C.  
The purification was performed by Cu2+ affinity column chromatography using a CIM® 
IDA-8f ml Tube Monolithic Column purchased from BIA Separations GmbH (Villach, 
Austria). The affinity chromatography was carried out as described by Silva et al, 2011. 
The imidazole was removed using PD-10 columns (GE Healthcare). 
 
DETERMINATION OF THE OPTIMAL CONDITIONS OF THE ENZYMATIC 
REACTIONS 
MODDE Version 7.0.0.1 (Umetrics AB, Umeå, Sweden) was used as a tool to 
design the experimental frame and to fit and analyze the data. The factors influencing 
the reactions yields were tested: pH, temperature - for all the investigated enzymes 
(endo-1,4-β-galactanase from Emericella nidulans; Trypanosoma rangeli mutant 
sialidase with 6 point mutations, Tr6; Trypanosoma rangeli mutant sialidase from Tr6 
parent with 7 point mutations, Tr13). Moreover, enzyme to substrate ratio E/S (v/w) and 
reaction time were tested for endo-1,4-β-galactanase from E. nidulans´, and acceptor 
concentration was investigated for Tr6 and Tr13. The donor substrate, casein 
glycomacropeptide (cGMP) for Tr6 and Tr13 was kept at constant concentration. The 
yield of the product was determined by reducing sugar assay in case of optimization of 
reaction conditions for endo-1,4-β-galactanase from E. nidulans and by HPAEC or 
LC/MS of the products in case of optimization of reaction conditions for Tr6 and Tr13. 
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ENZYMATIC REACTIONS 
The enzymatic reactions were done in conditions determined as the best for the 
characterized enzymes: endo-1,4-β-galactanase from E. nidulans, Tr6 and Tr13. The 
products were then fractionated by filtration – in case of degradation of galactan or 
solubilised potato pulp polysaccharides (SPPP), or purified by anion exchange 
chromatography in case of synthesis of human milk oligosaccharides (HMOs) and 
human milk- like oligosaccharides. 
 
ANALYTICAL METHODS 
High- performance size exclusion chromatography (HPSEC) was applied to determine 
progress of enzymatic degradation of potato galactan and SPPP. 
High-performance anion exchange chromatography with pulsed amperometric detection 
was used to monitor profile of oligosaccharides released from potato galactan 
(Megazyme) by the endo-1,4-β-galactanase from E. nidulans; to determine 
concentration of monosaccharides obtained by acid hydrolysis of complex saccharides;  
to determine concentration of 3’-sialyllactose, a model human milk oligosaccharide, and 
sialic acid which were produced by both Tr6 and Tr13; to detect release of arabinose 
and galacturonic acid from modified SPPP samples treated with arabinofuranosidase 
and exo-polygalacturonase, respectively. 
Acid hydrolysis of the galactan and SPPP was done by a modified method described by 
Garna et al., 2004. At a concentration of 2.5 g/L or 4 g/L each substrate was treated with 
0.2 M trifluoroacetic acid for 72 h at 80◦C. The recovery of monosaccharides was 
determined by performing the same hydrolysis on L-rhamnose, L-arabinose, D-
galactose, D-glucose, and D-galacturonic acid. 
 
BACTERIAL GROWTH ASSAYS 
The saccharide samples were dissolved in water at 10% (w/v) and sterilized by sterile 
filtration or by UV-radiation for 30 s. Different bacterial strains were tested including 
prebiotic, pathogenic and commensal bacteria. These strains were incubated in mono-
cultures with the individual substrates at concentrations of 1% (w/v) in multiwell plates 
in a Bioscreen® C system (Labsystems, Helsinki, Finland) as described by Mäkeläinen 
et al., 2010. The bacterial growth was determined as a function of OD600 and time. The 
baseline growth in the media without addition of carbohydrates was used as a control 
and subtracted from growth obtained in the presence of substrate. 
Fructooligosaccharides (Raftilose®, Beneo, Belgium) or galactan (Megazyme 
International LTD) were used as an established prebiotic standard. 
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METHODS SPECIFIC FOR CHARACTERIZATION OF ENDO-1,4-β-
GALACTANASE FROM E. NIDULANS EXPRESSED IN P. PASTORIS 
Thermostability investigation 
The thermal stability was evaluated by preincubation of the enzyme in 5 mM NaH2PO4 
buffer (pH 5) at 50, 60 and 70 ◦C for 2–60 min. After a set exposure time at the selected 
temperature, an aliquot of the enzyme solution was cooled to 50 ◦C, galactan solution 
was added and the residual enzyme activity was measured via the reducing sugar assay. 
 
Influence of metal ions on enzyme activity 
The enzyme was incubated with 10 mM EDTA for 40 min at room temperature. The 
control sample was incubated with 5 mM phosphate buffer pH 5 instead of the EDTA 
solution. After incubation with EDTA, the EDTA was removed by gel filtration (PD-10 
columns, GE Healthcare). The relevant metal ion solution was added (1 mM) to aliquots 
of EDTA pretreated and control samples, respectively (no metal addition was a 
benchmark both in the EDTA pretreated and in the control samples). The reducing sugar 
assay was used to determine the residual enzyme activity. 
 
METHODS SPECIFIC FOR MODIFICATION OF SPPP 
The SPPP was at first treated with an α-amylase to remove the residual starch. 
Subsequently it was deactetylated and demethylated by use of NaOH solution. This was 
followed by treatment with RGI lyase to degrade the remaining RGI backbone and 
make it more available for other enzymes. Obtained material was divided in four 
fractions, which were enzymatically modified in four different ways. The first fraction 
was treated with endo-1,4-β-galactanase; the second with α- L- arabinofuranosidase and 
subsequently with endo-1,4-β-galactanase; the third one with exo-polygalacturonase and 
subsequently with endo-1,4-β-galactanase; the fourth one with exo-polygalacturonase, 
then with α- L- arabinofuranosidase and eventually with endo-1,4-β-galactanase. The 
monomers that were released during incubation with arabinofuranosidase and exo-
polygalacturonase were removed by dialysis. The chain of chemical and enzymatic 
modifications that the SPPP was subjected to is shown in Figure 17 in chapter 7. 
Removal of residual starch 
The SPPP was treated with an α-amylase from Bacillus licheniformis to remove the 
residual starch present in the material. The reaction was performed in 50 mM sodium 
dihydrogen phosphate buffer pH 6, at 70°C for 85 min. The substrate concentration was 
6 g/L and the enzyme to substrate ratio (E/S) was 0.2% (v/w). The reaction was stopped 
by boiling for 10 minutes. The post-reaction mixture was then dialyzed against 
deionized water using a cross-flow Hydrosart membrane system with 2 kDa cut-off 
(Sartorius AG, Goettingen, Germany). The permeate containing glucooligosaccharides 
was discarded. 
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Deesterification 
The retentate obtained in starch removal process was subjected to treatment with 40 
mM sodium hydroxide as described by Holck et al., 2011. The mixture was then 
neutralized by use of 1 M HCl. Subsequently, filtration with a cross-flow Hydrosart 
membrane system with 2 kDa cut-off was performed to remove salts and the reaction 
product was freeze-dried. 
RGI lyase treatment 
The obtained material was incubated with RGI lyase from B. licheniformis. Reaction 
was performed for 1 h at 60°C in 10 mM EPPS buffer at pH 8. The reaction mixture 
comprised of 5 g/L of SPPP and enzyme to substrate ratio (w/w) of 2.3%. To enhance 
the enzyme activity 2 mM solution of MnCl2 was applied in the reaction mixture, as 
described by Silva et al., 2011. To stop the reaction the enzyme was heat-inactivated. 
The post-reaction mixture was dialyzed against deionized water using the same cross-
flow system as described above, and the manganese ions and EPPS buffer were 
removed from SPPP solution. The modified SPPP was lyophilized.  
α- L- Arabinofuranosidase treatment 
The incubation of SPPP material with α- L- arabinofuranosidase from E. nidulans was 
performed at substrate concentration of 6 g/L and enzyme to substrate ratio (v/w) of 
0.5%. The reaction was allowed to proceed for 2 h at 60°C and pH 5. The pH was 
adjusted with 0.5 M HCl or 0.5 M NaOH (if the reaction was done after incubation with 
exo-polygalacturonase). After heat-inactivation of the enzyme, the post-reaction mixture 
was dialyzed to remove arabinose. The retentate - product was freeze-dried. 
Exo-polygalacturonase treatment 
SPPP was incubated with exo-polygalacturonase from E. nidulans at 6 g/L of substrate 
concentration and enzyme to substrate ratio (w/w) of 1% for 2 h. The reaction 
conditions were 40ºC and pH 4, which was adjusted with 0.5 M HCl. After heat-
inactivation of the enzyme, the post-reaction mixture was dialyzed to remove 
galacturonic acid. The obtained product was lyophilized.  
Endo-1,4-β-galactanase treatment 
The incubation of SPPP with endo-1,4-β-galactanase from E. nidulans was done at 
substrate concentration of 6 g/L and enzyme to substrate ratio (v/w) of 0.3%. The 
reaction was allowed to proceed for 15 min at 50°C and pH 5. The pH was adjusted 
with 0.5 M HCl and 0.5 M NaOH. After inactivation of the enzyme, the product was 
freeze-dried 
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4 ENZYMATIC SYNTHESIS OF HUMAN MILK 
OLIGOSACCHARIDES 
This chapter is based on the publication “Biocatalytic production of 3’-sialyllactose by 
use of a modified sialidase with superior trans-sialidase activity” enclosed in chapter 
10.1. 
 
4.1 SPECIFIC HYPOTHESES AND OBJECTIVES 
Hypotheses for synthesis of human milk oligosaccharides: 
- It is possible to tune a mutated sialidase from Trypanosoma rangeli (Tr6) to 
trans-sialidase by optimizing the reaction conditions. 
- Tr6 has a potential to catalyse synthesis of human milk oligosaccharides 
(HMOs) from casein glycomacropeptide (cGMP) and oligosaccharides. 
These hypotheses were verified by conducting the following activities: 
- Optimization of reaction conditions for mutated sialidase from T. rangeli, Tr6 to 
promote its trans-sialidase activity. 
- Synthesis of human milk oligosaccharides catalysed by Tr6. 
 
4.2 RESULTS AND DISCUSSION 
An enzymatic synthesis of HMOs can be achieved by a trans-sialidase from T. cruzi, the 
causative agent of Chagas disease. However, for industrial production of food-grade 
HMOs, it is a drawback that the enzyme constitutes an important virulence factor within 
T. cruzi. Producing mutants of the non-pathogenic T. rangeli sialidase which possesses 
some trans-sialidase activity (Paris et al., 2005) is an attractive alternative for 
application in production of functional food.  
4.2.1 Production and characterization of mutant sialidase Tr6 
The enzyme produced for the purpose of generating HMOs was a mutant sialidase from 
T. rangeli, Tr6, which contained following mutations: M96V, A98P, S120Y, G249Y, 
Q284P and I37L (Paris et al., 2005). It was expressed in P. pastoris after codon-
optimization. The Tr6 contained six point mutations and included C-terminal c-myc and 
6xHis tag. A positive transformant expressing the Tr6 enzyme was selected and used for 
enzyme production at a 5 L-scale. The enzyme concentration reached 1 g/L at the end of 
fermentation. This may be considered as a high concentration, since the concentration of 
produced previously T. cruzi trans-sialidase reached only 5 mg/L (Sabesan and Paulson, 
1986). The relatively high yield of Tr6 production may be ascribed to the codon 
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optimization or to the more controlled fermentation conditions and higher cell density 
achieved in the fermentor than in the shaking flasks. 
The produced enzyme had an apparent molecular weight of about 80 kDa by SDS-
PAGE. The treatment of the Tr6 with EndoH followed by Western blotting analysis 
revealed that the expressed protein was glycosylated and the molecular weight of Tr6 
was 75 kDa after deglycosylation. 
The Tr6 mutant enzyme showed a high level of sialidase activity and a relatively low 
level of trans-sialidase activity (Paris et al., 2005). In order to change the ratio between 
hydrolytic and trans-sialidase activities, the reaction conditions were investigated. pH, 
temperature, donor and acceptor concentrations optimal for trans-sialylation were 
determined in statistically designed experiments. The optimization of reaction 
conditions was done for a model reaction of synthesis of HMOs, i.e. for production of 
3’-sialyllactose. Casein glycomacropeptide (cGMP) and lactose, side-streams from 
dairy industry, were used as substrates in synthesis of 3’-sialyllactose. Promotion of 
trans-sialidase activity occurred at 25 °C and pH of 5.5. However, in the reaction 
conducted at these conditions and with 36.8 mM lactose and 2.6 mM sialic acid bound 
in cGMP the concentration of sialyllactose was relatively low and the exhibited 
hydrolytic activity was still significant (Figure 5A). Therefore, higher concentrations of 
acceptor were tested, since the high acceptor: donor ratios are known for promoting 
trans-glycosylation reactions. The increase in lactose concentration led to the production 
of high concentration of 3’-sialyllactose by Tr6 (Figure 5B). The established conditions: 
pH 5.5., 25°C, 4.6 mM sialic acid bound in cGMP (equivalent to 26 g/L of cGMP) and 
117 mM lactose (40 g/L) tuned the mutated sialidase from T. rangeli, Tr6 into an 
effective sialyl-transferase with more than 93% trans-sialidase activity and only 7% 
residual sialidase activity. 
At the high acceptor concentration of 117mM the specific trans-sialidase activity of the 
Tr6 was determined to be 16.2 μmol·min-1·mg-1. The specific activity was thus 4 times 
higher than the reported Vmax of the T. cruzi trans-sialidase which was 3.8 nmol·min- 
1·μg-1 measured using 3’-sialyllactose as the donor and lactose as the acceptor (Paris et 
al., 2005). It was also 450 times higher than the rate at which trans-sialidase from T. 
cruzi catalysed synthesis of sialyllactose when 5 g/L cGMP and 20 g/L lactose were 
used as substrates (Pelletier et al., 2001). A sialidase from Bifidobacterium infantis 
catalysed trans-sialylation, employing high levels of both cGMP and lactose (McJarrow 
et al., 2003), and produced only low level of sialyllactose at a rate which was 87-fold 
lower than that obtained with Tr6. 
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A) 
 
B) 
 
Figure 5. A) Accumulation of 3’-sialyllactose and sialic acid over time (25 min) at low 
concentration of lactose: 36.8 mM lactose, at 25°C, pH 5.5, and 2.6 mM sialic acid contained in 
cGMP; measured by HPAEC-PAD; 3’-sialyllactose is shown in violet and sialic acid in green. 
B) Accumulation of 3’-sialyllactose over time at high lactose concentration, 117 mM lactose, 
25°C, pH 5.5, and 4.6 mM sialic acid bound in cGMP; measured by LC/MS. No free sialic acid 
was detected. 
4.2.2 Production of HMOs 
When the reaction conditions promoting transfer of sialic acid were established, the 
synthesis of 3’-sialyllactose was performed in a 5L scale. 5.3 mg/L of Tr6 was 
incubated for 20 min at pH 5.5, 25 °C, with 117 mM lactose and 4.6 mM sialic acid 
residues bound in cGMP. After heat-inactivation of the enzyme, the product was 
purified in two steps: at first by ultrafiltration to remove cGMP and Tr6, which was 
followed by freeze-drying, and then by anion exchange chromatography using 
ammonium formate as the eluent (Figure 6). 
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Figure 6. Purification of 3’-sialyllactose by anion exchange chromatography. The green line 
indicates the elution gradient with 40 mM ammonium formate. 
The high quality of the separation of 3’-sialyllactose from sialic acid and lactose, as 
well as the identity of this compound was confirmed by capillary LC/MS and NMR 
spectroscopy. The removal of ammonium formate was, however, troublesome. The 
samples had to be lyophilized six times to remove the buffer and achieve its content in 
the product below 5%. The final yield of 3’-sialyllactose was 3.6 g, and the amount of 
free sialic acid was 133 mg. About 50% of the sialic acid residues in the cGMP are 
bound at the 3’- position, whereas the rest is bound at the 6’-position (Saito and Itoh, 
1992). Since Tr6 catalysed only the production of 3’-sialyllactose, it can be assumed 
that only 3’-bound sialic acid, i.e. about 50% of the total sialic acid in cGMP, was 
available for this enzyme. Therefore, the molar yield of 3’-sialyllactose was 47.7% 
based on the available 3’-sialic acid in cGMP. The molar yield of the 3’-sialyllactose 
was 1% on the lactose, and the yield of free sialic acid was 2% based on the total sialyl-
residues in the cGMP.  
The Tr6 was also able to catalyse the transfer of sialic acid moiety to lacto-N-tetraose 
(LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I) and lacto-N-
fucopentaose V (LNFP V) (their structures are shown in Figure 7). The trans-sialidation 
of these compounds was done at much smaller scale that the 3’-sialyllactose production 
due to the limited amount of the acceptors. The yields of these products were lower than 
the yield of 3’-sialyllactose. 5-12 mg of sialylated LNT, LNnT, LNFP I and LNFP V 
were produced at pH 5.5, 25 °C and as high as possible acceptor/donor ratio.  
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Figure 7. The structures of sialylated oligosaccharides; a) LNT; b) LNnT; c) LNFP I; d) LNFP 
V. 
 
4.3 CONCLUSION 
The mutant sialidase from T. rangeli, Tr6 was tuned into an effective trans-sialidase by 
manipulating the reaction conditions. At the improved conditions the enzyme 
synthesized 3'-sialyllactose from lactose and cGMP donating sialic acid. Other 
sialylated HMOs molecules were also produced by this enzyme, i.e. lacto-N-tetraoses 
and lacto-N-fucopentaoses. The versatility of the Tr6 trans-sialidase for generating 
different HMOs was therefore demonstrated. The possibility to create a value-added 
product from side-streams was demonstrated too. This constitutes an asset for 
developing a competitive process for novel functional food ingredients. 
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5 ENZYMATIC SYNTHESIS OF HUMAN MILK-
LIKE OLIGOSACCHARIDES 
This chapter is founded on the publication “Rational design of a new Trypanosoma 
rangeli trans-sialidase for efficient sialylation of glycans” enclosed in chapter 10.2.  
 
5.1 SPECIFIC HYPOTHESES AND OBJECTIVES 
The hypotheses were following: 
- It is possible to diminish hydrolytic activity or increase trans-sialidase activity of 
T. rangeli mutant sialidase Tr6 by introducing further mutations.  
- It is possible to synthesize human milk and human milk-like oligosaccharides by 
use of a new mutant sialidase, Tr13. 
- Human milk-like oligosaccharides exhibit similar biological properties as these 
of HMOs, including prebiotic activity. 
The aims were: 
- To compare hydrolytic and trans-sialidase activities of parent clone Tr6 and the 
derived new mutants. 
- To determine reaction conditions for trans-sialylation catalysed by the best 
mutant, Tr13. 
- To use Tr13 to catalyse synthesis of human milk-like oligosaccharides. 
- To investigate prebiotic properties of sialylated glycans produced by means of 
Tr13. 
 
5.2 RESULTS AND DISCUSSION 
5.2.1 Production and characterization of trans-sialidase Tr13 
In order to identify mutations likely to affect enzyme activity, amino acids within 14 Å 
of the sialic acid-binding site were investigated. Basing on an alignment between 
mutated T. rangeli sialidase Tr6 and the efficient trans-sialidase of T. cruzi, the 
chemical difference between amino acids, assuming that larger chemical differences, 
correlating with lower probability of occurrence by random evolution, were the most 
likely candidates for conferring increased trans-sialidase activity and/or reduce 
unwanted hydrolysis. Seven amino acids 197-203 at the border of substrate binding cleft 
were substituted in Tr6 from IADMGGR to VTNKKKQ to achieve the same amino 
acids as in T. cruzi trans-sialidase (TcTS). The new motif introduced in Tr6 had a net 
charge change from neutral to +3. The new enzyme was called Tr13. A homology 
model of mutant Tr13 based on Tr6 with the additional seven mutations is shown in 
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Figure 8. The mutations are relatively far, ~14 Å, from the acceptor binding cleft and 
therefore unlikely to affect acceptor binding directly. The highly unusual +3 charge and 
increase of hydrogen bond donation implies that the water network may be inverted. 
This could change the electrostatic field in the cleft, and potentially disrupt or even 
reverse the water network in the active site, which could result in decreased hydrolytic 
activity of the enzyme. 
 
 
 
Figure 8. Close-up of active site with sialyllactose docked (blue). Acceptor binding site residues 
Tyr-120 and Trp-313, and catalytic nucleophile Tyr-343 side chains are shown in grey. The 
seven introduced amino acids are shown in yellow. 
 
Besides the seven-amino acids motif introduced in Tr13, several single mutations were 
made from Tr6. The mutations were chosen because of their positions close to the 
binding cleft and/or by their chemical difference. The mutants were produced in P. 
pastoris shaking flasks cultures and their trans-sialidase activity was tested. Only Tr13 
and Tr6 D363E performed at a level comparable to Tr6 while all other mutants 
displayed a decreased trans-sialidase activity. 
Mutants Tr13 and Tr6 D363E were then produced in 5L scale. This enabled further 
evaluation of their hydrolytic and trans-sialidase activities (Figure 9). Hydrolase activity 
was tested on para-nitrophenyl neuraminic acid (pNP-NeuAc), cGMP, 3’-sialyllactose and 
6’-sialyllactose. None of the enzymes: Tr6, Tr6 D363E and Tr13 was active on 6’-
sialyllactose. Therefore it was unlikely that the α-2,6-linked sialic acid in cGMP was used 
by these enzymes in trans-sialylation reaction. The α-2,6-linked sialic acid constitutes about 
50 % of total sialic acid content in cGMP (Saito and Itoh, 1992). 
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Figure 9. Enzyme activity of Tr6 and selected mutants Tr13 and Tr6 D363E. A) Hydrolase 
activity on substrates pNP-NeuAc, 3’-sialyllactose (3-SL), and cGMP. B) Trans-sialidase 
activity using cGMP as sialic acid donor and 4-methylumbelliferyl-β-D-galactopyranoside 
(MU-Gal) as acceptor. 
Tr13 had lower hydrolytic activity than Tr6 on p-nitrophenyl neuraminic acid, cGMP 
and 3’-sialyllactose. Tr6 D363E had hydrolytic activity lower than Tr6 only on the 
artificial substrate pNP-NeuAc (Figure 9 A). Figure 9 B shows results of trans-sialidase 
activity assay. The initial reaction rate represents the trans-sialidase reaction. The 
maximal product concentration represents both trans-sialidase and hydrolase activity, 
since the product is created and hydrolysed at the same time by the enzyme. As can be 
seen, Tr13 and Tr6 have the same transferase activity, but Tr13 has lower hydrolytic 
activity and therefore more product can be accumulated in the reaction mixture. The 
product concentration is two times higher in case of Tr13 than Tr6. This can be 
attributed to the seven-amino acids motif introduced into Tr13 structure. The improved 
product yield, in case of Tr13, suggests that this motif does not influence acceptor 
binding affinity, but reduces the hydrolytic activity. Tr13 is then hydrolysis-impaired 
sialidase mutant. 
Determination of reaction conditions favouring the trans-sialidase activity of Tr13 was 
performed by statistically designed experiments. Temperature (20-60 °C), pH (3-5) and 
acceptor – lactose concentration (117-351 mM) were investigated, whereas donor- 
cGMP concentration was kept fixed at 8mM cGMP-bound sialic acid. Reactions were 
performed for 20 min and stopped by heat-inactivation of the enzyme at 90 °C. The 
product- 3’-sialyllactose concentration was determined by HPAEC. No product 
formation was observed in controls with heat-inactivated enzyme. The highest product 
yield was obtained at 351 mM lactose, pH 3 and 20 ºC. A time study was conducted at 
these conditions (Figure 10) and the enzyme specific trans-sialidase activity was 
measured to be 4.4 ± 0.7 nmol*min-1 per μg of enzyme. From the time study depicted in 
Figure 10 it can be seen that the reaction time could be extended to 100 min with 
beneficial increase of product concentration. 
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Figure 10. Time study of trans-sialylation catalysed by Tr13. Accumulation of 3’-sialyllactose 
over time in 20°C, pH 3, 351 mM lactose and 8mM cGMP-bound sialic acid. 
 
5.2.2 Production of human milk- like oligosaccharides 
When the reaction conditions for trans-sialidase activity of Tr13 were established, the 
acceptor specificity of the enzyme was tested by incubating Tr13 with different acceptor 
molecules. The purpose was to synthesize molecules of similar structures to the human 
milk oligosaccharides, since they could exhibit similar biological effects and at the same 
time, they would be cheaper to produce, because production of HMOs other than 
sialyllactose is very expensive due to the expensive acceptor substrates. The acceptors 
for production of human milk- like oligosaccharides were some prebiotics, i.e. 
galactooligosaccharides, iso-maltooligosaccharides and lactulose. Combining the 
prebiotic effect with sialic acid could result in enhanced beneficial activity. 
Furthermore, two compounds similar in structure to lactose, i.e. maltose and melibiose 
were chosen as substrates, because they seemed to be relatively easy to sialylated by the 
enzyme. One monosaccharide – fucose was used as a substrate as well, since the human 
milk oligosaccharides contain fucose and sialic acid in their structures. It seemed to be 
interesting to synthesize and investigate the properties of molecule, which possess both 
these functional moieties - sialylfucose. 
For TcTS it is generally accepted that terminal galactose is an acceptor of sialic acid 
moiety (Cross and Takle, 1993). By the means of Tr13 it was possible to employ not 
only terminal galactose, but also terminal glucose, as well as glucose and fucose 
monomers as attachment sites for sialic acid. The sialylated oligosaccharides were 
produced at pH 3, ambient temperature, 351 mM sialic acid acceptor and 8 mM cGMP-
bound sialic acid by incubation for 20 minutes. After deactivation of the enzyme, the 
products were purified by ultrafiltration to remove cGMP and enzyme and subsequently 
by anion exchange chromatography with ammonium formate as eluent (Figure 11). In 
the purification by chromatography the unbound fraction contained unreacted neutral 
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acceptor, which was eluted with water. Sialylated products, negatively charged, were 
eluted with 40 mM ammonium formate. They were followed by free sialic acid, also 
eluted with 40 mM ammonium formate. According to LC/MS analysis the products 
were completely separated from sialic acid and their precursor acceptor. The highest 
yields were achieved when fucose (1.5 mM) and lactulose (1.9 mM) were used as the 
acceptors (Table 6). The product yields of GOS and IMO were lower. GOS and IMO 
were mixtures of oligosaccharides of different DP. The product yields for different DP 
might have been different from the average. There were four sialylated oligosaccharides 
generated from GOS, including 3’-sialyllactose, and five created from IMO, including 
sialylglucose (Table 6). Since sialyllactulose was produced in the highest molar yield, it 
could be speculated that the presence of galactose and the 1,4-β bond between galactose 
and fructose might make it more easily accessible for Tr13, since the yield of the 
similar-size acceptors melibiose (1,6-α-bound galactose) and maltose (1,4-α-bound 
glucose) was more than 40 % lower.  
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Figure 11. Anion exchange chromatogram of purification of sialylated glycans.  
 
The fact that Tr13 sialylated not only terminal galactose, but also terminal glucose and 
even glucose and fucose monomers was surprising and indicated a high level of 
acceptor substrate promiscuity. This broad specificity may have a great potential in the 
synthesis of many sialylated glycans. 
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acceptor m/z product product 
conc. 
product yield 
 [M-H]-  [g/L] [wprod/waccep] [mM] 
GOS 632 SA-α-Gal-1,4-β-Glc 1.0 0.44% ND 
 794 SA-α-Gal-1,4-β-Gal-1,4-β-Glc    
 956 SA-α-Gal-1,4-β-Gal-1,4-β-Gal-1,4-β-Glc    
 1118 SA-α-Gal-1,4-β-Gal-1,4-β-Gal-1,4-β-Gal-1,4-β-Glc    
Fucose 454 SA-α-Fuc 0.66 1.17% 1.46 
Melibiose 632 SA-α-Gal-1,6-α-Glc 0.62 0.52% 0.98 
Lactulose 632 SA-α-Gal-1,4-β-Fru 1.2 0.97% 1.84 
Maltose 632 SA-α-Glc-1,4-α-Glc 0.66 0.55% 1.04 
IMO 470 SA-α-Glc 0.72 0.60% ND 
 632 SA-α-Glc-α-Glc    
 794 SA-α-Glc-α-Glc-α-Glc    
 956 SA-α-Glc-α-Glc-α-Glc-α-Glc    
 1118 SA-α-Glc-α-Glc-α-Glc-α-Glc-α-Glc    
 
Table 6. Products of sialylation of various glycans analysed by LC/MS. Yields are given as 
product concentration and as % (w/w) of product produced from acceptor used. ND: the molar 
concentration of sialylated GOS and IMO could not be calculated since the distribution of 
different chain lengths was not determined. Abbreviations: SA, sialic acid; Gal, galactose; Glc, 
glucose; Fuc, fucose; Fru, fructose. 
5.2.3 Investigation of prebiotic properties of sialylated glycans 
The enzymatically synthesized sialylated glycans were tested in single bacterial cultures 
towards potential prebiotic properties. Six strains of bifidobacteria were tested: B. 
longum longum (Danisco Global Culture Collection DGCC 232), B. longum infantis 
(DGCC 233), B. longum infantis (DGCC 1497), B. longum infantis (DGCC 2238), B. 
longum (Bl-05, DGCC 9917), B. lactis (HN019, DGCC 2013). L. acidophilus (NCFM, 
ATCC 700396) and C. perfringens (ATCC 13124) were tested as well. The experiments 
were done in a Bioscreen microtiter system, and the bacterial growth was expressed as 
an area under the growth curve (Mäkeläinen et al., 2010). 
The results of bacterial growth on sialylated glycans are presented in Table 7. Sialylated 
melibiose and maltose did not promote growth of prebiotic bacteria. The growth of B. 
infantis 233, B. infantis 1497, and B. longum 232 was promoted by different sialylated 
compounds while sialylated fucose promoted growth of all three. The growth of B. 
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infantis 2238, B. lactis, L. acidophilus, and B. longum 9917 was not promoted by the 
sialylated compounds.  L. acidophilus, however, grew well on the prebiotic control-
galactan. L. acidophilus is known for possessing β-galactosidase which should enable 
its growth on galactan (Schwab and Gänzle, 2011). Moreover, in the publication by 
Schwab and Gänzle, 2011, L. acidophilus was reported to exhibit only a very weak 
growth on 3’sialyllactose, whereas it grew well on 6’-sialyllactose. This could explain 
why it did not grow on other oligosaccharides containing 3’-sialyl group. C. perfringens 
grew significantly better than all the probiotic strains on the sialylated compounds, 
except sialylmelibiose, on which the growth was not investigated due to the lack of 
material. 
Bacterial strain Area under the growth curve [OD600 x min] 
 MRS- S-GOS 
S-
fucose 
S-
melibiose 
S-
lactulose 
S-
maltose S-IMO galactan 
B. infantis 233 30 ± 14 
132 ± 
5 71 ± 6 14 ± 6 109 ± 20 30± 4 95 ± 23 55 ± 7 
B. infantis 
2238 
294 ± 
68 
274± 
18 
285± 
15 302 ± 2 269± 20 158± 24 269± 6 264± 7 
B. infantis 
1497 31± 10 
42 ± 
13 149 ± 2 ND 34± 2 ND 45± 1 40± 9 
B. longum 232 79± 20 162± 9 192 ± 20 104± 17 134± 19 122± 31 
107± 
19 42±13 
B. lactis 139± 70 
176 ± 
18 
192± 
27 ND 122±18 102± 8 
175± 
13 143± 15 
L. acidophilus 180± 28 159± 4 
188± 
18 192 ± 4 128± 2 193± 12 
217± 
19 371± 10 
B. longum 
9917 
106± 
30 71± 5 
114± 
15 70± 8 34± 14 101± 6 103± 9 93± 44 
C. perfringens 455± 32 
722± 
52 
811± 
48 ND 541± 17 844 ± 99 
1098± 
61 
447 ± 
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Table 7. Bacterial growth on sialylated glycans is given as an area under the growth. Growth 
responses for the substrates are shown for a substrate concentration of 10 g/L for all bacterial 
strains. Data are given as average values of 3 replicates  s.d. The growth of B. longum infantis 
1497, B. lactis and C. perfringens was not tested on sialylmelibiose, as well as growth of B. 
longum infantis 1497 on sialylmaltose (ND). Galactan was used as a control. 
Despite variations in growth, some of the probiotic bacteria were able to utilize 
sialylated saccharides. The sialylated compounds did not, however, stimulate selectively 
their growth. A prerequisite for utilizing the sialylated compounds should be the 
presence of a sialidase and/or the ability to degrade the prebiotic backbone. All the B. 
longum subsp. infantis strains contain a sialidase and C. perfringens also contains the 
necessary enzymes for metabolising sialic acid (Walters et al., 1999). Therefore, a 
mixed culture experiment that would reflect the conditions in the human gastrointestinal 
tract, e.g. cross-feeding effect between bacteria or release of short chain fatty acids and 
their influence on different strains, especially pathogenic, is required to assess the 
prebiotic properties of human milk-like oligosaccharides. In the publication by Yu et al., 
2013 three fucosylated HMOs were shown to stimulate bifidobacteria, while E. coli and 
C. perfringens were unable to utilize these compounds. The fermentation products, i.e. 
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SCFA inhibited the growth of pathogens. It might be speculated that this could also take 
place in a mixed cultures when sialylated glycans will be used. 
 
5.3 CONCLUSION 
Hydrolytic activity of sialidase from T. rangeli, Tr6 was decreased by introducing 
mutations on the border of substrate binding site. By the means of the new mutated 
sialidase, Tr13 it was possible not only to produce a model human milk oligosaccharide 
– sialyllactose, but also other sialylated glycans – human milk-like. The generated 
sialyloligosaccharides have a significant potential as functional food ingredients. Their 
production is expected to be cheaper than production of HMOs, since the acceptors used 
to obtain human milk- like oligosaccharides were much cheaper that these applied in 
HMOs production (with lactose being an exception). The presence of sialyl moiety in 
their structures raises expectations that they may act as pathogen decoy molecules and 
immune system modulators, as HMOs do. Moreover, they are presumed to possess 
prebiotic properties. The fact that they did not reveal distinguished bifidogenic 
properties in the single cultures experiments is disappointing, but can be reasonable 
explained by not including bacterial interactions in these experiments. Therefore further 
prebiotic tests with mixed bacterial cultures are required to evaluate the prebiotic 
properties of sialylated glycans. 
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6 ENZYMATIC DEPOLYMERIZATION OF 
POTATO POLYSACCHARIDES 
This chapter is based on the publication “Expression and characterization of an endo-
1,4-ß-galactanase from Emericella nidulans in Pichia pastoris for enzymatic design of 
potentially prebiotic oligosaccharides from potato galactans” enclosed in chapter 10.3., 
and on publication “The binding of zinc ions to Emericella nidulans endo-ß-1,4-
galactanase is essential for crystal formation” enclosed in chapter 10.4. 
 
6.1 SPECIFIC HYPOTHESES AND OBJECTIVES 
The hypotheses on enzymatic depolymerization of galactan and the so-called soluble 
potato pulp polysaccharides (SPPP) were as follows: 
- It is possible to produce galactopoly- and oligosaccharides from pure galactan 
and SPPP. 
- Endo-1,4-ß-galactanase from Emericella nidulans can be produced in P. pastoris 
in high amount and purified efficiently. 
- Both galactan and SPPP are the right substrates for endo-1,4-ß-galactanase from 
E. nidulans. 
- Products of enzymatic hydrolysis of SPPP and galactan possess prebiotic 
activity. 
Verification of these hypotheses was done by: 
- Production and purification of endo-1,4-ß-galactanase from E. nidulans. 
- Establishing the optimal working conditions of endo-1,4-ß-galactanase from E. 
nidulans using galactan as substrate. 
- Production and fractionation of galactose rich poly- and oligosaccharides by 
degradation of galactan and SPPP with endo-1,4-ß-galactanase. 
- Determination of prebiotic potential of SPPP and galactan-derived products. 
 
6.2 RESULTS AND DISCUSSION 
6.2.1 Production and characterization of endo-1,4-β-galactanase 
As mentioned above, the objective of this study was to use potato β-1,4-galactan and the 
SPPP as substrates for enzymatic production of potentially prebiotic compounds of 
lower and narrower molecular weight. To achieve that an endo-1,4-β-galactanase from 
Emericella nidulans, GH family 53, was produced in a recombinant Pichia pastoris 
strain. The endo-1,4-β-galactanase from E. nidulans expressed in P. pastoris was 
produced in 5L fermentor. The level of extracellular protein in the fermentation reached 
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2.11 g/L after 95 h. The endo-1,4- β-galactanase activity was 109 kU/L. After the 
fermentation centrifugation, sterile filtration and ultrafiltration was performed. The 
concentrated protein solution was purified by affinity chromatography. The imidazole 
buffer used for elution of the enzyme from the column was removed by gel filtration. 
The yield of endo-1,4-β-galactanase in fermentation was 1.6 g/L. This level of 
heterologously expressed protein may be considered as high (Macauley-Patrick et al., 
2005). 
The optimal reaction conditions of E. nidulans endo-1,4- β-galactanase were determined 
in statistically designed experiments, in which potato galactan bought from Megazyme 
was used a substrate. The following factors were investigated: pH, temperature, reaction 
time and enzyme to substrate ratio, E/S (v/w). The optimal pH and temperature were 
determined to 5 and 49 ◦C, respectively (Figure 12). 
The kinetic parameters KM and vmax for the endo-1,4-β-galactanase was determined to 
be 0.51 g/L and 73.3 U/mg of protein, respectively, using a Hanes plot. The 
investigation of the thermal stability showed that the enzyme was stabilized by the 
presence of the substrate. Without the substrate, the endo-1,4-β-galactanase had a half-
life time, t½ of 57 min at 40 ◦C, 27 min at 49 ◦C and 10 min at 60 ◦C. 
 
Figure 12. Surface response of the endo-1,4-β-galactanase activity as a function of temperature 
and pH. The colours vary from blue (low endo-1,4-β-galactanase activity) to red (high endo-1,4-
β-galactanase activity). 
The influence of metal ions on the enzyme activity was tested, too. The enzyme was 
pretreated with EDTA prior to incubation with the metal ions. The activity was not 
affected much by the metal ions. The strongest negative influence had Al3+, whereas the 
strongest positive effect was achieved by incubation with Zn2+ (Table 8). A minor 
increase in the enzyme activity occurred also in samples incubated with Ca2+ and Mn2+. 
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The literature describes the influence of metal ions on fungal galactanases as weak, but 
inhibitory. For example, Zn2+ and Ag+ decrease activity of endo-β-1,4-galactanases 
from Aspergillus niger and Aspergillus aculeatus (van de Vis et al., 1991). The 
explanation for improvement of activity of endo-β-1,4-galactanase from E. nidulans 
expressed in P. pastoris in the presence of divalent metal ions, especially Zn 2+, was 
found out during crystallization of the enzyme. 
pre-treatment metal added      activity (%) 
none None 100 ± 3.6 
none AlCl3 73.3 ± 6.4
none MgCl2 92.7 ± 3.3
none MnCl2 89.2 ± 1.9
none ZnCl2 105.7 ± 4.9
none CaCl2 98.7 ± 5.2
EDTA None 87.7 ± 1.2
EDTA AlCl3 51.3 ± 3.3
EDTA MgCl2 90.8 ± 4.9
EDTA MnCl2 104.4 ± 0.3
EDTA ZnCl2 107.5 ± 2.2
EDTA CaCl2 103.5 ± 2.7
Table 8. Influence of metal ions on the endo-1,4-β-galactanase activity. 
For the purpose of crystallization the endo-β-1,4-galactanase was purified by 
chromatography, as described above. The enzyme solution was concentrated and higher 
molecular weight aggregates of protein were removed by centrifugation. The 
crystallization trials were carried out at room temperature. After five months a box-
shaped single crystal appeared in only one crystallization mixture containing zinc 
acetate. The structure of endo-1,4-β-galactanase from E. nidulans expressed in P. 
pastoris was determined by the molecular replacement method using endo-1,4-β- 
galactanase from A. aculeatus (having 72.5% sequence identity) as a search model. The 
endo-1,4-β-galactanase from A. aculeatus crystallized in the presence of calcium ions 
revealed only one calcium ion located in its structure. One calcium ion was also found 
in the endo-1,4-β-galactanase from B. licheniformis, the least similar to E. nidulans 
enzyme. The structure of E. nidulans endo-1,4-β-galactanase showed 15 zinc ions 
bound in its structure. Figure 13 shows an overlay of endo-1,4-β-galactanase from E. 
nidulans with the closest galactanase from A. aculeatus and the least similar bacterial 
galactanase from B. licheniformis. 
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The fact that the galactanase from E. nidulans acted as a “zinc sponge” was surprising, 
especially in the context of the structures of other galactanases. Fourteen of fifteen zinc 
ions bound to the structure of E. nidulans endo-1,4-β-galactanase were bound to the 
surface of the enzyme. Furthermore, about half of the zinc ions bridged the enzyme 
molecules in the unit cells. This phenomenon explains why zinc ions were indispensable 
for crystallization of the enzyme. In the literature there are known examples of proteins 
with metal ions from the crystallization conditions bound to the surface (Fass et al., 
1997). Moreover, the 15 zinc ions compensate the 29 negative charges of the E. 
nidulans galactanase polyanion and this also helps in the crystallization process and 
bridges different enzyme molecules in the unit cell. 
 
 
Figure 13. Endo-1,4-β-galactanase from E. nidulans (in green) superimposed on endo-1,4-β-
galactanases from A. aculeatus (in blue) and B. licheniformis (in violet). Zinc ions are shown as 
green spheres and calcium ion in B. licheniformis endo-1,4-β-galactanase is shown as violet 
sphere. 
Since the structure did not suggest any catalytic role of the zinc ions, the slightly 
increased activity of the endo-1,4-β-galactanase in the presence of the zinc ions may be 
explained by their stabilizing effect on the enzyme structure by neutralization of the 
surface charge and by better interactions of neutral enzyme with the substrate. 
6.2.2 Production of galactosaccharides by means of endo-1,4- β-galactanase  
The SPPP, which molecular weight was higher than 400 kDa, were prepared from 
potato pulp via a short, minimal enzyme treatment with pectin lyase and 
polygalacturonase, as described by Thomassen et al., 2011. Products of degradation of 
SPPP with endo-1,4-β-galactanase from E. nidulans expressed in P. pastoris were 
obtained by treatment of the substrate for 15 min at enzyme to substrate ratio E/S (v/w) 
ratio of 0.3%. After incubation for 15 min the enzyme was heat-inactivated. The size 
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exclusion chromatogram of the post-reaction mixture is shown in Figure 14. This 
mixture was separated by filtration with 10 kDa membrane and two fractions were 
obtained, the permeate fraction SPPP1 and the retentate fraction SPPP2. 
 
Figure 14. HPSEC analysis of E. nidulans endo-1,4-β-galactanase-catalysed hydrolysis of 
SPPP. 
The potato galactan from Megazyme, which had molecular weight of about 150 kDa, 
was treated with endo-1,4-β- galactanase in the same manner as SPPP. Different 
reaction conditions were used: 15 min of incubation and E/S (v/w) ratio of 0.3%, 270 
min and E/S (v/w) ratio of 0.3%, and 60 min with E/S (v/w) ratio of 0.03% (Figure 15). 
The obtained post-reaction mixtures were filtered. The mixture produced by incubation 
for 60 min was separated with 3 and 10 kDa into two fractions: below 3 kDa (fraction 
PG1; where PG means potato galactan) and between 3 and 10 kDa (PG2). From the 
substrate incubated for 15 min a fraction below 10 kDa (PG3) and between 10 and 100 
kDa (PG4) was produced. From the substrate incubated with enzyme for 270 min a 
fraction of oligosaccharides below 3 kDa (PG5) was generated 
Analysis by HPAEC showed that the products of galactan degradation with endo-1,4-β- 
galactanase from E. nidulans contained free galactose, especially fraction PG5. The 
long incubation time in connection with high enzyme dosage supported the release of 
galactose. Therefore the exo-β-1,4-galactosidase activity of the enzyme was 
investigated. The endo-1,4-β- galactanase from E. nidulans was not, however, able to 
hydrolyse p-nitrophenyl-β-D-galactopyranoside, the compound commonly used to 
determine the exo-galactosidase activity. Another explanation of generating galactose 
monomer by endo-1,4-β- galactanase was that this enzyme acted according to the 
multiple attack mechanism. The theory of the multiple attack mechanism assumes 
sliding of the enzyme along the substrate polysaccharide chain without dissociation 
between successive cleavages (Mazur and Nakatani, 1993). The multiple attack 
mechanism may result in the production of saccharides of different DP, including 
monomers. Moreover, the high content of galactose was reported also in the products 
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obtained by hydrolysis with other endo-1,4-β- galactanases, for example in the 
publication by Yamaguchi et al., 1995. 
 
Figure 15. HPSEC analysis of E. nidulans endo-1,4-β-galactanase – catalyzed hydrolysis of 
potato galactan. 
6.2.3 Investigation of prebiotic potential of produced galactosaccharides 
The potential prebiotic properties of the produced fractions of poly- and 
oligosaccharides generated by enzymatic catalysis of SPPP and galactan were evaluated 
by single cultures growth using a Bioscreen microtiter system. The growth performance 
expressed as an area under the growth curve (Mäkeläinen et al., 2010) was assessed for 
three probiotic strains, L. acidophilus (NCFM, ATCC 700396), B. longum (Bl-05, 
Danisco Global Culture Collection, DGCC 9917), and B. lactis (HN019, DGCC 2013), 
one pathogenic strain of C. perfringens (ATCC 13124), and one commensal strain of E. 
coli (ATCC 11775). Fructooligosaccharides and galactan were used as established 
prebiotic standards (Ziemer and Gibson, 1998). 
The growth of each bacterium was affected differently by the different compounds and 
different bacteria responded differently to one substrate (Figure 16). The PG5 fraction 
(<3 kDa, 270 min, E/S 0.3%) stimulated the growth of L. acidophilus and B. longum 
significantly better than other products of enzymatic hydrolysis. The stimulation of the 
growth of L. acidophilus was at the same level as that achieved with FOS but 
significantly better (p < 0.05) than that obtained with pure galactose and substrate for 
enzymatic hydrolysis - galactan. The stimulation of B. longum was more than 6-fold 
better than that by FOS and significantly better (p < 0.05) than that achieved by 
galactose and galactan. On the other hand, the growth of E. coli and C. perfringens on 
PG5 was higher than their growth on FOS, although for E. coli the same as on galactose 
and for C. perfringens lower than on galactose.  
The PG1 fraction (<3 kDa, 60 min, E/S 0.03%) and the SPPP1 (<10 kDa fraction 
generated by digestion of SPPP for 15 min, E/S 0.3%) stimulated the growth of L. 
acidophilus and B. longum to a significant extent too. The stimulation of B. longum 
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growth by PG1 and SPPP1, as well as by PG4 was significantly better than that 
obtained with either FOS, galactose or galactan (p < 0.05). Another positive finding was 
that the stimulation of growth of C. perfringens by samples PG1, PG4 and SPPP1 was 
lower than the stimulation by FOS. The only drawback of these substrates was relatively 
high growth of E. coli - higher than on FOS. 
 
Figure 16. Growth of bacterial strains on E. nidulans endo-1,4-β-galactanase catalysed  
hydrolysis products from potato galactan and SPPP. Substrates were used at concentration of 10 
g/L for all bacterial strains. Data are given as average values of 3-6 growth assay replicates and 
shown  s.d. Galactose and FOS were used as controls. 
The fractions PG1, PG3, PG5, and SPPP1 all contained low molecular weight oligomers 
and some galactose, which might explain some of the growth stimulation of L. 
acidophilus and B. longum promoted by these substrates. However, the growth of B. 
longum was better on all these fractions than on galactose. This may indicate that each 
of these hydrolysates contained structures, of relatively low molecular weight, which 
stimulated the growth of B. longum very effectively. The data also showed that the 
growth of both E. coli and C. perfringens was not supported by low molecular weight 
samples, besides PG5, as well as by PG2 and PG4 – high molecular weight fractions 
and galactan. 
The high molecular weight fraction SPPP2 was tested at lower concentration than the 
other samples due to its high viscosity in the solution at this dosage level. Therefore, it 
is not possible to compare it with the others. It can be, however, concluded that SPPP2 
did not support the growth of any of the investigated microorganisms to a high extent. 
Analysis of the Bioscreen data showed that among the tested samples the lower 
molecular weight fractions exhibited more potentially prebiotic features. Whether the 
observed low or no growth supporting effects on C. perfringens have any effect in the 
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competition among the bacteria in the mixed microbiota in the gut needs further 
research. The studies in mixed bacterial cultures will enable not only to investigate the 
stimulation or its lack for pathogens, but also may result in revealing enhanced prebiotic 
properties of the tested compounds. This depends on the pool of enzymes possessed by 
the probiotic and pathogenic microorganisms. It seems that the growth of bifidobacteria 
should be promoted effectively by the galactooligo- and polysaccharides, since these 
bacteria are often mentioned to possess endo- and exo- galactanase activities. On the 
other hand, the pathogens may exhibit the same enzyme activities or may benefit from 
the products of metabolism of bifidobacteria and thus grow well in the gastrointestinal 
tract. However, the widely described products of bifidobacteria metabolism are SCFA, 
which should decrease pH in the large intestine and therefore prevent growth of 
pathogens. 
 
6.3 CONCLUSION 
A very active endo-1,4-β-galactanase from E. nidulans expressed in P. pastoris was 
successfully produced in a high yield. It was purified efficiently by affinity 
chromatography and gel filtration, and the purification enabled crystallization of the 
enzyme. The crystallization revealed that there were fifteen zinc ions bound to the 
protein. The enzyme was characterized by determination of its kinetic parameters and 
thermostability. 
The endo-1,4-β-galactanase was used to produce a range of poly- and oligosaccharides 
from high molecular weight galactan-rich potato fibers (SPPP), as well as from isolated 
potato galactan. The hydrolysis of polysaccharides by endo-1,4-β-galactanase resulted 
in many fractions of different molecular size, depending on the applied enzyme amount 
and reaction time. The products of polysaccharides degradation were separated by 
filtration. Majority of obtained fractions revealed significant prebiotic potential on 
single strain cultures. 
The production of galactosaccharides from potato pulp, a side-stream from starch 
manufacturing, demonstrated possibility to generate a new value-added product for an 
agricultural industry. The release of galactosaccharides from potato waste can be 
therefore an important step in developing competitive process for new functional food 
ingredients. 
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7 MODIFICATION OF SPPP 
This chapter is based on un-published results obtained after publication of the journal 
article described in chapter 6 and attached in chapter 10.3. 
 
7.1 HYPOTHESES AND OBJECTIVES 
Hypotheses: 
- Pretreatment of SPPP with sodium hydroxide and/or pectin-degrading enzymes 
makes it more susceptible to the action of endo-1,4-ß-galactanase from E. 
nidulans. 
- Multistep modification of SPPP can be used to generate prebiotics. 
Objectives: 
- Multi-step treatment of SPPP with sodium hydroxide, pectin-degrading 
enzymes, and endo-1,4-ß-galactanase to release oligosaccharides, followed by 
compositional and MW analysis. 
- To investigate prebiotic potential of the products. 
 
7.2 RESULTS AND DISCUSSION 
7.2.1 Chemical and enzymatic modification of SPPP 
The incubation of SPPP with endo-β-1,4-galactanase from E. nidulans resulted in two 
product fractions (Figure 14), as mentioned in section 6.2.2. The first one of molecular 
weight below 10 kDa contained 93% of galactose. The second one of MW higher than 
10 kDa was composed of only 54% of galactose. The other components of the high MW 
fraction were arabinose, galacturonic acid, glucose, mannose and rhamnose, which 
constituted 20, 11, 7, 5, 3%, respectively. As can be seen from the composition, the 
fraction of MW above 10 kDa was mainly derived from arabinogalactan. However, the 
high content of galacturonic acid indicated that the rhamnogalacturonan backbone was 
present as well and because of the high MW of this fraction, it could be assumed that 
RGI was not degraded. It was hypothesized that the degradation of the residual RGI 
backbone in SPPP would make the substrate better available for endo-galactanase 
enabling more complete hydrolysis of galactan by this enzyme. This would result in 
higher release of lower MW products, which exhibited higher prebiotic potential. It 
would also support better utilization of the material and thus generation of better value-
added product from potato pulp. The degradation of the backbone of RGI before 
applying endo-β-1,4-galactanase could also result in the products of different 
composition than the ones reported before. The new composition of 
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galactooligosaccharides could influence the prebiotic properties of these compounds. 
Following this idea, other enzymes could be applied to modify oligosaccharides from 
SPPP. Arabinofuranosidase and exo-polygalacturonase could potentially remove 
arabinose and galacturonic acid from the substrate and, as an outcome, galactose content 
in the product would rise.  
The scheme of all the modifications to which solubilized potato pulp polysaccharides 
were subjected is shown in Figure 17 and the names of produced samples are denoted in 
Table 9. At first the substrate was treated with α- amylase from B. licheniformis 
(TermamylSC) in order to remove the residual starch present in the material. Incubation 
with this enzyme resulted in release of glucose and glucooligosaccharides, which were 
removed from SPPP by filtration with 2 kDa membrane. 
 
Figure 17. Scheme of modifications of SPPP. 
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Sample Name
Crude SPPP 0 
SPPP treated with α-amylase 1 
SPPP treated with α-amylase and NaOH 2 
SPPP treated with α-amylase, NaOH and RGI lyase  3 
SPPP treated with α-amylase, NaOH, RGI lyase and endo-galactanase 4 
SPPP treated with α-amylase, NaOH, RGI lyase,  α-arabinosidase and endo-galactanase 5 
SPPP treated with α-amylase, NaOH, RGI lyase,  exo-polygalacturonase and endo-
galactanase 
6 
SPPP treated with α-amylase, NaOH, RGI lyase,  exo-polygalacturonase, α-arabinosidase 
and endo-galactanase 
7 
  
Table 9. The name codes of produced SPPP derivatives. 
 
Some preliminary experiments performed to loosen the structure of RGI present in 
SPPP revealed that treatment of SPPP with RGI lyase from Bacillus licheniformis 
resulted only in a slight profile change in its size exclusion chromatogram (Figure 18). 
That was not considered as satisfying degradation of RGI backbone of SPPP. Therefore 
sodium hydroxide was applied to remove acetyl and methyl groups present in RGI 
structure (Sun et al., 1987; Normand et al., 2010), since the acetylation and methylation 
may hinder the action of RGI lyase. After deesterification of galacturonic acid contained 
in RGI by incubation with NaOH, size exclusion chromatogram of SPPP did not 
indicate any change in the molecular weight (Figure 18). However, combining 
incubation of SPPP with NaOH and subsequently with RGI lyase resulted in significant 
decrease of molecular size of SPPP (Figure 18) indicating that the ester moieties 
obstructed the degradation of RGI by RGI lyase from B. licheniformis. This is 
consistent with literature. For example, activity of RGI lyase from Aspergillus aculeatus 
decreases when the degree of acetylation of the substrate increases (Mutter et al., 1998). 
In the next steps of SPPP degradation three carbohydrate-degrading enzymes were used 
in different combinations. SPPP was divided into four samples. The first one was 
treated with endo-1,4-β-galactanase and poly- and oligosaccharides of molecular weight 
below 10 kDa were produced. The second sample was incubated at first with α- L- 
arabinofuranosidase resulting in release of arabinose detected by HPAEC and 
subsequently with endo-1,4-β-galactanase resulting in formation of poly- and 
oligosaccharides. The third sample was treated at first with exo-polygalacturonase 
creating free galacturonic acid and subsequently with endo-1,4-β-galactanase forming 
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again poly-and oligosaccharides. The fourth was subjected to action of exo-
polygalacturonase, then α-L-arabinofuranosidase and eventually endo-1,4-β-
galactanase. That resulted in release of monosaccharides and subsequently 
galactosaccharides of different chain length. The monosaccharides produced by the 
incubation with arabinofuranosidase and exo-polygalacturonase were removed by 
filtration prior to employing endo-galactanase. The incubation with exo-
polygalacturonase was done to remove terminal galacturonic acid residues, still present 
in the RGI component of SPPP. 
 
Figure 18. HPSEC analysis of SPPP modification by sodium hydroxide and RGI lyase from 
Bacillus licheniformis. 
In general, the degradation of the NaOH and RGI lyase- treated SPPP with endo-1,4-β-
galactanase from E. nidulans resulted in a range of products of molecular weight mainly 
between 1 and 10 kDa (samples 4 -7). Whereas treatment of crude SPPP with this 
enzyme gave two ranges of products: one of them of MW between 1 and 10 kDa and 
the second above 100 kDa. The fraction above 100 kDa contained high level of 
galacturonic acid. This indicated that the RGI remained intact when NaOH and RGI 
lyase were not used. 
The treatment of SPPP, which was earlier modified by deesterification and RGI lyase, 
with galactanase, as well as with arabinosidase and/or exo-polygalacturonase and 
subsequently with galactanase gave the same size-exclusion profile of poly- and 
oligosaccharides (Figure 19). The monosaccharide composition of crude and modified 
SPPP– after each step of modification is summarized in Table 10. The composition was 
investigated by acid hydrolysis of the materials and analysis by HPAEC. The main 
ingredient of all the samples was galactose. Its content increased after application of 
amylase, because α-amylase removed the residual starch and therefore decreased the 
content of glucose in the material. However, glucose content was still relatively high in 
the sample incubated with α-amylase. That can be attributed to a drawback of filtration, 
which did not provide full separation. In the sample coming from the next step of the 
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process the glucose content was much lower – due to the second filtration of low MW 
compounds, and it stayed at the same level until the end of SPPP processing. The 
content of mannose increased in the process of SPPP modification. This was connected 
to the presence of mannose in the structures of applied enzymes. The enzymes were not 
removed from the post-reaction mixture when acid hydrolysis was performed to assess 
the monosaccharide composition. With an addition of each enzyme, the content of 
mannose increased. It happens often that enzymes expressed in P. pastoris are 
glycosylated with mannose (Macauley-Patrick et al., 2005). 
A surprising result was a presence of fucose in the hydrolysed material. It was not 
detected in the study where SPPP was treated with endo-1,4-β-galactanse alone 
(publication attached in chapter 9.3). However, another batch of potato pulp was used in 
that study. The literature also mentions that fucose may be present in potato RGI (Byg 
et al., 2012). 
 
 
Figure 19. HPSEC analysis of modification of SPPP with α-amylase from B. licheniformis, 
sodium hydroxide, RGI lyase from B. licheniformis, endo-1,4-β-galactanse from E. nidulans, α- 
L- arabinofuranosidase from E. nidulans, exo-polygalacturonase from E. nidulans. 
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Sample Composition [mol %] 
Fucose Rhamnose Arabinose Galactose Glucose Mannose Galacturonic acid 
0 2.0±0.4 3.7±1.8 14.±0.4 64.0±6.1 11.3±0.4 3.2±0.4 8.6±3.9 
1 1.8±0.1 3.1±0.6 15.2±0.3 67.4±1.6 7.3±0.3 3.0±0.1 7.2±1.1 
2 1.8±0.3 4.6±0.9 14.3±0.7 62.8±1.8 6.3±0.1 3.5±0.2 10.6±1.6 
3 1.6±0.2 4.9±0.1 12.2±0.7 66.9±0.9 5.5±0.2 8.8±0.2 5.4±2.1 
4 1.9±0.6 3.8±0.1 11.1±0.4 69.3±2.0 3.9 ±0.1 10.0±0.6 4.6±1.5 
5 2.1±0.2 3.8±0.3 10.2±0.4 68.2±3.0 3.5±0.1 10.8±0.7 5.8±2.3 
6 2.0±0.0 3.7±0.2 10.3±0.2 66.9±0.5 3.5±0.1 12.0±0.3 6.0±0.3 
7 2.1±0.4 3.8±0.3 10.4±0.6 67.4±1.8 3.4±0.1 12.8±0.3 4.4±1.1 
  
Table 10. Composition of products of SPPP modifications. 
 
7.2.2 Investigation of prebiotic properties of modified SPPP 
The growth of probiotic bacteria including species of B. longum, B. longum subsp. 
infantis, B. lactis and L. acidophilus, as well as a pathogen, C. perfringens was 
investigated by measurement of optical density at 600 nm. The growth of each 
bacterium was assessed on crude and modified SPPP (Figure 20). B. infantis 233 grew 
to the highest extent among all the bacteria on the samples treated with endo-
galactanase (samples 4, 5, 6, 7), but it did not grow well on pure galactan used as a 
reference prebiotic. L. acidophilus, on the other hand, grew well on all endo-
galactanase- modified samples and on galactan. 
A few of probiotics used sample 2 as a carbon source. Those were B. longum 232, B. 
infantis 233, B. infantis 1497 and B. lactis. Particularly B. infantis 1497 grew relatively 
well on this sample. It grew also to some extent on crude SPPP and samples 1 and 3. On 
the contrary to the other strains, B. infantis 1497 grew on samples 0-3 to, more or less, 
the same extent as on samples 4-7. It could be therefore speculated that there was a 
structure motif in all these samples that was vulnerable to enzymes produced by the B. 
infantis 1497 strain. 
All the prebiotic strains were stimulated by the SPPP fractions modified with endo-
galactanase and thus showed a prebiotic potential. In general, there was not a significant 
growth stimulation difference between the specific samples incubated with galactanase, 
i.e. samples 4, 5, 6 and 7. The modifications of SPPP caused by the action of α-
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arabinosidase and exo-polygalacturonase did not influence the bacterial growth to high 
extent.  
C. perfringens was stimulated by the produced compounds, whereas it was not 
stimulated by galactan. The fact that C. perfringens did not grow on galactan, but grew 
to some extent on SPPP treated with endo-galactanase is in agreement with the previous 
findings (section 6.2.3). The sample of MW below 10 kDa obtained by treatment of 
crude SPPP with endo-1,4-β-galactanase from E. nidulans stimulated the growth of C. 
perfringens to an extend when its area under the growth curve reached approximately 
130 units (Figure 16, section 6.2.3.). In the present experiments the areas under the 
growth curve for C. perfringens were between 41 for sample 5 and 151 for sample 6. It 
can be, therefore, concluded, as in section 6.2.3., that mixed cultures study is required to 
investigate cross-feeding effects between strains. 
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Figure 20. Differential growth of bacterial strains on fractions of modified SPPP; galactan was 
used as a control; growth responses for all the substrates are shown for a substrate concentration 
of 10 g/L for all bacterial strains. Data are given as average values of 3 growth assay replicates 
and shown ± S.D. 
 
7.3 CONCLUSION 
The treatment of SPPP with sodium hydroxide and subsequent incubation with RGI 
lyase from B. licheniformis resulted in decrease of molecular size of SPPP from above 
400 kDa to 40 kDa, whereas the treatment of SPPP exclusively with RGI lyase changed 
the molecular size of the substrate only slightly, since it was still bigger than 400 kDa. 
The chemical deesterification of rhamnogalacturonan I contained in SPPP improved the 
efficiency of RGI lyase and enabled successful degradation of RGI present in the 
material. The application of RGI lyase in the process of production of galactopoly- and 
oligosaccharides of narrower molecular weight was successful, because 
galactosaccharides generated by endo-1,4-β-galactanase from E. nidulans from NaOH 
and RGI- treated material were within a relatively narrow range of 1 - 10 kDa, whereas 
the incubation of the crude SPPP with endo-1,4-β-galactanase (described in section 
6.2.2) resulted in a much broader range of products, i.e. in two distinct fractions: one of 
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MW around 3 kDa and the second one about 400 kDa. Moreover, the products of SPPP 
modifications and subsequent incubation with endo-1,4-β-galactanase revealed prebiotic 
potential on single strain cultures. 
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8 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
Two types of potentially prebiotic oligosaccharides were produced in enzyme-catalysed 
reactions. The first type of produced oligosaccharides was sialylated oligosaccharides 
obtained in reaction catalysed by mutated sialidases. The sialylated oligosaccharides 
represented structures of human milk oligosaccharides, as well as other glycans. The 
HMOs were synthesized by transfer of sialic acid from casein glycomacropeptide, a 
dairy side stream, catalysed by mutated sialidase of T. rangeli possessing six point 
mutations, Tr6. The other sialylsaccharides, human milk- like oligosaccharides were 
generated by mutant enzyme with thirteen point mutations, Tr13. The substrates for this 
reaction were compounds of established prebiotic properties, compounds similar in 
structure to lactose – a model substrate in synthesis of HMOs, and monomers such as 
fucose and glucose. Obtained products were purified by anion exchange 
chromatography. Prebiotic potential of human milk-like oligosaccharides was tested in 
the single cultures experiments. 
The second type was galactooligosaccharides which were produced from commercially 
available galactan and from an agricultural waste, i.e. potato pulp. The potato pulp was 
modified by different methods, mainly enzymatic, prior to release of 
galactooligosaccharides by the action of an endo-1,4-β-galactanase from E. nidulans 
expressed in P. pastoris. Together with oligosaccharides compounds of higher MW 
were released. The products were fractionated by membrane systems and their prebiotic 
potential was investigated by incubation with single bacterial strains. The 
galactosaccharides revealed promising prebiotic potential. 
The results of this work pave the way to develop new functional food ingredients. The 
mutant sialidase from T. rangeli, Tr6 has been successfully tuned into trans-sialidase 
and a few structures of human milk oligosaccharides were produced by this enzyme. 
Application of another T. rangeli enzyme with 13 point mutations, Tr13 for the 
synthesis of sialylated glycans provides an opportunity to produce a range of novel 
oligosaccharides. These new sialylated glycans could be used in infant formula as 
potent prebiotics, and to combat the food-borne pathogens by adhesion (decoy 
molecules). Use of Tr13 ensures not only relatively high reaction yields but also, on the 
contrary to production of HMO, possibility of employing cheap acceptor compounds. 
Moreover, this work has also provided a positive foundation for biocatalytic design of 
β-galactooligosaccharides from potato pulp with potential health effects. It has also 
shown a direction for potential valorisation of the potato pulp by-product. 
The present work resulted in generation of potential value-added products from side-
streams from agriculture and dairy industry. Sialylated oligosaccharides and 
galactosaccharides are compounds of great biological and market potential. They are 
recognized as prebiotics, immune system stimulators and factors preventing infections. 
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GOS are already available on the market but the alternative way of their production and 
possibility to produce compounds of DP higher than nine may be a valuable asset. A 
possibility of adding HMOs to the infant formulas makes these products novel and 
significantly improves their properties and market image. The production of HMOs may 
also add up an opportunity to create new products, which would have not only a 
nutritional and prophylactic, but also therapeutic properties. The HMO-like saccharides 
could be used in products for both infants and adults. Their production should be in 
some cases cheaper than production of the real HMOs.  
The oligosaccharides described above have to be studied further before they can be used 
commercially. Adjustment of their production process to the requirements of the 
industrial scale needs also further effort. The prebiotic properties should be confirmed 
in mixed cultures fermentations and human trials. Especially, the biological properties 
of potential ingredients of infant formulas require more investigation. Furthermore, their 
purity should be ensured at very high level. Therefore the chromatographic method of 
purification should be exchanged to another one or altered, e.g. by use of another buffer 
than ammonium formate, which is not easy to remove from the product, or by 
enhancement of the buffer removal step. The characterization and purification of the 
donor substrate, cGMP should be improved as well. The development of HMO 
production process could be accomplished by reuse of enzyme and employing a 
membrane reactor. Since the trials of immobilization of the mutant sialidase Tr6 done at 
our department recently did not result in an improved performance, the membrane 
reactor seems to be a promising solution. Especially continuous system could promote 
the process by steady removal of the product by filtration. The fouling caused by the 
cGMP would have to be diminished in that case and the low molecular weight acceptor 
used in the process would have to be supplied continuously, since it would leave the 
reactor together with the low molecular weight product of the reaction. One more 
problem connected to HMOs production which has to be addressed is the price of the 
sialic acid acceptors which, besides lactose, are very expensive. Their cheaper source 
should be sought. An additional method of improving the economics of production of 
sialylated glycans could be use of residual, sialic acid- deprived cGMP to generate 
another useful product, for example, biofuels. 
The mutated sialidases could be manipulated further at the gene level to achieve enzyme 
possessing exclusively trans-sialidase activity. That would enable use of the same molar 
concentrations of donor and acceptor in the reaction, because the product would not be 
hydrolysed any more and the excess of the acceptor would not be required any longer. 
Thermostability is also a desired feature of trans-sialidase. The application of 
thermostable trans-sialidase would improve the substrates solubility and prevent the 
contamination of the reaction mixture. Moreover, the promiscuity of Tr13 could be 
tested further and other interesting sialylated saccharides could be obtained. 
The scale of galactosaccharides production should be also gradually enlarged in case of 
industrial interest in the production of these compounds from the potato pulp. A 
continuous membrane reactor appears to be a good solution for that purpose, since the 
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steady state created in this type of equipment would enable release of products of 
narrow MW and would prevent degradation of GOS to monosaccharide catalysed by the 
endo-1,4-β-galactanase. The immobilization of the enzyme could be tested as well. 
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a  b  s t  r  a c t
Casein  glycomacropeptide  (cGMP)  and  lactose,  which  are puriﬁed  (or  semi-puriﬁed)  components
obtained  from  side  streams  from  dairy  industry operations, were  used  as  substrates  for  enzyme  cat-
alyzed production of  3′-sialyllactose,  a  model  case compound  for  human  milk  oligosaccharides  (HMOs).
The enzyme  employed  was  a mutated sialidase,  Tr6,  derived  from  Trypanosoma  rangeli, and  expressed
in Pichia pastoris after  codon-optimization.  The  Tr6  contained  6 point mutations  and  exhibited  trans-
sialidase activity.  The  Tr6 trans-sialidase  reaction conditions were tuned for  maximizing Tr6 catalyzed
3′-sialyllactose  production  by  optimizing  pH,  temperature,  acceptor, and donor concentrations  using
response surface designs. At the  optimum  reaction  conditions,  the  Tr6 catalyzed the  transfer  of sialic
acid from cGMP  to lactose  at high  efﬁciency  without substantial  hydrolysis  of the  3′-sialyllactose  prod-
uct. The robustness  of  the  Tr6  catalyzed reaction  was veriﬁed  at  5 L-scale providing  a  yield of  3.6  g
3′-sialyllactose  at an estimated molar  trans-sialylation  yield of  50% on the  3′-sialyl  in cGMP.  Lacto-N-
tetraose and lacto-N-fucopentaoses  also functioned  as  acceptor molecules  demonstrating  the  versatility
of the  Tr6 trans-sialidase for  catalyzing  sialyl-transfer  for  generating  different HMOs.  The  data  signify  the
applicability of enzymatic  trans-sialylation  on  dairy  side-stream  components  for  production  of human
milk oligosaccharides.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Human milk oligosaccharides (HMOs) appear to constitute an
innate immunologic mechanism by  which human milk confers
breast-fed infants some level of protection against infections [1].
HMOs constitute the third most abundant component of human
milk after lactose and lipids, and levels of up to  8 g/L have been
reported [2], mainly during the ﬁrst days of lactation. The HMOs
function as soluble receptors that inhibit pathogens such as Campy-
lobacter jejuni and Escherichia coli K1 from adhering to their target
Abbreviations: cGMP, casein glycomacropeptide; HMOs, human milk oligosac-
charides; LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP I,  lacto-N-
fucopentaose; LNFP V, lacto-N-fucopentaose V.
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receptors on the mucosal surface of the host gastrointestinal tract,
and thereby help reduce the incidence of diarrhea and other dis-
eases in breast-fed infants [1,3].  HMO  molecules are also substrates
for probiotic gut bacteria, including Biﬁdobacterium longum subsp.
infantis [4]  (previously known as Biﬁdobacterium infantis)  and thus
seem to support the development of  a  healthy gut microﬂora in
breast-fed infants by  acting as biﬁdogenic prebiotics [4].
All HMO  molecules contain lactose (Gal1-4Glc) at their reduc-
ing end and are  built from sequential elongations via linkage
to one or more units of N-acetylglucosamine and galactose (N-
acetyllactosamine) and can be decorated with several sialic acid
(N-acetyl-neuraminic acid) and fucose residues [1,2,5]. Because
of the different backbone lengths, bonds, decorations via various
bond types, and different combinations of the basic building blocks
many different HMO  structures can exist. About 180 different HMO
species have thus been identiﬁed in a  pooled human milk sample
from ﬁve individuals, and nearly 16% of the total oligosaccharide
abundances were found to correspond to  sialylated oligosaccha-
rides [5].  Only a  few HMOs are present in bovine milk and only at
low concentrations.
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Biﬁdobacterium longum subsp. infantis (ATCC15697) is  consid-
ered an “archetypical HMO-utilizing bacterium” [6],  and has been
found to harbor genes for sialidase and fucosidase glycosyl hydro-
lases [6]. Exo--sialidase activity (EC 3.2.1.18) has also been
positively demonstrated in two strains of Biﬁdobacterium biﬁdum
(JCM1254 and JCM7004) [7].
Enzymatic synthesis (analytical scale) of sialylated oligosaccha-
rides by use of the trans-sialidase from the pathogenic parasite
Trypanosoma cruzi was reported already in  2000 [8]. The T. cruzi
trans-sialidase has been studied intensively due to its suggested
involvement in the mammalian host cell invasion process and
pathogenesis of T. cruzi leading to Chagas disease [9]. Hence, recom-
binant, catalytic domain forms of this enzyme have been expressed
in E. coli [10,11] and it has also  been reported that the recombinant
enzyme can catalyze the sialylation of  lactose derivatives such as
lactitol and lactobionic acid using 3′-sialyllactose (-Neu5Ac-(2-
3)-gal--(1-4)-glc) as donor [12].  The recombinant version of the
T. cruzi enzyme expressed in E. coli has also  been used for prepar-
ative sialylation of a synthetic pentasaccharide from the mucins
of T. cruzi [13] and methods for enriching bovine milk with 3′-
sialyllactose employing the T.  cruzi trans-sialidase and claims for
using a sialidase from other organisms have also been patented
[14,15]. The full T. cruzi dual-domain trans-sialidase enzyme is
considered a virulence factor for the invasive T.  cruzi phenotype
[16], but the recombinant T. cruzi trans-sialidase used in synthesis
would not be virulent, and would moreover be inactivated when
heating and separation steps are included in  the trans-sialylation
process. Nevertheless, due to  its origin from a pathogenic organ-
ism it may  be difﬁcult to obtain approval and consumer acceptance
for using the T. cruzi trans-sialidase as  an aid for producing
functional food ingredients for infant consumption. Regarding
catalysis facilitated by  sialidases, i.e. sialidase glucosyl hydrolases
(neuraminidases) (EC 3.2.1.18), the problem is  that the reaction
will invariably result in  hydrolysis of  the target 3′-sialyllactose
product.
However, mutants of the sialidase from the non-pathogenic Try-
panosoma rangeli have been reported to exhibit low trans-sialidase
activity (maximum 11% of the trans-sialidase activity of the T.
cruzi trans-sialidase) [17]. We  hypothesized that the use of such
a sialidase mutant from T.  rangeli exhibiting trans-sialidase activ-
ity could provide an alternative route for enzymatic, biomimetic
in vitro synthesis of HMOs. The present study was  undertaken
to assess the catalytic ability of such a T. rangeli derived trans-
sialidase mutant for (i)  enzymatic in vitro production of  gram-levels
of 3′-sialyllactose, and (ii) enzymatic sialyl-transfer to other HMO
structures such as lacto-N-tetraose and lacto-N-fucopentaoses. An
additional objective was to  utilize abundantly available food-grade
co-processing products from the dairy industry, i.e.  lactose and
casein glycomacropeptide (cGMP), as substrates for the enzymatic
reaction to make the process relevant in relation to the prospective
use of sialylated HMOs as  functional food ingredients.
2. Materials and methods
2.1. Substrates
-d-lactose and standard of N-acetylneuraminic acid (sialic acid) were pur-
chased from Sigma–Aldrich (Steinheim, Germany). Standards of  3′-sialyllactose
and 6′-sialyllactose were purchased from Carbosynth (Compton, United Kingdom).
Lacto-N-tetraose (LNT), Lacto-N-neotetraose (LNnT), Lacto-N-fucopentaose I (LNFP
I), and Lacto-N-fucopentaose V (LNFPV) were purchased from Elicityl SA  (Crolles,
France). Casein glycomacropeptide (cGMP) in the form of the commercially available
product Lacprodan® CGMP-20 (intended for use in infant formulas and PKU-
products), containing a total of 5.7% (w/w), equivalent to 0.2 mmol/g dry matter,
of  covalently linked sialic acid was  a  gift from Arla Foods Ingredients amba (Viby,
Denmark). Before use, as a  technical precaution in relation to HPAEC-analysis, low
molecular weight impurities in the cGMP solution were removed by ﬁltration on  a
5 kDa membrane (Sartorius AG, Goettingen, Germany).
2.2. Vector and strain construction
A Trypanosoma rangeli sialidase gene (Genbank accession no. U83180.1) with
the following mutations, M96V, A98P, S120Y, G249Y, Q284P and I37L [17] was
codon-optimized and synthesized by DNA 2.0 (Menlo Park, CA,  USA). The gene
was  inserted into pPICZC (Invitrogen, Life Technologies Corp. Carlsbad, CA, USA)
between the XbaI  and XhoI restriction sites generating a translational fusion to  the
-factor signal sequence and C-terminal c-myc and 6xHis tag. The vector was  named
pPicZC  Tr6 (the gene sequence is available in supplementary material Figure S1).
Transformation and selection of Pichia pastoris X-33 expressing the Tr6 gene were
carried out  according to  the manufacturer’s instructions. Zeocin resistant transfor-
mants were analyzed for protein expression by Western blot using a c-myc antibody
[18].
2.3. Production of the  Tr6 enzyme in P. pastoris, puriﬁcation and characterization
The enzyme, Tr6, was  produced in a 5 L Sartorius Biostat Aplus fermentation
of P. pastoris, in a fermentation run principally as detailed previously [19], with the
exception that the methanol fed-batch phase was  done at  25 ◦C. The Tr6 enzyme
was  puriﬁed by  Cu2+ afﬁnity column chromatography using a  CIM® IDA-8f mL Tube
Monolithic Column (BIA Separations GmbH,  Villach, Austria) [18]. The protein con-
centration was  measured at 280 nm using Gene5TMTAKE3 module version 1.09
according to the manufacturer’s instructions (Biotek® Instruments, Inc.).
The purity of the Tr6  was  evaluated by SDS-PAGE (BioRad, CA, US) using
Coomassie brilliant blue staining as described previously [18].  To test for N-
glycosylation the puriﬁed Tr6 was  treated with endoglycosidase H (EndoH,
Medinova) for 1 h at 37 ◦C. Proteins treated with and without endoglycosidase H
were analyzed by Western blot, using monoclonal anti-poly-histidine–peroxidase
antibodies, principally as detailed previously [18].
2.4. Investigation of conditions for  trans-sialylation by statistically designed
experiments
MODDE Version 7.0.0.1 (Umetrics AB, Umeå, Sweden) was used as a tool to
design the experimental frame, a quadratic central composite design, and to ﬁt and
analyze the data by multiple linear regression analysis. Lactose was used as an accep-
tor and cGMP as donor of sialic acid. The buffer used in the reactions was 15  mM
phosphate-citrate buffer with pH values indicated below. Tr6 was  incubated at a
concentration of 5.3 mg/L. Three pH regimes 5.5, 6.5 and 7.5 were tested. Incuba-
tion temperatures were 15, 20 and 25 ◦C. Lactose concentration varied from 0.34 to
351 mM and concentration of sialic acid residues bound in  cGMP varied from 0.6
to 4.6 mM in the experimental design frame: lactose and cGMP were solubilized in
buffer and pre-incubated at  speciﬁc temperatures, before the reactions were initi-
ated  by addition of enzyme. The biocatalysis process was  allowed to proceed for
20 min, and then stopped by  heating for 10 min  at 90 ◦C. Subsequently each sample
was  ﬁltered on a  5 kDa polyethersulfone membrane to  remove cGMP (Vivaspin, Sar-
torius AG, Goettingen, Germany). Concentrations of 3′-sialyllactose and sialic acid
were determined by  HPAEC and/or LC/MS as described below.
2.5. Time study of trans-sialylation catalyzed by  Tr6 expressed in  P.  pastoris
Tr6 was  incubated as described above at two different conditions: 25 ◦C,  pH 5.5
with 36.8 mM lactose and 2.6 mM sialic acid bound in cGMP or with 117 mM lactose
and 4.6 mM sialic acid bound in cGMP. The reaction was  followed for 100 min.
2.6. Enzymatic production of  3′-sialyllactose
The enzymatic trans-sialylation reaction was  accomplished in a  stirred reac-
tor vessel in a  total reaction volume of 5  L.  117 mM lactose and 4.6  mM sialic acid
linked to  cGMP was  dissolved in 15  mM  phosphate–citrate buffer (pH 5.5), and after
pre-incubation in the buffer at 25 ◦C for 10 min, 5.3 mg/L Tr6 was  added. The enzy-
matic catalysis lasted 20 min, then the reaction was  terminated by  inactivation of
the enzyme at 90 ◦C  for 10 min. cGMP was  removed from the reaction mixtures by
a  cross-ﬂow ﬁltration using a 5 kDa cutoff membrane (Sartorius AG,  Goettingen,
Germany). The  permeate containing 3′-sialyllactose, sialic acid, lactose and buffer
was  collected and freeze-dried. After re-solubilization in water (775 mL)  the reaction
products were separated by  anion exchange chromatography using a HiScale 50/20
column (GE Healthcare) with a packed bed of  Sepharose Q FF  on an ÄKTA puriﬁer 100
work station. The elution was  monitored at 210 nm. Before injection the column was
equilibrated with 2 L of water. After injection of  the sample, the column was  washed
with 1.2 L water and the products 3′-sialyllactose and sialic acid were then eluted
with 1.4 L of 40 mM ammonium formate. The products were lyophilized and residual
ammonium formate was  removed by repeated solubilization and lyophilization.
2.7. Production and puriﬁcation of sialylated lacto-N-tetraoses and
lacto-N-fucopentaoses
The reactions were carried out at 5–100 mL scale employing the same reaction
conditions as described for 3′-sialyllactose production except that LNT, LNnT, LNFP
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Fig. 1. (a) Coomassie stained SDS-polyacrylamide gel. Lane 1: marker, lane 2: the Tr6 enzyme after IMAC puriﬁcation. (b) Western blot analysis of the produced Tr6  enzyme:
lane 1, crude protein; lane 2,  protein after treatment with EndoH; lane 3, marker. For the Western blot proteins were incubated with monoclonal anti-poly-histidine-peroxidase
antibodies (Sigma–Aldrich) (as detailed in [18]).
I and LNFP V were used as acceptors instead of  lactose. LNT was  used at  117 mM,
whereas LNnT, LNFP I and LNFP V  were used at 25 mM.
2.8. High-performance anion exchange chromatography–pulsed amperometric
detection (HPAEC–PAD)
Separation and quantiﬁcation of 3′-sialyllactose and sialic acid were carried out
by HPAEC–PAD analysis using a  CarboPacTM PA1 (4 mm  × 250 mm) column and a
Dionex BioLC system. The eluent system comprised deionised water (A), 0.5 M NaOH
(B) and 1 M NaOAc (C) and the elution program was  modiﬁed from the method
described in [20] as follows: For the ﬁrst 3 min  a ratio of 80: 20 (% A:B) was  applied,
then a linear gradient from 80:20 (% A:B) to  60:20:20 (% A:B:C) was  used during
3–27 min. Strongly retained anions were removed from the column by isocratic
elution at 40:20:40 (% A:B:C) from 27  to  31 min. Subsequently the column was  re-
equilibrated for 7 min  with 80:20 (% A:B).
2.9. Capillary liquid chromatography/mass spectrometry
For liquid chromatography/mass spectrometry (LC/MS) analyses, an Agilent
1100 LC/Agilent 6340 ion trap MS system was  used. Oligosaccharides were sep-
arated using a Hypercarb porous graphitic carbon (PGC) column (0.32 × 150 mm,
5 m,  Thermo Scientiﬁc) at 30 ◦C. Samples (0.5 L) were loaded onto the column
in 10 mM ammonium bicarbonate. Gradient elution was  achieved using a binary
solvent system consisting of (A) 10 mM ammonium bicarbonate, adjusted to  pH 8.5
with ammonium hydroxide, and (B) 100% acetonitrile at  a  ﬂow rate of 5  L/min.
The gradient was  initially at 98:2 (% A:B) for 5 min, followed by a  linear increase to
42:58 (% A:B) at 33 min. This  concentration of B was  held for 3 min. Subsequently the
eluent was  returned to  98:2 (% A:B) at 40 min  and the system was  allowed to equil-
ibrate for 10 min  prior to  the next injection. All  solvents used were of the highest
HPLC grade. The mass spectrometry was  performed in negative ion mode, and was
scanned in the range m/z 150–2200 (2 microscans, maximum accumulation time of
150 ms,  an ion current count of 200,000) followed by data-dependent MS2 scans of
the four most abundant ions in each MS1  scan.
2.10. Nuclear magnetic resonance (NMR) spectroscopy
NMR  spectra were recorded in D2O (99.9% D,  Sigma–Aldrich) at 25 ◦C on  a Varian
Unity Inova 500 MHz spectrometer equipped with a  5 mm probe, using standard
1D and 2D pulse sequences. 1,4-dioxane was  used as an external chemical shift
reference (ıH 3.75 ppm and ıC 67.4 ppm).
3. Results
3.1. Expression in P. pastoris and characterization of the
trans-sialidase Tr6
Since it is  generally accepted that codon usage can affect (i.e.
decrease) recombinant protein yields [21] a  synthetic gene with
a codon distribution optimized for P. pastoris expression [22] was
synthesized for the production of the T. rangeli sialidase Tr6. The
secreted Tr6 polypeptide comprised 663 amino acids including a  23
amino acid C-terminal c-myc and 6xHis tag (Supplementary mate-
rial, Figure S1) with a theoretical molecular weight of 73  kDa. A
positive transformant expressing the Tr6 enzyme was  selected and
used for enzyme production at a 5  L-scale. This production gave a
concentration of Tr6 of 1 g/L. After puriﬁcation, the enzyme had an
apparent molecular weight of about 80 kDa by SDS-PAGE (Fig. 1a),
but treatment of the Tr6 enzyme with EndoH followed by Western
blot analysis revealed that the expressed protein was  glycosylated
and the molecular weight of Tr6 was 75 kDa after deglycosylation
(Fig. 1 b).
3.2. Tuning of the Tr6 reaction conditions for maximizing
trans-sialidase activity
The wild type sialidase from T.  rangeli and the derived Tr6
mutant enzyme have an inherent high level of sialidase activity, but
a relatively low level of trans-sialidase activity [17].  In the present
study we wanted to evaluate the relationship between Tr6 sialidase
and trans-sialidase activities and deﬁne the reaction conditions at
which the trans-sialidase activity would be maximal. For produc-
tion of  3′-sialyllactose, a  systematic evaluation of the inﬂuence of
the reaction factors, notably the reaction temperature, pH,  concen-
tration of  the sialic acid donor (cGMP) and concentration of the
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Fig. 2. (a) Accumulation of 3′-sialyllactose and sialic acid over  time (25 min) at low
concentration of lactose: 36.8 mM lactose, at 25 ◦C, pH 5.5, and 2.6 mM sialic acid
contained in cGMP; measured by HPAEC-PAD; 3′-sialyllactose; sialic acid. (b) Accu-
mulation of 3′-sialyllactose over time at high lactose, 117 mM lactose, 25 ◦C, pH 5.5,
and 4.6 mM sialic acid bound in cGMP; measured by LC/MS. No free sialic acid was
detected.
acceptor (lactose), revealed that increased temperature (from 15
to 25 ◦C) and decreased pH (from 7.5 to 5.5) gave rise to  enhanced
yields of 3′-sialyllactose (Supplementary material, Figure S2), but
at the reaction optimum at pH 5.5 and 25 ◦C, at low concentration of
the acceptor, lactose (4 mM),  only low levels of 3′-sialyllactose were
produced, and free sialic acid was released simultaneously (Fig. 2a).
These data signiﬁed that the reaction conditions did not sufﬁciently
suppress the sialidase activity of the enzyme. The retainment of
some sialidase activity was, however, in agreement with previous
results reported for T. rangeli mutants expressed in  E. coli [17].  Nev-
ertheless, when higher lactose concentrations (117–351 mM)  were
used, i.e. in effect a higher substrate acceptor:donor ration, the Tr6
enzyme was able to  catalyze the production of high amounts of
3′-sialyllactose by trans-sialidase action without simultaneously
catalyzing release of free sialic acid (Fig. 2b). At  this high accep-
tor concentration, and higher acceptor:donor ratio, the speciﬁc
activity of the Tr6 trans-sialidase activity was determined to be
16.2 mol  min−1 mg−1.
3.3. Enzymatic production, puriﬁcation and analysis of
3′-sialyllactose at 5 liter-scale
For the enzymatic production of 3′-sialyllactose 5.3 mg/L of Tr6
was  incubated for 20 min  at the optimal reaction conditions of pH
5.5, 25 ◦C, using 117 mM lactose (equivalent to  40 g/L) and 4.6  mM
sialic acid residues bound in cGMP (equivalent to 26  g cGMP/L).
After deactivation of the enzyme, the 3′-sialyllactose product was
puriﬁed via a two-step down-stream process: the ﬁrst step was
ultraﬁltration to remove cGMP and Tr6. The permeate was  then
collected and after freeze-drying 180 g of  dry product was  obtained
containing 3′-sialyllactose, unreacted lactose, sialic acid and buffer
used in the enzymatic process. In the second down-stream
processing step, the different compounds were then separated by
anion exchange chromatography using ammonium formate as the
eluent (Figure S3). The quality of the separation was  conﬁrmed by
Fig. 3. (a) 1H  NMR  spectrum of 3′-sialyllactose in D2O with assignments of distinc-
tive and discriminative resonances. The spectral region between 3.5 and 4 ppm holds
the remaining proton resonances for 3′-sialyllactose and besides a contamination
with formate the purity of the sample is  very high. 1H NMR  and 13C NMR  assign-
ment data of  3′-sialyllactose are given in Supplementary material S4. (b) Structure
of 3′-sialyllactose with selected atom numberings used in the NMR  assignment.
capillary LC/MS and NMR  spectroscopy (as discussed below).
In order to remove the ammonium formate, the samples were
lyophilized six times. The ﬁnal yield of  3′-sialyllactose was 3.6 g,
and the amount of free sialic acid was 133 mg.
Only approximately 50% of the sialic acid residues in  the cGMP
are bound at the 3′-position, whereas the rest is  bound at the
6′-position [23].  Since the Tr6 catalyzed the production of 3′-
sialyllactose, it can be assumed that only 3′-bound sialyl, i.e. ∼50%
of  the total sialic acid in cGMP, was  available for this enzyme. There-
fore, the molar yield of 3′-sialyllactose was  ∼50% [47.74%] based on
the available 3′-sialic acid in cGMP.
The corresponding molar yield of the sialyllactose was  1%  on the
lactose, and for the free sialic acid the yield was  ∼2% based on the
total sialyl-residues in the cGMP.
The identity of the 3′-sialyllactose product was conﬁrmed by
capillary LC/MS and NMR  (Fig. 3). 3′-Sialyllactose obtained from
the 5 L  scale reaction eluted at the same time as  the standard 3′-
sialyllactose (data not shown), indicating that the structure of the
compound produced was  3′-sialyllactose. Both 6′-sialyllactose and
3′-sialyllactose standards were fully resolved conﬁrming the ability
of the PGC column to  provide good separation of different oligosac-
charides and stereoisomers [24].  No 6′-sialyllactose was  detected
in the product proﬁle, only 3′-sialyllactose.
The 1H and 13C NMR  assignments obtained using 1D and 2D
NMR (Fig. 3 and supplementary material Figure S4) agreed with
literature values for 3′-sialyllactose [25,26]. Besides resonances of
3′-sialyllactose the 1H NMR  spectrum also showed a singlet reso-
nance at 8.44 ppm (data not shown), which resulted from residual
ammonium formate from the puriﬁcation buffer.
3.4. Enzymatic production of sialylated lacto-N-tetraose and
fuco-N-pentaoses
It was  also demonstrated that the Tr6 was  able to  catalyze
the sialylation of lacto-N-tetraose and fuco-N-pentaoses, albeit the
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Fig. 4. Mass spectrum of ions eluted (at 17.6 and 18.8 min, respectively) in the post-reaction mixture of LNT incubated with cGMP and the Tr6 trans-sialidase: ion at m/z
706.3, LNT; ion at m/z 997.3, sialylated LNT.
yields of the products were quite low; hence 5–12 mg  of sialylated
LNT, LNnT, LNFP I and LNFP V were obtained employing the opti-
mal  reactions conditions for the Tr6 (pH 5.5, 25 ◦C), and as high as
possible acceptor/donor ratio (see Section 2.7) (Figure S5).  LC/MS
analysis showed the molecular species of LNT and sialylated-LNT
with the mass of sialylated-LNT at 997.3 (Fig. 4), corresponding to
the sum of the LNT ion (706.3) and dehydrated sialic acid (291) [27].
The mass of sialylated LNnT was also 997.3, whereas the masses for
sialylated LNFP I and LNFP V, respectively, were both determined
to be 1143 in agreement with the mass increment of  146 produced
by addition of fucose (data not shown). From the LC-MS results it
was  evident that the sialylated products of LNT, LNnT, LNFP I and
LNFP V were predominantly singly sialylated (Figure S5).
4. Discussion
In the present study, the mutated T.  rangeli sialidase, Tr6, was
codon optimized and expressed at a relatively high yield in  P.
pastoris (1 g/L). In comparison, previously, only 5 mg/L of the trans-
sialidase from T. cruzi was produced in  the same expression host,
P. pastoris [28]. This gene shared 67% homology to that of the wild
type gene from T.  rangeli.  The relatively high yield of Tr6 in  the
present study could be due to  the codon optimization or the more
controlled conditions and higher cell density attained in a  fer-
mentor as compared to shake ﬂasks. A high amount of Tr6 was
furthermore a prerequisite for a  careful examination of the trans-
sialidase catalytic abilities of Tr6 at a  range of process conditions
examined in the present study. At the optimal process conditions it
was  observed, that the Tr6 sialidase from T.  rangeli,  could be tuned
into an efﬁcient trans-sialidase with more than 93% trans-sialidase
activity and only 7% residual sialidase activity. These results dif-
fered from the trans-sialidase and sialidase activities recorded for
a Tr6 enzyme produced in E. coli, which showed relatively lower
trans-sialidase activity [17].
Whereas high substrate concentrations in  general promote high
catalytic rates according to Michaelis–Menten kinetics, high accep-
tor:donor ratios are advantageous for promoting trans-sialidase
reactions, and generally used in  T. cruzi trans-sialidase cataly-
sis studies [e.g. 8,  29] as well as in  -galactosidase catalyzed
galacto-oligosaccharide synthesis reactions [30,31].  When lactose
is the acceptor for the trans-sialidase catalysis a  high excess of
acceptor is not an economic problem, but once more expen-
sive tetra- and penta-saccharides are acceptors, measures such
as recycling of the unused acceptor may  have to be consid-
ered when comparing the application potential. Another issue
is enzyme re-use to improve biocatalytic productivity. A time
study performed at high lactose acceptor concentration was
used in the present work to determine the maximal, speciﬁc
trans-sialidase activity of  Tr6. The speciﬁc Tr6 trans-sialidase activ-
ity was determined to 16.2 nmol min−1 per g of pure protein
(i.e. 16.2 mol  min−1 mg−1). This speciﬁc activity was in essence
equivalent to the apparent Vmax of 14.7 nmol min−1g−1 reported
for the similarly mutated T. rangeli sialidase expressed in  E. coli
with 3′-sialyllactose as donor and lactose as  acceptor substrate
[17], indicating that the maximal conversion rate found, was  in
fact equal to the maximum catalytic rate of the Tr6 enzyme. It is
also interesting to  note, that the speciﬁc Tr6 trans-sialidase activity
(of 16.2 mol  min−1 mg−1) was  ∼4  times higher than the reported
Vmax of  the T. cruzi trans-sialidase (Vmax 3.8 nmol min−1g−1)  mea-
sured using 3′-sialyllactose as the donor and lactose as the acceptor
[17], and ∼40,000 times higher than the maximal speciﬁc activity
(Vmax 0.41 nmol min−1 mg−1)  reported by Agusti et al. [32] for T.
cruzi trans-sialidase catalyzed transfer of sialyl from 3′-sialyllactose
to terminal galactose in  (synthetic) Galp(1 → 6)GlcNAc mucins of
the type involved in  infection and pathogenesis of T. cruzi. With
cGMP as the donor (at 5 g/L) and lactose as the acceptor molecule (at
20 g/L) the rate of sialyllactose synthesis using the trans-sialidase
from T. cruzi occurs at a  rate which is ∼450 times less than that
obtained in  the present study with Tr6 [14].  As well, Biﬁdobacterium
infantis sialidase catalyzed trans-sialylation, employing high levels
of both cGMP and lactose [15],  producing only a low level of sia-
lyllactose, took place at a rate which was  87-fold lower than that
obtained for Tr6 in  the present study.
However, the speciﬁc Vmax rates reported recently for optimal
galactose transfer reactions for galacto-oligosaccharide synthesis
using sucrose as donor and lactose as acceptor, employing the
widely studied Bacillus circulans -galactosidase (commercially
known as Biolacta FN5′)  may  reach ∼2 mM min−1 [31]. This spe-
ciﬁc activity is ∼12 times higher than the speciﬁc trans-sialidase
activity of  Tr6 of 16.2 nmol·min−1g−1 assuming an enzyme dos-
ing of the Biolacta FN5′ based on a para-nitrophenol galactoside
activity of the B. circulans -galactosidase of ∼1 U/mg [31,33].
In general it has been shown that a  few hydrolases can carry out
a reverse reaction to  synthesize organic molecules when the enzy-
matic process conditions have been optimized. This optimization
can be performed by changing the reaction conditions such as tem-
perature in the case of -galactosidase for galactooligosaccharide
production [34], glucose content in the case of the acyltrans-
ferase for production of  glucose emulsiﬁers [35],  and maltose level
in the case of generating isomaltooligosaccharides (IMO)  by glu-
coamylase [36].  These studies also showed that optimized process
conditions can have a  profound, stimulating effect on the rate of
production and ﬁnal yield of the products. The latter is in  agreement
with the present work whereby a  sialidase with low trans-sialidase
has been tuned by favorable process conditions to  exert a  very
high trans-sialidase activity. The level of Tr6 produced in P. pas-
toris allowed a  scaling of the enzymatic process to 5 L  to  establish
proof-of-concept for the Tr6 trans-sialidase productivity at scale,
providing 3.6 g of 3′-sialyllactose. To further validate the in vitro
concept with the new biocatalyst, LNT, LNnT, LNFP I and LNFP
V were also successfully decorated with sialic acid derived from
cGMP using the same procedure as  employed for 3′-sialyllactose
production. The availability of optimized enzymes able to  act on
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components from large scale side-streams from the agricultural
and dairy industries is a  very important ﬁrst part of  the decision
base for the food industry for developing competitive processes
for new functional food ingredients. The further interplay between
molecular evolution of the biocatalyst, i.e. Tr6, and biochemical
engineering optimization could further increase the yield of the
process developed here.
Acknowledgements
We express our gratitude to  “The Strategic Research Council”
(DSF) for the ﬁnancial support to the strategic project “Enzymatic
production of human milk oligosaccharides”.
We also acknowledge the gift of the cGMP from Arla Foods (A/S),
and we thank Jesper Holck and Stine Jørgensen, Center for Bio-
Process Engineering, DTU Chemical Engineering, for analysing the
sialic acid content in cGMP.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.procbio.2013.10.023.
References
[1] Bode L. Human milk oligosaccharides: every baby needs a  sugar mama.  Glyco-
biology 2012;22:1147–62.
[2] Kunz C, Rudloff S,  Klein WN,  Strobel S. Oligosaccharides in human milk: struc-
tural, functional and metabolic aspects. Ann Rev Nutr 2000;20:699–722.
[3] Morrow AL, Ruiz-Palacios GM,  Jiang X,  Newburg DS. Human milk glycans that
inhibit pathogen binding protect breast-feeding infants against infectious diar-
rhoea. J Nutr 2005;135:1304–7.
[4] Ward RE, Ninonuevo M,  Mills DA, Lebrilla CB, German JB. In vitro fermenta-
tion of breast milk oligosaccharides by Biﬁdobacterium infantis and Lactobacillus
gasseri. Appl Environ Microbiol 2006;72:4497–9.
[5] Ninonuevo MR,  Park Y, Yin H, Zhang J, Ward RE, Clowers BH, et al. A strategy
for annotating the human milk glycome. J Agric Food Chem 2006;54:7471–80.
[6] Sela DA, Chapman J, Adeuya A, Kim JH, Chen F, Whitehead TR, et al. The
genome sequence of Biﬁdobacterium longum subsp. infantis reveals adapta-
tions for milk utilization within the infant microbiome. Proc Natl Acad Sci
2008;105:18964–9.
[7] Kiyohara M, Tanigawa K, Chaiwangsri T, Katayama T, Ashida H, Yamamoto K.
An exo--sialidase from biﬁdobacteria involved in the degradation of sialy-
loligosaccharides in human milk and intestinal glycoconjugates. Glycobiology
2011;21:437–47.
[8] Singh S, Scigelova M,  Hallberg ML,  Howarth OW, Schenkman S, Crout DHG.
Synthesis of sialyloligosaccharides using the trans-sialidase from Trypanosoma
cruzi: novel branched and di-sialylated products from digalactoside acceptors.
Chem Commun 2000;101:1013–4.
[9] Schenkman SP, Eichinger D. Trypanosoma cruzi trans-sialidase and cell invasion.
Parasitol Today 1993;9:218–22.
[10] Schenkman S, Chaves LB, de Carvalho LCP, Eichinger D. A proteolytic fragment
of  Trypanosoma cruzi trans-sialidase lacking the carboxyl-terminal domain is
active, monomeric, and generates antibodies that inhibit enzymatic activity. J
Biol Chem 1994;269:7970–5.
[11] Buschiazzo A, Frasch ACC, Campetella O.  Medium scale production and puriﬁca-
tion to homogeneity of a  recombinant trans-sialidase from Trypanosoma cruzi.
Cell Mol  Biol 1996;42:703–10.
[12] Agustí R, París G, Ratier L, Frasch ACC, de Lederkremer RM.  Lactose derivatives
are inhibitors of Trypanosoma cruzi trans-sialidase activity toward conventional
substrates in vitro and in vivo. Glycobiology 2004;14:659–70.
[13] Mendoza VM,  Agusti R, Gallo-Rodriguez C,  de Lederkremer RM.  Synthesis of  the
O-linked pentasaccharide in glycoproteins of  Trypanosoma cruzi and selective
sialylation by  recombinant trans-sialidase. Carbohydr Res 2006;341:1488–97.
[14] Pelletier M,  Barker WA,  Hakes DJ, Zopf DA.  Methods for producing sialy-
loligosaccharides in a dairy source. US  patent Nov. 27. 2001. US 6,323,008
B1.
[15] McJarrow P, Garman J, Harvey S, Van Amelsfort A. Dairy process and product.
International patent June19. 2003. WO 03/049547 A2.
[16] Pereira ME,  Zhang K,  Gong Y, Herrera EM,  Ming M.  Invasive phenotype of
Trypanosoma cruzi restricted to  a population expressing trans-sialidase. Infect
Immun  1996;64:3884–92.
[17] París G, Ratier L, Amaya MF,  Nguyen T,  Alzari PM, Frasch ACC. A sialidase mutant
displaying trans-sialidase activity. J  Mol  Biol 2005;345:923–34.
[18] Silva IR, Larsen DM,  Meyer AS, Mikkelsen JD. Identiﬁcation, expression, and
characterization of a novel bacterial RGI lyase enzyme for the production of
bio-functional ﬁbers. Enzyme Microb Technol 2011;49:160–6.
[19] Michalak M,  Thomassen LV, Roytio H, Ouwehand AC, Meyer AS, Mikkelsen JD.
Expression and characterization of an  endo-1,4--galactanase from Emericella
nidulans in Pichia pastoris for enzymatic design of potentially prebiotic oligosac-
charides from potato galactans. Enzyme Microb Technol 2012;50:121–9.
[20] Kunz C,  Rudloff S, Hintelmann A, Pohlentz G,  Egge H. High-pH anion-exchange
chromatography with pulsed amperometric detection and molar response fac-
tors  of  human milk oligosaccharides. J Chromatogr B 1996;685:211–21.
[21] Gustafsson C,  Govindarajan S, Minshull J.  Codon bias and heterologous protein
expression. Trends Biotechnol 2004;22:346–53.
[22] De Schutter K, Lin Y-C, Tiels P, Van Hecke A, Glinka S, Weber-Lehmann J, et al.
Genome sequence of the recombinant protein production host Pichia pastoris.
Nat Biotechnol 2009;27:561–6.
[23] Saito T, Itoh T.  Variations and distributions of O-glycosidically linked sugar
chains in bovine -casein. J  Diary Sci 1992;75:1768–74.
[24] Ruhaak LR, Deelder AM,  Wuhrer M. Oligosaccharide analysis by  graphi-
tized carbon liquid chromatography–mass spectrometry. Anal Bioanal Chem
2009;394:163–74.
[25] Sabesan S, Paulson JC.  Combined chemical and enzymatic synthesis of
sialyloligosaccharides and characterization by 500-MHz 1H and 13C NMR  spec-
troscopy. J Am Chem Soc  1986;108:2068–80.
[26] Platzer N, Davoust D. Structural analysis of  ﬁve lactose-containing oligosaccha-
rides by improved high-resolution, two-dimensional 1H-NMR spectroscopy.
Carbohydr Res 1989;191:191–207.
[27] Egge H, Peter-Katalinic J.  Fast atom bombardment mass spectrometry for struc-
tural elucidation of glycoconjugates. Mass Spectrom Rev 1987;6:331–93.
[28] Laroy W, Contreras R. Cloning of Trypanosoma cruzi trans-sialidase and expres-
sion in Pichia pastoris. Protein Expres Purif 2000;20:389–93.
[29] Lee SG, Shin DH, Kim BG. Production of  sialyloligosaccharides by trans-sialidase
catalyzed reaction using fetuin as a sialic acid donor. Enzyme Microb Technol
2002;31:742–6.
[30] Gänzle MG. Enzymatic synthesis of galacto-oligosaccharides and other lac-
tose derivatives (hetero-oligosaccharides) from lactose. Int  Dairy J  2012;22:
116–22.
[31] Gosling A, Stevens GW,  Barber AR, Kentish SE, Gras SL.  Effect of the substrate
concentration and water activity on  the yield and rate of the transfer reaction
of -galactosidase from Bacillus circulans. J  Agric Food Chem 2011;59:3366–72.
[32] Agustí R, Giorgi ME, Mendoza VM,  Gallo-Rodriguez C, de Lederkremer
RM.  Comparative rates of sialylation by recombinant trans-sialidase and
inhibitor properties of synthetic oligosaccharides from Trypanosoma cruzi
mucins-containing galactofuranose and galactopyranose. Bioorg Med  Chem
2007;15:2611–6.
[33] Palai T, Bhattacharya PK. Kinetics of lactose conversion to galacto-
oligosaccharides by -galactosidase immobilized on  PVDF membrane. J  Biosci
Bioeng 2013;115:668–73.
[34] Rodriguez-Colinas B, Poveda A, Jimenez-Barbero J, Ballesteros AO,  Plou FJ.
Galacto-oligosaccharide synthesis from lactose solution or skim milk using the
-galactosidase from Bacillus circulans. J Agric Food Chem 2012;60:6391–8.
[35] Brunstedt J, Sørensen JF, Mikkelsen JD, Cervin MA.  Lipid acyltransferase pro-
teins and methods of making them. International patent. WO 2011/045629
A1.
[36] Gofﬁn D, Wathelet B, Blecker C, Deroanne C, Malendier Y, Paquot M.  Com-
parison of the glucooligosaccharide proﬁles produced from maltose by two
different transglucosidases from Aspergillus niger. Biotechnol Agron Soc Environ
2010;14:607–16.
 81 
 
 
 
10.2 Rational design of a new Trypanosoma rangeli trans-sialidase for 
efficient sialylation of glycans 
Jers C., Michalak M., Larsen D.M., Kepp K.P., Li H., Guo Y., Kirpekar F., 
Meyer A.S., Mikkelsen J.D; PLOS ONE, 
e83902.doi:10.1371/journal.pone.0083902. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rational Design of a New Trypanosoma rangeli
Trans-Sialidase for Efficient Sialylation of Glycans
Carsten Jers1, Malwina Michalak1, Dorte M. Larsen1, Kasper P. Kepp2, Haiying Li3, Yao Guo1,
Finn Kirpekar3, Anne S. Meyer1, Jørn D. Mikkelsen1*
1Center for BioProcess Engineering, Department of Chemical and Biochemical Engineering, Technical University of Denmark, Lyngby, Denmark, 2Department of
Chemistry, Technical University of Denmark, Lyngby, Denmark, 3Department of Biochemistry and Molecular Biology, Southern University of Denmark, Odense, Denmark
Abstract
This paper reports rational engineering of Trypanosoma rangeli sialidase to develop an effective enzyme for a potentially
important type of reactivity: production of sialylated prebiotic glycans. The Trypanosoma cruzi trans-sialidase and the
homologous T. rangeli sialidase has previously been used to investigate the structural requirements for trans-sialidase
activity. We observed that the T. cruzi trans-sialidase has a seven-amino-acid motif (197–203) at the border of the substrate
binding cleft. The motif differs substantially in chemical properties and substitution probability from the homologous
sialidase, and we hypothesised that this motif is important for trans-sialidase activity. The 197–203 motif is strongly
positively charged with a marked change in hydrogen bond donor capacity as compared to the sialidase. To investigate the
role of this motif, we expressed and characterised a T. rangeli sialidase mutant, Tr13. Conditions for efficient trans-sialylation
were determined, and Tr13’s acceptor specificity demonstrated promiscuity with respect to the acceptor molecule enabling
sialylation of glycans containing terminal galactose and glucose and even monomers of glucose and fucose. Sialic acid is
important in association with human milk oligosaccharides, and Tr13 was shown to sialylate a number of established and
potential prebiotics. Initial evaluation of prebiotic potential using pure cultures demonstrated, albeit not selectively, growth
of Bifidobacteria. Since the 197–203 motif stands out in the native trans-sialidase, is markedly different from the wild-type
sialidase compared to previous mutants, and is shown here to confer efficient and broad trans-sialidase activity, we suggest
that this motif can serve as a framework for future optimization of trans-sialylation towards prebiotic production.
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Introduction
For production of human milk oligosaccharides (HMOs), glycan
sialylation can be achieved chemically as well as enzymatically [1].
To achieve enzymatic synthesis, a trans-sialidase (TcTS) derived
from T. cruzi, the causative agent of Chagas disease, has previously
proven useful by transferring sialic acid from a donor to an
acceptor glycan [2]. However, for industrial production of food-
grade HMOs, it is a drawback that the enzyme constitutes an
important virulence factor within T. cruzi [3]. Redesigning mutants
of the non-pathogenic T. rangeli sialidase (TrSA) that possesses
relatively low trans-sialidase activity [4] provides an attractive
alternative for application in bioconversion processes. TrSA is
70% identical to TcTS and has the same overall tertiary structure.
Both enzymes have been extensively characterised by biochemical,
mutational and structural studies, and they share a common
double displacement mechanism with a tyrosine as the catalytic
nucleophile [5,6].
In TcTS, the acceptor binding site consists of Y119 and W312
which form stacking interactions with the acceptor sugar [7]. In
TrSA, W313 (corresponds to W312 in TcTS) is found in a
different conformation due to a Q284P substitution, while the
Y120 (corresponds to Y119 in TcTS) is replaced by serine [8]. In
addition to these differences in the acceptor binding site, a
conserved D97 hydrogen bonds differently to sialic acid in the two
enzymes, possibly due to the substitutions V96M and P98A.
Correction of both the acceptor-binding site (S120Y, G249Y, and
Q284P) and the sialic acid binding pocket (M96V, and A98P) is
required to confer trans-sialidase activity (1% of TcTS activity) to
TrSA, and the additional single mutations I37L (in this study
named Tr6) and G342A further increase activity to 10% of the
TcTS activity [9,4]. Kinetic data, however, indicate that the
mutants display a .25-fold lower affinity for lactose and .100-
fold higher kcat for the undesired, competing hydrolysis [4],
indicating ample room for further improvement.
In this study, we carried out a rational design of the T. rangeli
mutant sialidase Tr6 based on the identification of a major
difference (the motif constituted by amino acids 197–203) close to
the binding cleft. We hypothesised that this motif might affect the
trans-sialidase vs. hydrolase activity, notably due to the extremely
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unusual (and substitution-wise unlikely) +3 charge change in this
segment of the native trans-sialidase. Our production and
characterisation of a T. rangeli mutant sialidase (Tr13) from the
Tr6 parent incorporating this motif confirmed this hypothesis,
since a reduced hydrolytic activity was observed which promoted
overall trans-sialylation efficiency. Using a side-stream component
from the dairy industry, casein glycomacropeptide (cGMP), as
sialic acid donor for Tr13, we were able to sialylate a number of
established and potential prebiotic glycans, demonstrating a broad
acceptor specificity of Tr13.
Materials and Methods
Substrates
para-Nitrophenyl neuraminic acid (pNP-Neu5Ac) was pur-
chased from Sigma-Aldrich (Steinheim, Germany). 39-sialyllactose
and 69-sialyllactose were obtained from Carbosynth (Compton,
United Kingdom). The commercial casein glycomacropeptide
(cGMP) product LACPRODAN CGMP-20 with a sialic acid
content of about 9% (w/w) was supplied by Arla Foods (Viby,
Denmark), and low molecular weight impurities were removed by
filtration with a 5 kDa membrane. 4-methylumbelliferyl-b-D-
galactopyranoside (MU-Gal), b-lactose, lactulose, melibiose, malt-
ose, and fucose were purchased from Sigma-Aldrich (Steinheim,
Germany). Galactooligosacchardies (GOS) were purchased from
Gulio Gross (Trezzano, Italy). Iso-maltooligosaccharides (IMO)
were kindly provided by Taka Hayashi from Kyoto University,
RISH (Gokasho, Japan).
Rational mutant selection
Sialidase catalytic domains were identified using NCBI Con-
served Domain Search [10]. Pymol v1.3 (Schro¨dinger) was used to
identify amino acids within 14 A˚ of the sialic acid binding site,
based on the crystal structure with PDB code 1WCS, and was also
used for preparing the figures. The T. rangeli sialidase mutant Tr6
(see below) and trans-sialidases from T. cruzi (TcTS) (Uniprot ID
Q26966), Trypanosoma congolense (Uniprot ID G0WJG3) [11] and
Trypanosoma brucei (Uniprot ID Q57XJ2) [12] were aligned using
ClustalW [13]. Ranking of chemical difference between substitut-
ed amino acids in Tr6 vs. TcTS was done based on being first- or
second sphere relative to the substrate and based on the polar/
nonpolar and small/large distinction; such property-based selec-
tion turned out to correlate well with standard substitution
matrices (BLOSUM62), i.e. the most unlikely substitutions were
considered noteworthy. A comparison of loop structures in T. cruzi
and T. rangeli with and without a substrate analogue DANA (2, 3-
Dehydro-2-deoxy-N-acetylneuraminic acid) bound was made
using structures of TcTS (PDB codes 1MS1 and 1MS3) and
TrSA (PDB codes 1N1S and 1N1T). A 3D-model of Tr13 was
made using the Modeller software [14] with 1WCS as the
template.
DNA manipulations and strain construction
A gene encoding Tr6, T. rangeli sialidase mutant TrSA5mut (the
sequence was extracted from PDB file 1WCS) with an additional
mutation I37L [4], was codon-optimized for expression in Pichia
pastoris and synthesized by DNA2.0 (Menlo Park, CA, USA). The
synthesized gene was inserted in the P. pastoris expression vector
pPICZaC (Invitrogen) between the XhoI and XbaI restriction sites
generating a translational fusion to the a-factor signal sequence as
well as a C-terminal c-myc epitope and a 6xHis tag (Figure S1). The
plasmid was propagated in Escherichia coli NM522 grown at 37uC
with shaking in low salt LB medium (10 g/L tryptone, 5 g/L yeast
extract, and 5 g/L NaCl) supplemented with 25 mg/mL zeocin.
This vector, pPICZa-Tr6, was used as a template for introduction
of additional mutations by PCR using overlapping primers
(Table 1). The PCR products were inserted in pPICZaC between
the XhoI and XbaI sites. Constructs were sequenced to confirm the
mutations and to assure that no unwanted mutations had been
introduced by PCR. In the following, the mutants are denoted by
the amino acid change compared to the parent (e.g. Tr6 Q123R),
except for the multi-mutant denoted Tr13, in which amino acids
197–203 were changed from IADMGGR to VTNKKKQ. P.
pastoris X-33 was transformed with the constructs by electropora-
tion following the manufacturer’s instructions (Invitrogen).
Protein synthesis and purification
For small-scale protein synthesis, P. pastoris X-33 strains
harboring pPICZa with mutated genes were grown for three days
in 180 mL BMMY (10 g/L yeast extract, 20 g/L peptone,
100 mM potassium phosphate (pH 6), 13.4 g/L yeast nitrogen
base, 0.4 mg/L biotin and 0.5% methanol) shaking at 30uC.
Protein synthesis was induced every 24 hours by addition of
methanol to a final concentration of 0.5%. Cells were removed by
centrifugation for 5 min at 3000 g and the supernatant was
subsequently sterile filtered using a 0.2 mM Minisart filter
(Sartorius AG). The supernatant was concentrated about 100-fold
using Vivaspin20 concentrators with a 30 kDa cutoff (Sartorius
AG). The 6xHis-tagged protein was purified from concentrated
samples using Ni-sepharose (GE Healthcare) columns in accor-
dance with manufacturer’s instructions, followed by desalting on
PD-10 columns (GE Healthcare) using 20 mM sodium phosphate
buffer (pH 7.4), containing100 mM NaCl, and 10% glycerol. The
protein sample was finally concentrated to about 200 mL using a
Vivaspin0.5 concentrator with a 50 kDa cutoff (Sartorius AG).
For large-scale production, Tr6, Tr13, and Tr6 D363E were
produced in a 5 L Sartorius Biostat Aplus fermentor as described
previously [15]. The enzymes were purified by Cu2+ affinity
column chromatography as described previously [16]. Protein
concentrations were determined using the BCA protein assay
(Thermo Scientific) with bovine serum albumin as standard.
Sialidase activity assays
Sialidase activity was measured in a reaction containing 50 mM
phosphate-citrate buffer (pH 7), 0.75 mM pNP-NeuAc, and 3 mg/
mL sialidase enzyme. The reactions were initiated by addition of
substrate and were then followed spectrophotometrically at
410 nm at 30uC. pH 7 was chosen to enable detection of released
pNP in a continuous assay. Reaction rates were normalized as
percent of the activity of Tr6. For measurement of hydrolysis of
natural substrates, the assay was done with either 1 mM 39-
sialyllactose, 1 mM 69-sialyllactose, or 1 mM cGMP-bound sialic
acid in 50 mM phosphate-citrate buffer (pH 5) using 1 mg/mL
enzyme. Reactions were started by addition of enzyme and
stopped by adding H2SO4 to a final concentration of 45 mM.
Quantification of free sialic acid was done using a 2-thiobarbituric
acid assay [17] with the modification that butanol extraction was
substituted with mixing with dimethyl sulfoxide (DMSO) [18].
Trans–sialidase activity assay
Trans-sialidase activity was assayed as described previously [19]
but with several modifications. Reactions were done in 50 mM
phosphate-citrate (pH 6) at 30uC using 2.9 mg/mL enzyme. As
donor substrate, 1 mM cGMP-bound sialic acid was used, and
MU-Gal was used as acceptor. The low solubility in aqueous
solution prevented the use of higher concentrations of MU-Gal
than 0.5 mM. A solution of 87 mM MU-Gal in DMSO was
diluted to 2 mM in 50 mM phosphate-citrate buffer (pH 6)
Trans-Sialidase for Efficient Glycan Sialylation
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immediately before preparing the reactions. When crude enzyme
preparations from P. pastoris were used, a background signal likely
related to cleavage of MU-Gal by endogenous b-galactosidase was
present. This background signal could be removed by washing the
column eight times with 440 mL of 5 mM HCl after sample
application without desorbtion of the sialylated product and this
was therefore done routinely.
Optimisation of conditions for trans-sialylation
To determine the optimal conditions (pH, temperature, and
concentration of donor and acceptor), a quadratic central
composite design was used. MODDE Version 7.0.0.1 (Umetrics
AB, Umea˚, Sweden) was used as a tool to design the experimental
frame and to fit and analyse the data by multiple linear regression
analysis. The pH regimes 3, 4 and 5, incubation temperatures 20,
40 and 60uC, and concentrations of the acceptor lactose of 117,
234 and 351 mM were tested. Reactions were done using a fixed
concentration of cGMP-bound sialic acid of 8 mM in 15 mM
phosphate-citrate buffer with specified pH values, and using
15 mg/mL of Tr13 enzyme. Lactose and cGMP were solubilised in
buffer and preincubated at specific temperatures, before the
reactions were initiated by addition of enzyme. The biocatalysis
process was allowed to proceed for 20 min before the reaction was
stopped by heating for 10 min at 90uC. The concentration of
sialyllactose was determined by HPAEC as described below.
For a time study of the trans-sialylation reaction, Tr13 was
incubated as described above at pH 3 with 351 mM lactose,
8 mM cGMP-bound sialic acid and a reaction temperature of
25uC. The reaction was followed by sampling over a 100 min
period, and the concentration of sialyllactose was determined by
LC/MS as described below. Measurement at zero time was done
using heat-inactivated enzyme. Three replicates were made and
each data series fitted to a second-order polynomial function. For
each data series, the slope at time zero was used to calculate the
specific activity and the standard deviation.
Enzymatic production and purification of sialylated
glycans
The reactions were carried out in stirred glass bottles in reaction
volumes of 50 mL for melibiose and maltose, 88 mL for fucose,
100 mL for lactulose, and 250 mL for GOS and IMO. The
reaction was performed in 15 mM phosphate-citrate buffer (pH 3)
with 351 mM sialic acid acceptor (GOS, IMO, lactulose,
melibiose, maltose and fucose) and 8 mM cGMP-bound sialic
acid at 25uC using 15 mg/mL enzyme. Prior to the reaction, the
substrates were pre-incubated in the buffer. The reaction was
carried out for 20 minutes and then stopped by enzyme
inactivation by heating at 90uC for 10 minutes.
The reaction mixture was applied to a HiScale 50/20 (GE
Healthcare) anion exchange chromatography column packed with
Table 1. List of primers.
Name Sequence Description
Tr_fwd GCTCTCGAGAAGAGAGAGGCTGAAG XhoI, Tr 59
Tr_rev CGCTCTAGAAATGCTGCTGTACCAGC XbaI, Tr 39
Q123S_F CTATTGGACCTCTCACAGAGATGGATCTGACTGG Q123S
Q123S_R CATCTCTGTGAGAGGTCCAATAGTTCCTTGTCTTG Q123S
R125G_F GACCCAGCACGGAGATGGATCTGACTGGGAACC R125G
R125G_R CAGATCCATCTCCGTGCTGGGTCCAATAGTTCC R125G
G127A_F GCACAGAGATGCTTCTGACTGGGAACCATTGTTG G127A
G127A_R CCCAGTCAGAAGCATCTCTGTGCTGGGTCCAATAG G127A
E175Q_F ACTTACTAAGCAGTTCGTAGGTGGAGTAGGCG E175Q
E175Q_R CTCCACCTACGAACTGCTTAGTAAGTATGCCGTCGAACTC E175Q
V177L_F TAAGGAATTCTTGGGTGGAGTAGGCGCCG V177L
V177L_R CCTACTCCACCCAAGAATTCCTTAGTAAGTATGCCGTCG V177L
V180A_F CGTAGGTGGAGCTGGCGCCGCCATCGTG V180A
V180A_R TGGCGGCGCCAGCTCCACCTACGAATTCCTTAGTAAG V180A
G202K_F TGCTGACATGAAGGGAAGAGTATTTACAAAAATTATGTATTCC G202K
G202K_R ATACTCTTCCCTTCATGTCAGCAATTTGCACAG G202K
N250R_F AGTCGATTACAGAAGACGTCTGGTGTACGAATCC N250R
N250R_R CCAGACGTCTTCTGTAATCGACTCGGTTATTAATGATTAGC N250R
D363E_F GAGATTAATACTAATGAGGTTTATTCTCTTGTTTTTGTCCG D363E
D363E_R CAAGAGAATAAACCTCATTAGTATTAATCTCATGTAGGGAATATAATTTATC D363E
13MUT_F CCCTGTGCAAGTAACTAATAAGAAGAAGCAAGTATTTACAAAAATTATGTATTCCGAGG 13MUT
13MUT_R TTGTAAATACTTGCTTCTTCTTATTAGTTACTTGCACAGGGTATACCAAATTAC 13MUT
P98A_F GGTTGTCGATGCTACGGTCATAGTAAAGGGAAATAAGTTG P98A
P98A_R CTATGACCGTAGCATCGACAACCCTTGAAACTG P98A
Y249G_F CCGAGTCGATGGAAATAGACGTCTGGTGTACGAATC Y249G
Y249G_R GACGTCTATTTCCATCGACTCGGTTATTAATGATTAGC Y249G
Restriction sites are underlined and mutated nucleotides in bold.
doi:10.1371/journal.pone.0083902.t001
Trans-Sialidase for Efficient Glycan Sialylation
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e83902
402 mL of Sepharose Q FF. The separation was done at ambient
temperature with an A¨KTA purifier 100 work station equipped
with a P-900 pump, UV-900 monitor, and Frac-950 fraction
collector, all controlled by UNICORN software (GE Healthcare).
The elution was monitored at 210 nm. Elution was performed at a
flow rate of 70 mL/min. Before injection, the column was
equilibrated with 5 column volumes (CV) of water. After injection,
the column was washed with 3 CV of water, followed by elution
with 3.5 CV of 40 mM ammonium formate and subsequently
with 2 CV of 400 mM ammonium formate for cleaning the
column. After elution, the column was regenerated with 3 CV of
water. Fractions of interest were collected automatically. The
products were lyophilized and ammonium formate was removed
by repeated solubilization and lyophilization. Product structures
were determined by LC/MS, as described below.
High-performance anion exchange chromatography
(HPAEC-PAD)
Quantification of sialyllactose was carried out by HPAEC-PAD
analysis using a Dionex BioLC system consisting of GS50 gradient
pumps, ED50 electrochemical detector, AS50 chromatography
compartment coupled to an AS50 autosampler (Dionex Corp.,
Sunnyvale, CA). Samples (10 mL) were injected on a CarboPacTM
PA1 (4 mm6250 mm) analytical column (Dionex Corp., Sunny-
vale, CA) at a flow rate of 1 mL/min. The elution program was
based on the method described in [20] except for the modifications
in the eluent system given below. The eluent system comprised of
deionised water (A), 0.5 M NaOH (B), 1 M NaOAc (C). For the
first 3 min an isocratic elution of 80: 20 (% A:B) was applied,
which was followed by a linear gradient from 80:20 (% A:B) to
60:20:20 (% A:B:C) from 3 to 27 min. Strongly retained anions
were removed from the column by isocratic elution at 40:20:40
(% A:B:C) from 27 to 31 min. Subsequently, the column was re-
equilibrated for 7 min with 80:20 (%A:B).
Capillary Liquid Chromatography/Mass spectrometry
For liquid chromatography/Mass spectrometry (LC/MS) anal-
ysis, an Agilent 1100 LC/Agilent 6340 ion trap MS system was
used. Oligosaccharides were separated using a Hypercarb porous
graphitic carbon (PGC) column (0.326150 mm, 5 mm, Thermo
scientific) at 30uC. Samples (0.5 mL) were loaded onto the column
in 10 mM ammonium bicarbonate. Gradient elution was achieved
using a binary solvent system consisting of (A) 10 mM ammonium
bicarbonate, adjusted to pH 8.5 with ammonium hydroxide, and
(B) 100% acetonitrile at a flow rate of 5 mL/min. The gradient was
initially at 98:2 (% A:B) for 5 min, followed by a linear increase to
42:58 (% A:B) at 33 min. This concentration of B was held for
3 min. Subsequently the eluent was returned to 98:2 (% A:B) at
40 min and the system was allowed to equilibrate for 10 min prior
to the next injection. All solvents used were of the highest HPLC
grade. The mass spectrometry was performed in negative ion
mode, and was scanned in the range m/z 150–2200 (2 microscans,
maximum accumulation time of 150 ms, an ion current count of
200,000) followed by data-dependent MS2 scans of the four most
abundant ions in each MS1 scan.
Bacterial growth assays on sialylated glycans
For testing growth of bacterial strains on sialylated glycans the
following strains were used: Bifidobacterium longum longum (Danisco
Global Culture Collection DGCC 232), Bifidobacterium longum
infantis (DGCC 233), Bifidobacterium longum infantis (DGCC 1497),
Bifidobacterium longum infantis (DGCC 2238), Lactobacillus acidophilus
(NCFM, ATCC 700396), Bifidobacterium longum (Bl-05, DGCC
9917), Bifidobacterium lactis (HN019, DGCC2013), and Clostridium
perfringens (ATCC 13124). Galactan from potato (Megazyme
International LTD, Bray, Co. Wicklow, Ireland) was used as an
established prebiotic standard control. The substrates were
dissolved in water at 10% (w/v) and sterilized by sterile filtration
(0.2 mm Minisart, Sartorius AG, Go¨ttingen, Germany) except for a
control substrate, galactan from potato (Megazyme International
LTD, Bray, Co. Wicklow, Ireland), that due to its high viscosity
was sterilised by UV-radiation for 30 seconds. The strains were
precultured in MRS2 medium (de Man, Rogosa and Sharpe
medium without glucose) with no additional sugars added for 24 h
at 37uC under anaerobic conditions before being diluted with fresh
MRS2 medium to 1% (v/v). Growth on test substrates was done
by adding 20 mL of 10% test substrates and 180 mL 1% cell
suspension in multiwell plates and growth was followed by
measurement of optical density at 600 nm (OD600) using BiolinkH
software (Labsystems) in a BioscreenH C system (Labsystems,
Helsinki, Finland) as described previously [21]. The growth in
MRS2 medium without addition of carbohydrates was used as
control. The experiments were done in three replicates for each
strain, and carbohydrate substrate and growth was determined as
the area under the growth curve. Data are given as mean values 6
standard error.
One-way analyses of variances (one-way ANOVA): 95%
confidence intervals were compared as Tukey-Kramer intervals
calculated from pooled standard deviations (Minitab Statistical
Software, Addison-Weseley, Reading, MA).
Results and Discussion
Rational design of the T. rangeli sialidase mutant Tr13
In order to identify mutations likely to affect enzyme activity, we
used two initial criteria: First, we considered only amino acids
within 14 A˚ of the sialic acid-binding site. Secondly, based on an
alignment between Tr6 and the efficient trans-sialidase TcTS, we
considered the chemical difference between the amino acids,
assuming that larger chemical differences, correlating with lower
probability of substitution by random evolution, would be the most
likely candidates for conferring increased trans-sialidase activity
and/or reduce unwanted hydrolysis. We also inspected the impact
of changes in surface exposure, hydrogen bonding, and the
distance from the acceptor binding site. A sequence alignment
with amino acids within 14 A˚ of the sialic acid-binding site and
sites selected for mutagenesis are shown in Figure 1.
Among significant differences, the motif composed of amino
acids 197–203 is IADMGGR in TrSA and Tr6, but is substituted
to VTNKKKQ in TcTS. These substitutions cause a change in
net charge of +3, and the MGGR R KKKQ sequence of
substitution is highly unlikely to occur randomly (24 in total from
a BLOSUM62 matrix [22]). The substitution of two Gly residues
to Lys could alter the rigidity of the loop. This changed rigidity
might affect exclusion of water from the active site which could in
turn explain the reduced hydrolytic activity observed in TcTS. To
investigate this hypothesis, we compared the loops in structures of
TcTS and TrSA with and without a ligand bound (Figure 2). A
comparison of the loops shows little difference in the backbone
position between the two enzymes and neither of them appeared
to change conformation upon ligand binding. This indicates that
the chemical properties of the side chains, rather than the size and
backbone dynamics of the loops, are likely to determine differences
in catalytic activity. Consequently, an alternative explanation for
the role of the VTNKKKQ motif was sought in the introduction
of a +3 charge difference between the two loops. This charge
difference is also seen in the less similar trans-sialidase from
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T. congolense (ARNKANR, charge +3), but not in that of T. brucei
(ARNEDNA, charge –1). We hypothesised that the charge
difference and/or the substantial change towards hydrogen-bond
donors could affect the affinity for lactose or reverse the water
network in the substrate-binding cleft (or reduce water affinity, i.e.
increase Km for hydrolysis to favour competitive binding of
lactose), all to the effect of reducing hydrolysis. Energetically, the
free energy cost of aligning water molecules in the cleft
(rearrangement free energy of ,6.3 kJ/mol [23]) should be lower
than for fully excluding them (free energy of hydration of water
into water with an upper cost of ,35 kJ/mol [24]).
A homology model of mutant Tr13 based on Tr6 with the
additional seven mutations of the VTNKKKQ motif is shown in
Figure 3. The mutations are relatively far, ,14 A˚, from the
acceptor binding site and therefore unlikely to affect acceptor
binding directly. Water structure is from recent work known to be
a combination of symmetric, directed tetrahedral structure and
momentaneous asymmetry from breaking of hydrogen bonds [25].
The substantial increase of hydrogen bond donation from the loop
side suggests that a tetrahedral water network of the symmetric
type will be more likely to be inverted. This would change the
electrostatic field in the cleft and potentially disrupt or even reverse
the water network in the active site. Hydrolysis requires a water
network aligned with oxygen lonepairs towards the sialic acid,
whereas a strong positive charge and hydrogen-donor tendency at
the edge of the binding cleft, as seen in the native trans-sialidase
would work towards a partial reversal of such a network, turning
oxygen lone pairs towards the field of the lysines and correspond-
ingly impairing the nucleophilicity of the water network in the
cleft. Such a disruption of the water network could be the
explanation for TcTS’s exquisite quenching of hydrolysis, not
achieved by previous T. rangeli sialidase mutants [4].
In addition to the VTNKKKQ motif probed by Tr13, we also
investigated several single-site mutations from Tr6, to understand
the properties of previously described mutants in more detail. Two
such mutations were reverting mutations of the parent, P98A and
Y249G, while V180A was the mutant previously reported to at
least partially reduce hydrolase activity [4]. As further candidates
for improving trans-sialidase activity, several new single mutations
were also made from Tr6: R125G, E175Q, G202K, N250R,
Figure 1. Sequence alignment of sialidase catalytic domain from Tr6 and related trans-sialidases. Tr6 and trans-sialidases from T. cruzi
(Uniprot ID Q26966), T. congolense (Uniprot ID G0WJG3) and T. brucei (Uniprot ID Q57XJ2) were aligned using ClustalW. Amino acids within 14 A˚ of
sialic acid binding site are shown in bold. The seven amino acid motif is indicated with filled circles, reverting mutations are indicated with a triangle
while other mutated sites are indicated with asterisks.
doi:10.1371/journal.pone.0083902.g001
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Q123R, G127A, I177L, and D363E. These mutations were
notable either by their positions close to the binding cleft and/or
by conferring a chemical difference.
Sialidase mutant Tr13 displays increased trans-sialylation
activity
To assess the performance of the mutants, we produced them in
P. pastoris shake flask cultures and tested their trans-sialidase
activity using a fluorescence-based assay using cGMP as sialic acid
donor and methylumbelliferyl-b-D-galactopyranoside (MU-Gal)
as acceptor (Figure S2). The enzyme amounts obtained were too
low to allow a detailed characterization of the mutants. Since the
detected maximum product yield will be a measure of both the
trans-sialidase activity (product formation) and the hydrolase
activity (donor and product degradation) of the enzyme, it was
considered a relevant assay for an initial screen of the mutants.
Figure 2. Comparison of the loop motif in TcTS and TrSA. Structures of TcTS (PDB 1MS1; grey and 1MS3; light red) and TrSA (PDB 1N1T; blue
and 1N1S; green), with and without the sialic acid analogue DANA bound respectively, were compared. The loop motif constituted by amino acids
196–202/197–203 and DANA bound in active site between catalytic residues Glu-230/231, Tyr-342/343 and Asp59/60 in TcTS and TrSA respectively
are displayed.
doi:10.1371/journal.pone.0083902.g002
Figure 3. Homology model of Tr13. Close-up of active site with sialyllactose docked (blue). Acceptor binding site residues Tyr-120 and Trp-313
and catalytic nucleophile Tyr-343 side chains are shown in grey. The seven introduced amino acids are shown in yellow.
doi:10.1371/journal.pone.0083902.g003
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Although all the mutants were active, only Tr13 and Tr6 D363E
performed at a level comparable to Tr6 while all other mutants
displayed a decreased trans-sialidase activity. These two mutants
were therefore selected for further analysis, since the primary
objective of this work was to generate mutants displaying
improved trans-sialidase activity. It is worth noting that the single
mutation G202K, which is part of the VTNKKKQ motif,
reduced trans-sialidase activity. This indicates a co-operation effect
of the amino acids of the motif and not an effect additively derived
from the single-site mutations. For the reverting mutations P98A
and Y249G it could be concluded that they improve but are not
essential for trans-sialidase activity.
For further evaluation we produced the parent enzyme Tr6 and
the two mutants Tr13 and Tr6 D363E in a 5 L fermentor. This
allowed us to evaluate both hydrolase and trans-sialidase activity
(Figure 4). Hydrolase activity was tested on the artificial substrate
pNP-Neu5Ac as well as on the natural substrates 39-sialyllactose,
69-sialyllactose, and cGMP. None of the enzymes exhibited
detectable activity on 69-sialyllactose (data not shown) in turn
indicating that the a-2,6-linked sialic acid in cGMP was not used
as a sialyl donor when cGMP was employed as donor substrate for
the T. rangeli mutants. The a-2,6-linked sialic acid constitutes
about 50% of total sialic acid content in cGMP [26]. While both
Tr13 and Tr6 D363E had a decreased activity on pNP-Neu5Ac,
only Tr13 had a lower hydrolase activity on 39-sialyllactose and
cGMP (Figure 4A).
In the trans-sialidase activity assay, the initial reaction rate
represents the trans-sialidase reaction rate, while maximum
product formation is a measure of both trans-sialidase activity
(product formation) and hydrolase activity (product degradation).
Thus, Tr6 and Tr13 appeared to have similar trans-sialidase
activities (as measured by their initial reaction rates), while Tr6
D363E had a slightly lower activity, but under the applied reaction
conditions Tr13 accomplished twice the maximal yield (Figure 4B),
underscoring the importance of the VTNKKKQ motif for total
yields due to reduced hydrolysis activity on the product.
The improved maximal yield obtained for Tr13 catalysis
suggests that the VTNKKKQ motif does not affect the acceptor
binding affinity, but rather uniquely reduces the hydrolytic activity
(water kcat and/or Km), probably by impairing water nucleophi-
licity for attack on sialic acid (partial reversal of the water network)
and/or by reducing water’s retention time in the active site in
competition with the acceptor. The effect may be acceptor-
dependent, as the total extent of hydrolysis not only depends on
the impaired water network, but also the Km of the acceptor during
trans-sialylation, which affects acceptor vs. water retention time
and thus, the competition between hydrolysis and trans-sialylation.
Of the three lysines introduced in Tr13, K200 and K201 are
partly shielded from the active site (Figure 3) while K202 points
towards the center of the site. Changing only K202 led to a
reduced activity compared to the parent. The exact mechanism by
which the mutations exert their effect remains unclear and
certainly these mutations do not completely account for the
exceptionally low hydrolase activity and the higher affinity for
lactose in TcTS compared to Tr6. Tr13 however, represents a
major step forward by providing the first-ever design of a markedly
hydrolysis-impaired sialidase mutant. Within protein engineering
at large, viable mutants with improved properties that deviate so
substantially from a wild type (by 13 site changes including a 7-
amino acid loop structure with a +3 charge difference) are
unusual.
Optimization of reaction conditions for Tr13
Statistically designed experiments were performed to determine
reaction conditions that favour the trans-sialidase activity of Tr13.
The influence of the following factors was investigated: temper-
ature (20–60uC), pH (pH 3–5) and concentration of a standard
acceptor for this reaction, lactose (117–351 mM), while using a
fixed concentration of cGMP (8 mM). Reactions were allowed to
proceed for 20 min, and after terminating the reactions, the
concentration of 39-sialyllactose was determined by HPAEC. No
product formation was observed in controls with heat-inactivated
enzyme. The highest product yield was obtained at 351 mM
lactose (highest tested), pH 3 (lowest tested) and at 20uC (lowest
tested) (data not shown). A time study was performed at these
conditions and the specific trans-sialidase activity of the enzyme
was determined from this study shown in Figure 5. The specific
trans-sialidase activity, measured as number of sialyl-moieties
transferred, of Tr13 was 4.4 +/20.7 nmol*min21 per mg of
enzyme on cGMP. It was apparent that for a higher product yield,
the reaction time could be successfully extended from 20 to 100
minutes with no detectable product degradation, since no free
sialic acid was detected by LC/MS. Although the maximum yield
was not determined in the study, it could be concluded that at least
Figure 4. Enzyme activity of Tr6 and selected mutants Tr13 and Tr6 D363E. A) Hydrolase activity on substrates pNP-Neu5Ac, 39-sialyllactose,
and cGMP. B) Trans-sialidase activity using cGMP as sialic acid donor and MU-gal as acceptor.
doi:10.1371/journal.pone.0083902.g004
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,2.5 mM 39-sialyllactose could be produced. In cGMP, a-2, 3-
and a-2,6-bound sialic acid is in a ratio of about 1:1 [26], and
hence only 4 of the 8 mM cGMP-bound sialic acid was
theoretically accessible giving a yield of about 63%.
That the highest product yield was obtained at very low pH is
surprising, since pHopt for TcTS (using N-acetyllactosamine as
acceptor) is pH 7 [27]. The introduction of charged residues in the
vicinity of the catalytic residues might modulate the pH optimum
but unlikely by such magnitude. A temperature optimum of 13uC
has been reported for TcTS at low acceptor concentration
(7.2 mM) due to increased affinity for the acceptor at low
temperature while increasing acceptor concentration increased
Topt [28]. In our case, however, a very high acceptor concentra-
tion was used, indicating a different mechanism for the optimum
at low temperature.
Sialylation of various prebiotic glycans revealed
promiscuous acceptor substrate specificity of Tr13
We also examined the possibility of using Tr13 for synthesis of
chimeric molecules, probing the possibility of combining the
prebiotic effect with sialic acid as found in many HMO molecules
to assess potential, enhanced beneficial properties. To this end, we
sialylated the well-documented prebiotics GOS, IMO, and
lactulose as well as three other compounds, melibiose, maltose,
and fucose. This also provided a possibility to probe the acceptor
substrate specificity of this enzyme. For TcTS it is generally
accepted that terminal galactose moieties function as acceptor with
lactose being a better acceptor than melibiose and galactose,
glucose being a poor one [29]. Here we tested terminal galactose,
terminal glucose, and glucose and fucose monomers as acceptor
substrates for Tr13.
The sialylated oligosaccharides were enzymatically produced in
phosphate-citrate buffer at pH 3 at ambient temperature.
351 mM sialic acid acceptor and 8 mM cGMP-bound sialic acid
was used. After incubation for 20 minutes, the enzyme was heat-
inactivated and the sialylated products were purified by anion
exchange chromatography (Figure 6). In the unbound fractions,
there was always neutral, unreacted acceptor, which was eluted
with water. Applying 40 mM ammonium formate led to elution of
negatively charged compounds, i.e. sialylated products and
afterwards free sialic acid. According to LC/MS analysis, the
sialylated compounds were completely separated from sialic acid
as well as from the acceptor used in the reaction. The highest
yields were achieved when fucose (1.5 mM) and lactulose
(1.9 mM) were used as the sialic acid acceptors. Due to the
relatively low yield compared to the concentration of acceptor
substrates, it was relevant to assure that the substrates did not
contain sialylated compounds. Analysis of the lactulose and
melibiose preparations by LC/MS identified no contamination
with sialylated compounds or sialic acid. The yields of sialylation
products of GOS and IMO were lower. GOS and IMO
preparations were a mixture of oligosaccharides of different chain
length. The yields for each of the different chain lengths might
have differed from the average since sialylation of smaller species
appear to be favoured, at least for trans-sialylation with bacterial
sialidases [30]. The composition of products of sialylation of GOS
and IMO was complex (Table 2): Four and five different sialylated
compounds, respectively, were obtained. In the case of GOS, the
product of the lowest molecular weight was sialyllactose (m/z of
632), whereas incubation of IMO with cGMP led to production
also of sialylated glucose (m/z of 470), since the starting material
was abundant in that monomer.
Of the compounds produced, sialyllactulose was produced in
the highest molar yield. The presence of galactose and the 1,4-b
bond between galactose and fructose may make lactulose more
accessible for Tr13, since for the similar-size acceptors melibiose
(1,6-a-bound galactose) and maltose (1,4-a-bound glucose), yields
were less than 60% of those obtained with lactulose. It is well
established that glycans containing terminal galactose can be
sialylated by TcTS, but the fact that Tr13 could also sialylate
terminal glucose and even glucose and fucose monomers was
surprising and indicated a high level of acceptor promiscuity. To
our knowledge, this is the first report of such broad acceptor
substrate specificity, and it can potentially be a valuable asset for
enzymatic synthesis of a broad range of sialylated glycans using the
Tr13 enzyme as catalyst.
Potential prebiotic effect of various sialylated glycans
The end-goal for this ongoing research effort is the enzymatic
synthesis of novel functional food ingredients. As an initial
assessment of potential prebiotic properties of the sialylated
glycans, their growth promoting activity on selected bacterial
pure cultures comprising three strains of B. longum subs. infantis,
two B. longum subsp. longum, one B. lactis, one L. acidophilus and one
pathogenic strain of C. perfringens was evaluated. This was done
using a Bioscreen microtiter system, and the growth performance
was expressed as area under the growth curve [21]. To assess the
impact of sialylation it would have been relevant to compare with
growth on the unsialylated acceptor molecules, but since the
distribution of sialylated molecules of different chain length in case
of GOS and IMO was not quantified, we decided to use galactan
from potato as a control due to its confirmed prebiotic properties
[31].
The data presented in Table 3 revealed that within the group of
probiotic strains, sialylated melibiose and maltose did not appear
to promote growth. For B. infantis 233, B. infantis 1497, and B.
longum 232, growth was promoted by different sialylated
compounds while sialylated fucose promoted growth for all three.
In the case of B. infantis 2238, B. lactis, L. acidophilus, and B. longum
9917, none of the sialylated compounds promoted growth, while
L. acidophilus grew well on the prebiotic control substrate galactan.
C. perfringens grew significantly better than all the probiotic strains
on the sialylated compounds, except on sialylmelibiose where
growth was not tested due to only a limited amount of material
being available.
It was assumed that a prerequisite for utilising the sialylated
compounds would be the presence of a sialidase, as well as the
ability to degrade the prebiotic backbone. All the B. longum subsp.
Figure 5. Time study of trans-sialylation catalysed by Tr13.
Accumulation of 39-sialyllactose over time in 25uC, pH 3, 351 mM
lactose and 8 mM cGMP-bound sialic acid.
doi:10.1371/journal.pone.0083902.g005
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infantis strains contained a sialidase (data not shown) as does C.
perfringens, which contains the necessary enzymes for metabolising
sialic acid [32]. Although variations in growth were found on
different substrates, even within species, it was evident that the
majority of the bacteria tested, including C. perfringens, to some
extent were able to grow on the sialylated compounds. Recently,
three fucosylated HMOs were shown to stimulate bifidobacteria,
while E. coli and C. perfringens were unable to utilise the HMOs
[33]. More interestingly, the organic acid fermentation product
inhibited their growth, raising the possibility that this might also
take place in a mixed culture with the molecules synthesised in this
study. A mixed culture experiment taking into account bacterial
interactions would be required to assess this. Furthermore, the
potential functionality of these compounds as decoy molecules and
Figure 6. Anion exchange separation profiles for sialylated glycans. Sialylated glycans separated from sialic acid and unused acceptor
separated by Sepharose Q and detected at 210 nm.
doi:10.1371/journal.pone.0083902.g006
Table 2. Products of sialylation of various glycans analysed by LC/MS.
acceptor m/z product Product conc. Product yield
[M-H]2 [g/L] [wprod/waccep] [mM]
GOS 632 SA-a-Gal-1,4-b-Glc 1.0 0.44% ND
794 SA-a-Gal-1,4-b-Gal-1,4-b-Glc
956 SA-a-Gal-1,4-b-Gal-1,4-b-Gal-1,4-b-Glc
1118 SA-a-Gal-1,4-b-Gal-1,4-b-Gal-1,4-b-Gal-1,4-b-Glc
Fucose 454; SA-a-Fuc 0.66 1.17% 1.46
Melibiose 632 SA-a-Gal-1,6-a-Glc 0.62 0.52% 0.98
Lactulose 632 SA-a-Gal-1,4-b-Fru 1.2 0.97% 1.84
Maltose 632 SA-a-Glc-1,4-a-Glc 0.66 0.55% 1.04
IMO 470 SA-a-Glc 0.72 0.60% ND
632 SA-a-Glc-a-Glc
794 SA-a-Glc-a-Glc-a-Glc
956 SA-a-Glc-a-Glc-a-Glc-a-Glc
1118 SA-a-Glc-a-Glc-a-Glc-a-Glc-a-Glc
Yields are given as product concentration and as% (w/w) of product produced from acceptor used. ND; the molar concentration of sialylated GOS and IMO could not be
calculated since the distribution of different chain lengths was not determined. Abbreviations: SA, sialic acid; Gal, galactose; Glc, glucose; Fuc, fucose; Fru, fructose.
doi:10.1371/journal.pone.0083902.t002
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in modulation of the immune system will need to be addressed in
future work.
Concluding Remarks
Previous work by Paris and co-workers [4] identified important
residues in the acceptor binding site and in the sialic acid-binding
pocket that conferred trans-sialidase activity to the strict sialidase
of T. rangeli. However, these mutants all retained a much higher (at
least 100-fold) hydrolase activity compared to the native trans-
sialidase of T. cruzi, indicating that a major determinant of
impaired hydrolysis in the evolution of trans-sialidase was missing.
In this study, we have shown that a major chemical and
structural difference between the native trans-sialidase TcTS and
the homologous sialidase TrSA lies in the presence of a +3 charged
VTNKKKQ motif on the edge of the acceptor binding cleft, and
that this motif effectively reduces hydrolysis to promote trans-
sialidase activity. The most likely function of this motif is to
effectively disrupt (perhaps even reverse) the water binding
network, which must be aligned with the oxygen lone pairs
towards sialic acid in order to accomplish hydrolysis. Since the
motif is not conserved among characterized trans-sialidases its
beneficial effect might be context-dependent. Further structural
and enzymatic studies will certainly be needed to assess the validity
and generality of the proposed mechanisms.
A mutant, Tr13, was constructed from the parent Tr6 mutant,
with this identified motif incorporated and it was shown to display
a 4-fold lower hydrolase activity on 39-sialyllactose, while trans-
sialidase activity was essentially unaffected. As a result, a net
doubling of the yield of sialylated product was obtained using this
particular mutant Tr13, which also produced a better yield than a
series of controlling single-site mutants. The mutant is therefore
the first in a new class of envisioned mutants capable of reducing
hydrolysis in competition with trans-sialidase activity by disruption
of the water network of the acceptor-binding site and active site.
Tr13 is also remarkable by being chemically substantially different
from its wild type, with 13 sites mutated and a charge difference of
+3.
Furthermore, the native TcTS is generally believed to use only
terminal galactose as acceptor substrates [29], but Tr13 possessed
an unusually broad acceptor-substrate specificity, accommodating
terminal galactose but also terminal glucose and even monomers
of glucose and fucose. This, together with the substantially reduced
hydrolysis, should make Tr13 and its downstream mutants useful
for enzymatic sialylation of a broad range of glycans in the pursuit
of novel, functional food ingredients. To justify this approach, a
number of established and potential prebiotics, including GOS,
IMO, and lactulose, were sialylated in reasonable yields. An initial
examination of prebiotic potential demonstrated growth of
Bifidobacteria, although not selectively. Using Tr13 under optimal
conditions should further allow a synthesis-scale of these novel
molecules enabling further functionality tests including their
prebiotic effect in mixed culture, and their potential as anti-
adhesive antimicrobial and modulator of the immune system.
Supporting Information
Figure S1 The gene sequence and primary structure of
Tr6. Restriction sites used for vector construction are underlined.
pPICZaC (Invitrogen)-encoded N-terminus containing a-factor
signal sequence and Kex2 and Ste3 protease recognition sequence
(amino acids 1–89) and C-terminus containing c-myc and 6xHis-tag
(amino acids 730–752) in grey. Tr6 gene product (amino acids 90–
729) in bold.
(PDF)
Figure S2 Trans-sialidase activity of Tr6 and derived
mutants. Trans-sialidase activity measured using cGMP as sialic
acid donor and methylumbellferyl-pyrogalactoside as acceptor.
Product formation, for each of the mutant variants shown against
that of the parent Tr6, is shown in arbitrary units. Differences in
initial reaction rate might in part relate to differences in enzyme
amount used.
(PDF)
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Table 3. Bacterial growth on sialylated glycans.
Bacterial strain Area under the growth curve [OD600 x min]
MRS- S-GOS S-fucose S-melibiose S-lactulose S-maltose S-IMO galactan
B. infantis 233 30614 13265 7166 1466 109620 3064 95623 5567
B. infantis 2238 294668 274618 285615 30262 269620 158624 26966 26467
B. infantis 1497 31610 42613 14962 ND 3462 ND 4561 4069
B. longum 232 79620 16269 192620 104617 134619 122631 107619 42613
B. lactis 139670 176618 192627 ND 122618 10268 175613 143615
L. acidophilus 180628 15964 188618 19264 12862 193612 217619 371610
B. longum 9917 106630 7165 114615 7068 34614 10166 10369 93644
C. perfringens 455632 722652 811648 ND 541617 844699 1098661 447646
Area under the growth curve for growth of probiotic strains and pathogenic Clostridium perfringens on sialylated glycans; MRS- represents growth in the medium with
no carbohydrate added; galactan, an established prebiotic, was used as a positive control; growth responses for the substrates are shown for a substrate concentration
of 10 g/L for all bacterial strains. Data are given as average values of 3 replicates and shown 6 s.d. The growth of B. longum infantis 1497, B. lactis and C. perfringens was
not tested on sialylmelibiose, as well as, growth of B. longum infantis 1497 on sialylmaltose (ND).
doi:10.1371/journal.pone.0083902.t003
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a  b  s  t  r  a  c  t
Potato  pulp  is  a high-volume  side-stream  from  industrial  potato  starch  manufacturing.  Enzymatically
solubilized  -1,4-galactan-rich  potato  pulp  polysaccharides  of  molecular  weights  >100  kDa  (SPPP)  are
highly  biﬁdogenic  in human  fecal  sample  fermentations  in  vitro.  The  objective  of the  present  study  was
to  use  potato  -1,4-galactan  and the  SPPP  as  substrates  for  enzymatic  production  of  potentially  prebiotic
compounds  of lower  and  narrower  molecular  weight.  A  novel  endo-1,4--galactanase  from  Emericella
nidulans  (anamorph  Aspergillus  nidulans),  GH  family  53, was  produced  in  a  recombinant  Pichia  pastoris
strain.  The  enzyme  was  puriﬁed  by Cu2+ afﬁnity  chromatography  and  its  optimal  reaction  conditions  were
determined  to pH  5 and 49 ◦C  via  a statistical  experimental  design.  The  speciﬁc  activity  of  the  E.  nidulans
enzyme  expressed  in  P. pastoris  was  similar  to that  of  an  endo-1,4--galactanase  from  Aspergillus  niger
used as  benchmark.  The  E. nidulans  enzyme  expressed  in  P.  pastoris  generated  a  spectrum  poly-  and  oligo-
saccharides  which  were  fractionated  by  membrane  ﬁltration.  The  potential  growth  promoting  properties
of each  fraction  were  evaluated  by  growth  of  beneﬁcial  gut microbes  and pathogenic  bacteria.  All the
galactan-  and  SPPP-derived  products  promoted  the  growth  of probiotic  strains  of Biﬁdobacterium  longum
and  Lactobacillus  acidophilus  and  generally  did  not  support  the  propagation  of Clostridium  perfringens  in
single  culture  fermentations.  Notably  the  growth  of B.  longum  was  signiﬁcantly  higher  (p <  0.05)  or  at
least  as  good  on galactan-  and  SPPP-derived  products  as  fructooligosaccharides  (FOS).  Except  in  one  case
these  products  did  not  support  the  growth  of  the  pathogen  Cl. perfringens  to  any  signiﬁcant  extent.
© 2011 Elsevier Inc. All rights reserved.
1. Introduction
Potato pulp is primarily made up of the cell walls of the potato
tuber and is a poorly utilized by-product available in high amounts
from industrial potato starch manufacturing. In Europe, potato
starch production is tightly regulated by a quota system and potato
pulp is mainly used directly as cattle feed and sold to farmers
for less than 10 Euros per ton [1].  In order to maintain the eco-
nomical competitiveness of the potato starch industry improved
valorization of the pulp is important. The main polysaccharides
of potato pulp are pectin, cellulose, hemicelluloses, and some
residual starch [1,2]. The monomeric composition of destarched
potato pulp is dominated by galactose, but also includes galactur-
onic acid, arabinose, and rhamnose indicating that the cell wall
material in potato pulp is mainly made up of pectin, primarily
∗ Corresponding author. Tel.: +45 45252800; fax: +45 45932906.
E-mail address: am@kt.dtu.dk (A.S. Meyer).
rhamnogalacturonan I (RGI) with large galactan rich side chains
and homogalacturonan (HG) [2].  HG consists of linear stretches
of -1,4-linked d-galacturonic acid residues which can be methyl
esteriﬁed at C-6 and/or O-acetylated at O-2 and/or O-3 [3,4]. The
degree of methylation and acetylation in potato pectin has been
reported to 31 and 14%, respectively [5]. The RGI  backbone consists
of repeats of the disaccharide [→2)--l-rhamnose(p)–(1→4)--
d-galacturonic acid(p)-(1→] and may  have extensive side chains
attached to the O-4 of the rhamnose residues. The side chains
are composed principally of arabinose and galactose and consist
of -1,5-linked arabinosyl, -1,4-linked galactosyl and/or arabino-
galactan structures [6].  All three types of side chains are present
in potato RGI [7],  but -1,4-linked galactopyranosyl bonds dom-
inate, which is why  the side chains of potato RGI are considered
to mainly consist of -1,4-galactan chains, but with some of the
galactopyranosyl residues substituted at C-6 by -1,5-arabinans
[8,9].
Enzymatically solubilized polysaccharides from potato pulp
have been demonstrated previously to exert potentially beneﬁcial
0141-0229/$ – see front matter ©  2011 Elsevier Inc. All rights reserved.
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properties as dietary ﬁbers and prebiotics in both in vitro (human
fecal fermentations) and in vivo (rat and human) studies [10–12].
Recently, the enzyme catalyzed polysaccharide solubilization pro-
cess from potato pulp has been optimized further resulting in
release of high yields of pectinaceous polysaccharides with high
molecular weights, up to 400 kDa, via a one-step enzymatic process
using pectin lyase and polygalacturonase from Emericella nidulans
(formerly known as Aspergillus nidulans) and Aspergillus aculea-
tus, respectively [12,13]. These soluble, high molecular weight
potato pulp polysaccharides (SPPP), which are presumably made
up of mainly RGI -1,4-galactan chains, appeared to be partic-
ularly promising as prebiotics as this substrate selectively and
signiﬁcantly increased the densities of Biﬁdobacterium spp. and Lac-
tobacillus spp. when fermented in vitro by microbial communities
in human fecal samples; the stimulation of the Biﬁdobacterium spp.
was moreover better than that induced by commercially available
fructo-oligosaccharides (FOS, DP 2–8 Orafti®P95) used as a positive
control [12].
Different types of galacto-oligosaccharides are already well rec-
ognized in the literature for their biﬁdogenic and prebiotic effects.
We hypothesized that further enzymatic digestion of the SPPP to
form -1,4-galactan derived poly- and oligo-saccharides of lower,
and more narrow, molecular weights might unravel the ultimate
health beneﬁts of -1,4-galactans from potato pulp. In order to tar-
getly produce such galactosaccharides we produced and explored a
new cloned endo-1,4--galactanase from E. nidulans and examined
the optimal reaction conditions and product proﬁles generated. Our
aim of the present study was therefore to use the high molecular
weight potato pulp polysaccharides, SPPP, as a substrate for further
targeted enzyme catalysis to provide new opportunities for design-
ing functional food ingredients with signiﬁcant health beneﬁts and
at the same time provide for a valorization route for potato pulp.
2. Materials and methods
2.1. Substrates and enzymes
Galactan from potato was  purchased from Megazyme International LTD (Bray,
Co.  Wicklow, Ireland). Potato pulp was  supplied by Lyckeby Stärkelsen (Kristianstad,
Sweden). The high molecular weight solubilized potato pulp polysaccharides (SPPP)
were prepared from crude potato pulp via a short, minimal enzyme treatment with
pectin lyase and polygalacturonase, as described previously [12,13] (the SPPP were
coded as CPP > 100 in [12]).
The endo-1,4--galactanase (EC 3.2.1.89) from E. nidulans (GB accession no.
ABF50874.1; Swiss Prot Q5B153) was  produced by fermentation in Pichia pastoris
as  outlined below. The clone was  supplemented by FGSC, and had been constructed
from the chromosomal DNA of A. nidulans FGSC A4 (E. nidulans) as described by Bauer
et  al. [14]. Endo-1,4--galactanase from A. niger was purchased from Megazyme Intl
LTD.
2.2. Fermentation of endo-1,4-ˇ-galactanase from E. nidulans in P. pastoris
A  5 L Sartorius Biostat Aplus fermentor was inoculated with P. pastoris cells
grown for 20 h at 30 ◦C, at 150 rpm in shaking ﬂasks with minimal glycerol medium
as  detailed by Stratton et al. [15]. The 5 L scale production of recombinant protein
in  P. pastoris was  done essentially as described in [15] and as detailed by Silva et al.
[16],  except that the temperature for the Glycerol Batch and Glycerol Fed-Batch
phases was  30 ◦C and then adjusted to 25 ◦C for the Methanol Fed-Batch phase in
order to improve the stability of the enzyme. Agitation was speciﬁcally controlled
below 750 rpm to avoid excessive cell debris from the P. pastoris cells and to limit
the  downstream puriﬁcation process. Additional oxygen was added automatically to
accommodate optimal growth and enzyme expression. The total time of fermenta-
tion was 95 h. The biomass (OD600) and protein induction (by the CA assay explained
below) was  followed throughout the fermentation process by off-line sampling as
explained in [16].
2.3. Downstream process
At the end of the fermentation process the Pichia cells were collected by cen-
trifugation at 5300 × g, 5 ◦C for 1 h. The supernatant was  then subjected to sterile
ﬁltration, followed by concentration by ultraﬁltration using a cross-ﬂow bioreactor
system with a 10 kDa cutoff membrane (Millipore, Sartorius) as described in [16].
The  enzyme preparations containing 25% (w/v) glycerol were stored at −80 ◦C.
2.4. Gel electrophoresis and Western blotting
SDS-PAGE was  carried out using a Mini-Protean® Tetra System, Bio-Rad Labora-
tories (California, USA). The gel was  a Mini-Protean® TGXTM 12%. The running buffer
was  Tris/glycine/SDS. The power conditions were: 150 V, run time: 60 min, starting
current: 20 mA  and ﬁnal current: 3A. The proteins were visualized by staining with
Comassie brilliant blue.
Selected proteins were digested with endoglycosidase H (EndoH, Medinova) for
60 min  at 37 ◦C before they were electrophoretically transferred to PVDF (Hybond-
LFP) membranes using the standard wet  transfer method (10% methanol, 14.4 g/L
glycine and 3 g/L Tris buffer). After blocking with defatted milk proteins, the mem-
branes were incubated with monoclonal anti-poly-histidine-peroxidase antibodies
(Sigma–Aldrich), TBS, milk and Tween20 solution. Chemiluminescence was  induced
with Amersham ECL Plus Western Blotting Detection Reagents and the signals were
captured by exposure to Hyperﬁlm-ECL (Amersham).
2.5. Determination of protein concentration
The protein concentration was determined via reaction with bicinchoninic acid
(BCA) using The Thermo Scientiﬁc (Rockford, USA) Pierce® BCA Protein Assay Kit
according to the manufacturer’s instructions. Bovine serum albumin was used as a
standard.
2.6.  Enzyme puriﬁcation
The puriﬁcation was  performed by Cu2+ afﬁnity column chromatography using
a  CIM® IDA-8f ml  Tube Monolithic Column purchased from BIA Separations GmbH
(Villach, Austria). The afﬁnity chromatography was carried out as described previ-
ously [16]. The imidazole was removed using PD-10 columns (GE Healthcare).
2.7. Reducing sugars assay
The enzymatic hydrolysis of galactan was  assessed by a reducing sugars assay
modiﬁed from Lever [17,18]. The mixture of enzyme and substrate was  incu-
bated at 50 ◦C, pH 5 for 30 min. The substrate concentration was 6 g/L and the
enzyme/substrate ratio (E/S) (v/w) was 0.3%. The reaction was stopped by heat-
ing  for 10 min  at 100 ◦C. 20 l of ﬁltered sample was added to 3 ml of an alkaline
p-hydroxybenzoic acid hydrazide (PAHBAH) solution. Under alkaline conditions
PAHBAH reacted with reducing ends of saccharides giving yellow anions. The con-
centration of reducing ends was calculated from the absorbance at 410 nm using
d-(+)-galactose (Sigma–Aldrich, Steinheim, Germany) as the standard. One  unit
of  enzyme activity was deﬁned as production of 1 mol/ml min  of reducing ends
(galactose equivalents) in the assay mixture; and 1 kU = 1 M (gal equiv)/min.
2.8. Statistical design of the optimal conditions for hydrolysis of galactan from
potato by endo-1,4-ˇ-galactanase from E. nidulans expressed in P. pastoris
The endo-1,4--galactanase from E. nidulans expressed in P. pastoris was
incubated with a solution containing galactan from potato in 5 mM NaH2PO4
(Sigma–Aldrich, Steinheim, Germany). Three different pH regimes 4, 5 and 6 were
tested. Incubation temperatures were 40, 50 and 60 ◦C. The time of incubation was
1,  4.5 and 8 h. The tested enzyme to substrate ratios E/S (v/w) were 0.1, 0.3 and 0.5%.
A  quadratic central composite design was used. MODDE Version 7.0.0.1 (Umetrics
AB,  Umeå, Sweden) was used as an aid to design the experimental frame and to ﬁt
and  analyze the data by multiple linear regression analysis. Before the reaction, the
substrate was  preincubated for 5 min  at the appropriate temperature. The reaction
was stopped by heating for 10 min at 100 ◦C. The concentration of reducing ends
was then determined as described above.
2.9. Thermostability of endo-1,4-ˇ-galactanase from E. nidulans expressed in P.
pastoris
The thermal stability of the endo-1,4--galactanase from E. nidulans expressed
in P. pastoris was evaluated by preincubation of the enzyme in 5 mM NaH2PO4 buffer
(pH 5) at 50, 60 and 70 ◦C for 2–60 min. After a set exposure time at the selected tem-
perature, an aliquot of the enzyme solution was cooled to 50 ◦C, 500 l of galactan
solution was added to achieve an E/S (v/w) of 0.3%, and the residual enzyme activity
was measured via the reducing sugars assay as described above.
2.10. Inﬂuence of metal ions on enzyme activity
The E. nidulans endo-1,4--galactanase expressed in P. pastoris was  incubated
with 10 mM EDTA for 40 min  at room temperature. The control sample was  incu-
bated with 5 mM phosphate buffer pH 5 instead of the EDTA solution. After
incubation with EDTA, the EDTA was  removed by gel ﬁltration (PD-10 columns, GE
Healthcare). The relevant metal ion solution was added (1 mM)  to aliquots of EDTA
pretreated and control samples, respectively (no metal addition was a benchmark
both in the EDTA pretreated and in the control samples), and the reducing sugars
assay was used to determine the residual enzyme activity.
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2.11.  KM and Vmax determination of endo-1,4-ˇ-galactanase from E. nidulans
expressed in P. pastoris
The apparent KM and Vmax values for the endo-1,4--galactanase from E. nidulans
expressed in P. pastoris were determined using galactan from potato. The substrate
was  incubated in phosphate buffer at pH 5 for 5 min  at 50 ◦C. The enzyme was  added
and  samples were taken every minute for 5 min. The substrate concentrations were
varied to result in different E/S (v/w) levels of 0.3–1.7%. The activity of the enzyme
was  determined by the reducing ends assay described above.
2.12. Time-course hydrolysis of galactan polymers
The endo-1,4--galactanase from E. nidulans expressed in P. pastoris was  incu-
bated at its optimal temperature and pH with galactan (E/S (v/w) = 0.3%) for 15, 30,
60,  120 and 270 min  in 5 mM NaH2PO4. The polymer degradation over time was
evaluated by HPSEC analysis as detailed below.
2.13. 100 ml-scale enzymatic hydrolysis of potato galactan and SPPP
The reactions were performed in 100-ml scale to obtain sufﬁcient amounts of
oligosaccharides to perform in vitro growth curve determination. The enzymatic
reaction was  performed at the conditions optimal for the endo-1,4--galactanase
from E. nidulans expressed in P. pastoris. Four 50 ml  tubes each containing 25 ml  of
substrate solution in buffer were preincubated for 5 min  at 50 ◦C. The reaction was
carried out for 15, 60 or 270 min  at an E/S ratio of either 0.3% or 0.03%.
2.14. Membrane separation of the products from the enzymatic hydrolysis
After the enzymatic hydrolysis the reaction mixtures of oligomers and polymers
were separated using polyethersulfone or regenerated cellulose membranes (Mil-
lipore, Billerica, MA). The cut-offs of the membranes were 3, 10, 30 and 100 kDa.
The ﬁltration was  carried out in a stirred membrane reactor with a constant pres-
sure at 4 bar (Millipore, Billerica, MA). The reactor content was stirred carefully
to  decrease fouling. From each reaction mixture two fractions were obtained. In
case  of galactan, each mixture was ﬁltered two times, with 2 membranes of dif-
ferent cut off; e.g. to create samples PG3 and PG4 a membrane of 100 kDa was
applied to narrow the size of the investigated compounds and to remove the parts
of  the substrate, which were not hydrolyzed by the applied enzyme. Subsequently
a  membrane of 10 kDa cut-off was used. When SPPP was used as a substrate for
the reaction mixture, the separation was performed using only 1 membrane of
cut-off 10 kDa, since the products of the reaction of molecular weight higher than
100 kDa were the most abundant component of the post-reaction mixture and
moreover the high molecular weight compounds of SPPP revealed high biﬁdogenic
properties in fermentation in vitro in human fecal samples [12]. The yield of the
obtained fractions was  calculated in percentage as weight of produced sample to
weight of starting material. The molecular weights of the poly- and oligomers in the
permeates and retentates were evaluated by HPSEC analysis as described below.
2.15. Analytical methods
High-performance size exclusion chromatography (HPSEC): HPSEC was carried
out as described in [19] using a Shodex SB-806 HQGPC column (300 mm ×8 mm)
and a Shodex SB-G guard column (50 mm × 6 mm)  from Showa Denko K.K. (Tokyo,
Japan) on a system consisting of a P680 HPLC pump, an ASI-100 automated sample
injector, and an RI-101 refractive index detector (Dionex Corp., Sunnyvale, CA), but
with the modiﬁcation that the mobile phase was  a 0.5 M sodium acetate solution, pH
6.  The molecular mass markers were dextrans of molecular masses 110 ×103 g/mol,
70 × 103 g/mol, 40 × 103 g/mol, 17.2 × 103 g/mol, 10 × 103 g/mol and pullulan of
molecular mass 6 × 103 g/mol.
High-performance anion exchange chromatography (HPAEC-PAD): Separation
and quantiﬁcation of oligosaccharides were carried out by HPAEC-PAD analysis
using a Dionex BioLC system (Dionex Corp., Sunnyvale, CA) principally as described
in  [20], but with a slightly changed elution program of the three eluent system
comprised of deionised water (A), 0.5 M NaOH (B), 0.5 M NaOAc (C). For the ﬁrst
5  min  a linear gradient from 80:20 (%A:B) to 70:20:10 (%A:B:C) was applied, which
was  followed by an isocratic elution with 70:20:10 from 5 to 30 min. From 30 to
35  min  a linear gradient was  applied from 70:20:10 to 70:20:20 and then isocratic
elution from 35 to 45 min  with 70:20:20. Then, isocratic elution with 20:80 (%B:C)
was  applied for 10 min  to remove strongly retained anions and the column was
re-equilibrated for 10 min  with 80:20 (%A:B).
The monosaccharide compositions of the galactan and SPPP fractions were
determined by a mild, extended acid hydrolysis method modiﬁed from Garna et al.
[21]:  At a concentration of 2.5 g/L each substrate was  treated with 0.2 M triﬂuoric
acid  for 72 h at 80 ◦C. The recovery of monosaccharides was determined by perform-
ing  the same hydrolysis on l-rhamnose, l-arabinose, d-galactose, d-glucose, and
d-galacturonic acid. The samples were then ﬁltered through a 0.2 m ﬁlter prior to
HPAEC-PAD analysis (described below) and the recovery factors obtained were used
to  quantify the monosaccharides.
The separation and quantiﬁcation of monosaccharides were done by HPAEC-
PAD  analysis using an ICS-3000 system (Dionex Corp., Sunnyvale, CA) equipped with
a CarboPacTM PA20 (3 mm × 150 mm)  column and a CarboPac PA20 (3 mm × 30 mm)
guard column as described in [2],  but by use of a slightly modiﬁed elution pro-
ﬁle:  After injection of the sample a linear gradient from 15 to 5 mM NaOH was
applied from 0 to 1.5 min, followed by isocratic elution with 5 mM NaOH from
1.5 to 3 min. From 3 to 7 min a linear gradient from 5 to 2.5 mM NaOH was used
and  from 7 to 17 min  another isocratic elution was applied with 2.5 mM NaOH fol-
lowed by a third isocratic elution with 500 mM NaOH from 17 to 35 min. External
monosaccharides standards were d-galactose, d-glucose, l-rhamnose, l-arabinose,
d-galacturonic acid, and d-mannose.
Thin layer chromatography (TLC) analysis: The conversion of galactan to oligo-
saccharides was  followed by TLC using silica gel 60 plates from Merck (Darmstadt,
Germany). The solvent system was 1-butanol:formic acid = 2:3. The products were
visualized by spraying the plate with 10% (v/v) sulfuric acid in ethanol and subse-
quently charring it at 130 ◦C.
2.16. Bacterial growth assays on the prebiotic candidates and reference
compounds
The substrate samples were dissolved in water at 10% (w/v) and sterilized by
UV-radiation for 30 s. The bacterial strains were Lactobacillus acidophilus (NCFM,
ATCC 700396); Biﬁdobacterium longum (Bl-05, Danisco Global Culture Collection,
DGCC 9917); Biﬁdobacterium lactis (HN019, DGCC2013); Escherichia coli (ATCC
11775); and Clostridium perfringens (ATCC 13124). These strains were incubated in
mono-cultures with the individual substrates at concentrations of 1% (w/v) in des-
ignated multiwell plates in a Bioscreen® C system (Labsystems, Helsinki, Finland)
as  described previously [22]. Anaerobic growth was measured by monitoring the
increase of the biomass by optical density measurement at 600 nm (OD600) using
Biolink® software (Labsystems) according to the protocol detailed in [22]. The bac-
terial growth was determined as a function of OD600 and time. The baseline growth
in the media without addition of carbohydrates was used as control and subtracted
from growth obtained in the presence of substrate [22,23]. Glucose and galactose
were used as non-selective control substrates. Fructooligosaccharides (Raftilose® ,
Beneo, Belgium) were used as an established prebiotic standard control. Two  sets
of  experiments were done in three replicates for each strain and carbohydrate sub-
strate. Data are given as mean values ± standard error.
2.17. Statistics
One-way analyses of variances (one-way ANOVA): 95% conﬁdence intervals
were compared as Tukey–Kramer intervals calculated from pooled standard devia-
tions (Minitab Statistical Software, Addison-Wesley, Reading, MA).
3. Results and discussion
3.1. Fermentation of endo-1,4-ˇ-galactanase from E. nidulans in
P. pastoris
Throughout the high cell density fermentation of P. pastoris
containing the recombinant endo-1,4--galactanase the biomass
of P. pastoris was followed by measurement of the OD600, which
increased from 2 to 630 during the 95 h fermentation pro-
cess (Fig. 1). The level of extra-cellular protein including the
endo-1,4--galactanase reached 2.11 g/L after 95 h (Fig. 1). The
protein expression was  followed by SDS-PAGE and the endo-1,4-
-galactanase protein band at 39 kDa was  observed shortly after
methanol induction of the AOX1 promoter controlling the expres-
sion of the gene. The SDS-PAGE also showed that appreciable
amounts of endogenous protein from P. pastoris were present in
the extract. The endo-1,4--galactanase activity at the end of the
fermentation was  109 kU/L (equivalent to at total of 393 kU in the
3.6 L fermentation volume).
3.2. Enzyme puriﬁcation
The endo-1,4--galactanase produced in P. pastoris was  not
pure, but contained several other protein bands (Fig. 2). The fer-
mentation was  optimized to generate a very low level of cell wall
debris and to limit the accumulation of intracellular proteins from
P. pastoris in the supernatant. This improved the down-stream
processes, sterile-ﬁltration and ultra-ﬁltration, but was not sufﬁ-
cient to eliminate all the protein impurities. A ﬁnal puriﬁcation of
the enzyme was therefore necessary. The endo-1,4--galactanase
was puriﬁed on a CIM-Cu2+ afﬁnity column using the His-Tag
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Fig. 1. Evolution of key parameters during the 95 h fermentation of P. pastoris to produce the recombinant endo-1,4--galactanase from E. nidulans: Biomass measured as
optical density at 600 nm (OD600) (); enzyme activity (), and the methanol added during the fermentation (©) shown on the left Y-axis; protein concentration () shown
on  the Y-axis to the right.
binding module and an Äkta system [16]. The bound proteins were
desorbed with imidazole buffers and the combined fractions were
analyzed by SDS-PAGE and Western blot analysis. The yield of the
puriﬁed enzyme after the afﬁnity column chromatography was
82%, and the overall yield of endo-1,4--galactanase was 1.6 g/L.
This level of heterologous expression is high compared with the
levels for approx. 200 proteins listed by Cereghino and Cregg [24],
where only 7% have a titer higher than 1 g/L.
The endo-1,4--galactanase belongs to GH family 53 as catego-
rized in Carbohydrate-Active enZymes (CAZy) Database [25] (the
enzyme works via a retaining mechanism and the structure of the
GH53 domain is known to have a TIM barrel fold). The molecular
mass of the endo-1,4--galactanase as determined from the amino
acid sequence (Expasy Parameter program) was 38.6 kDa, in accor-
dance with the ﬁnding that the band obtained after puriﬁcation
was 39 kDa (Fig. 2). A glycosylation was therefore not expected,
although it is common among enzymes produced in P. pastoris.
Further analysis by Western blot and treatment with EndoH con-
ﬁrmed that the MW did not decrease which also indicated that the
endo-1,4--galactanase was not glycosylated (Fig. 2).
Alignment of the amino acid sequence from endo-1,4--
galactanase from E. nidulans expressed in P. pastoris with sequences
from other endo-1,4--galactanases using the blast program in the
NCBI server (http://www.ncbi.nlm.nih.gov) gave the highest iden-
tity of 71–77% with enzymes from Aspergillus tubingensis, A. niger,
A. terreus, and Penicillium chrysogenum (data not shown). Predic-
tion of the glycosylation sites by NetNGlyc tools (expasy.org/tools)
indicated two potential glycosylation sites in the endo-1,4--
galactanase, whereas a glycosylated rhamnogalacturonan I lyase
from Bacillus licheniformis expressed in P. pastoris was  recently
found to have 4 potential sites [16].
3.3. Optimal temperature and pH
To determine the pH and temperature optimum of the endo-
1,4--galactanase from E. nidulans expressed in P. pastoris a
statistically designed, quadratic central composite experiment
was applied to evaluate the individual and interactive effects
of 4 factors (pH, temperature, enzyme to substrate ratio, E/S
(v/w), and reaction time) in 24 experimental combinations. The
optimal pH and temperature combination was determined to
be pH 5 and 49 ◦C the regression model forming an almost
symmetric bell-shaped response surface optimum (Fig. 3). The
optimal pH of 5 was in agreement with the ﬁndings of Bauer
et al. [14], but the relatively high optimal temperature has
not been determined previously. As expected, increasing the
ratio of E/S (v/w) increased the yield of reducing ends. The
same was observed with increased reaction time up to 8 h, despite
that the enzyme lost half of the activity in 27 min  at 49 ◦C (Fig. 4);
the half life, t½ of the endo-1,4--galactanase from E. nidulans
expressed in P. pastoris was 57 min  at 40 ◦C, 27 min  at 49 ◦C and
∼10 min  at 60 ◦C as assessed in phosphate buffer (Fig. 4). Since the
temperature optimum of the investigated enzyme was 49 ◦C (in
the presence of substrate) and a relatively low thermal stability
was observed for the enzyme when incubated without the sub-
strate at elevated temperatures, the results strongly indicate that
the endo-1,4--galactanase is very stable in the presence of the
substrate.
Fig. 2. SDS-PAGE of enzyme samples from the separation steps; lane 0, molecular
mass marker; lane 1, crude enzyme preparation; lane 2, run off fraction from the
Cu2+ afﬁnity column; lane 3, pure enzyme eluted by the imidazoline buffer; lane 4,
Western blot of pure enzyme; and lane 5, Western blot of pure denatured enzyme
after treatment with EndoH.
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Fig. 3. Surface response as a function of temperature and pH of the endo-
1,4--galactanase activity. The colors vary from turquoise/green (low endo-
1,4--galactanase activity) to red (high endo-1,4--galactanase activity). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to  the web version of the article.)
3.4. Kinetic parameters and metal ions interactions
The kinetic parameters KM and Vmax for endo-1,4--galactanase
from E. nidulans expressed in P. pastoris were determined to 0.51 g/L
and 73.3 U/mg protein, respectively using a Hanes plot (data not
shown).
The catalysis of endo-1,4--galactanase from E. nidulans
expressed in P. pastoris was compared with that from A. niger.
The optimal pH for the latter enzyme was 4–4.5, and the optimal
temperature was 40 ◦C. The speciﬁc activity of the endo-1,4--
galactanase from A. niger was 70 U/mg (concentration 4.3 mg/ml
in the purchased preparation). Hence, the speciﬁc activity of the
endo-1,4--galactanase E. nidulans expressed in P. pastoris and the
speciﬁc activity of enzyme from A. niger were similar. The inﬂuence
of metal ions on the E. nidulans enzyme activity was also tested. The
enzyme was pretreated with EDTA prior to incubation with the spe-
ciﬁc metal ions (and the EDTA pre-incubation was  compared to the
results obtained without EDTA added). Except for the signiﬁcantly
Fig. 4. Thermal stability of endo-1,4--galactanase from E. nidulans; dashed lines
represent enzyme half lives, t½, for 60 ◦C (10 min), t½ for 49 ◦C (28 min) and t½ for
40 ◦C (57 min). Thermal stability was assessed in phosphate buffer.
Table 1
Inﬂuence of metal ions on enzyme activity. Different superscript letters a–c indicate
signiﬁcantly different values at p < 0.05 (one way ANOVA, pooled S.D. 3.7).
Pretreatment Metal added Activity (%)
None None 100 ± 3.6a
None AlCl3 73.3 ± 6.4b
None MgCl2 92.7 ± 3.3a
None MnCl2 89.2 ± 1.9a
None ZnCl2 105.7 ± 4.9a
None CaCl2 98.7 ± 5.2a
EDTA None 87.7 ± 1.2a
EDTA AlCl3 51.3 ± 3.3c
EDTA MgCl2 90.8 ± 4.9a
EDTA MnCl2 104.4 ± 0.3a
EDTA ZnCl2 107.5 ± 2.2a
EDTA CaCl2 103.5 ± 2.7a
lower activity in the presence of AlCl3, the endo-1,4--galactanase
activity was not affected by the metal ions (Table 1). The inﬂu-
ence of metal ions on fungal endo--1,4-galactanases performance
described in the literature is usually observed as weak or inhibitory.
Pb2+ and to a lesser extent Zn2+ and Ag+ have previously been found
to decrease the activity of endo--1,4-galactanases from A. niger
and A. aculeatus [9],  and the activity of an endo--1,4-galactanase
from A. sojae has also been reported to be signiﬁcantly inhibited
by Mn2+, Hg2+, Ag+, and Fe3+ [26]. The fact that the majority of
metal ions had no effect on the activity of endo-1,4--galactanase
from E. nidulans produced in P. pastoris could make this enzyme
better suited for the industrial applications than the other endo-
galactanases discussed above.
3.5. Release of poly- and oligosaccharides from potato galactan
The optimized conditions established above for endo-1,4--
galactanase from E. nidulans expressed in P. pastoris were used to
create potentially prebiotic poly- and oligosaccharides by enabling
enzyme catalyzed hydrolysis of the potato galactan polymer and
the SPPP substrate, respectively. The galactan polymer had a
molecular mass of about 150 kDa, and the composition of monosac-
charides (in mol%) was  86% galactose, 4% rhamnose, 7% arabinose,
3% galacturonic acid. The galactan polymer was progressively enzy-
matically degraded to lower molecular weight products in time
course experiments (2–270 min) using E/S ratios of 0.03% and
0.3% (Fig. 5). The molecular weights (MW)  of the products were
examined by HPSEC, and the experimental conditions yielding the
optimal level of the products were selected for further studies at
100-ml scale reactions. Galactan derived poly- and oligosaccha-
rides were separated according to molecular weight using 3 kDa,
10 kDa or 100 kDa membranes. A 3 kDa permeate referred to as
PG1 (potato galactan, 60 min; E/S 0.03%) was  obtained with a yield
of 28.7% (172 mg)  and contained oligosaccharides made up of 95%
galactose and 5% arabinose (mol%). PG2 was  the retentate cor-
responding to PG1; the hydrolyzate had been ﬁltered through a
10 kDa membrane prior to the 3 kDa membrane ﬁltration, and PG2
thus contained saccharides of 3–10 kDa (Fig. 5b); the molar com-
position of PG2 (yield 30%) was  93% galactose, 6% arabinose, 1%
rhamnose.
PG3 was  a 10 kDa permeate produced by 15 min hydrolysis
using an E/S ratio of 0.3%. The yield was  67% (402 mg) and the sugar
composition (mol%) was 93% galactose, 6% arabinose and 1% rham-
nose. PG4 was the retentate of PG3 (Fig. 5), and contained oligo-
and polysaccharides of ∼10–100 kDa (obtained at a yield of 29% by
weight) with a molar composition of 88% galactose, 8% arabinose,
2.5% rhamnose, and ∼1.5% galacturonic acid.
PG5 was  the 3 kDa permeate produced by an extended, inten-
sive endo--1,4-galactanase treatment of galactan for 270 min
at an E/S ratio of 0.3%. The yield was 43% (257 mg) and the
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Fig. 5. HPSEC analysis after enzymatic hydrolysis of potato galactan (Megazyme):
(a)  E/S (v/w) = 0.3% and (b) E/S (v/w) = 0.03%.
composition was ∼93% galactose, 7% arabinose and 0.3% rham-
nose. The yields and composition of all samples are summarized
in Table 2. The content of free galactose was relatively high in
both of the 3 kDa fractions, i.e. in PG1 and PG5. The high amounts
of low molecular weight galactose oligosaccharides were further
analyzed by HPAEC, where accumulation of galactose and galac-
tobiose coincided with extended incubation time and high E/S
ratio of 0.3% E/S (Fig. 6). One possibility for the high galactose
released could be that the endo--1,4-galactanase from E. nidu-
lans expressed in P. pastoris acted according to a multiple attack
mechanism and that the monosaccharide release therefore was an
“accidental” result of multiple attacks on the substrate as detailed
by van de Vis [9].  Another explanation may  be that the enzyme had
an ability to exhibit exo--1,4-galactosidase activity (EC 3.2.1.23)
as the reaction progressed. Similar ﬁndings of high galactose levels
have been reported in a number of studies with other endo--
1,4-galactanases derived from Aspergillus spp. [9,26–30]. Using
the p-nitrophenyl--d-galactopyranoside as the substrate did not
prove the presence of any exo-activity of the enzyme, however
(data not shown).
Fig. 6. Evolution proﬁle of oligosaccharides released from potato galactan
(Megazyme) by the endo-1,4--galactanase from E. nidulans expressed in P. pas-
toris,  used at E/S (v/w) 0.3%, with time: 1, galactose monomer eluted at 4.5 min; 2,
galactose dimer eluted at 7.4 min; 3, galactose trimer eluted at 9.6 min; 4, galactose
tetramer eluted at 14.5 min; and 5, galactose pentamer eluted at 24.1 min.
Although the potato galactan polymer contained some galac-
turonic acid (3.5%), the PG fractions obtained were almost devoid
of galacturonic acid although a little bit was analyzed in PG4. It
is expected that the galacturonic acid and RGI backbone stretches
remained intact in the undigested residues of the polymeric sub-
strate. A relatively high galacturonic acid content in some domains
of the polymer may  render it resistant to enzyme hydrolysis. This
phenomenon has been described previously for enzymatic degra-
dation of related polysaccharides [27].
3.6. Release of poly- and oligosaccharides from high molecular
weight solubilized potato pulp polysaccharides (SPPP)
The high MW SPPP were prepared from crude potato pulp via a
short, minimal enzyme treatment with pectin lyase and polygalac-
turonase, as described by Thomassen et al. [12,13]. The molecular
mass of the SPPP was higher than 400 kDa and the molar monosac-
charide composition (mol%) was 66% galactose, 2% rhamnose, 9%
arabinose, 14% galacturonic acid, 7% glucose, and 2% mannose. Dif-
ferent samples of oligosaccharides derived from the SPPP were
obtained by treatment of this substrate with an E/S ratio of 0.03% in
combination with incubation for 60 min  or by using an E/S 0.3% and
15 min  of incubation. The reaction was conducted in 100-ml scale.
The HPSEC chromatograms of the reaction products are detailed in
Fig. 7. After incubation for 15 min  the reaction mixture was sepa-
rated by a 10 kDa membrane and two  fractions were obtained, the
permeate fraction SPPP1 and the 10 kDa retentate (fraction SPPP2).
The yield of SPPP1 was  21% by weight (124 mg), and the products
had a molar composition of ∼93% galactose, 4% arabinose, 3% galac-
turonic acid, and 0.3% glucose. The majority of the galacturonic acid
was thus present in the SPPP2 fraction which constituted 65% by
weight (390 mg)  of the originally enzyme treated material and had
Table 2
Yields and details of produced galactan and SPPP fractionsa.
Sample Fraction details Yield (w/w %) Composition (mol%)
Galactose Arabinose Rhamnose Galacturonic acid Glucose Mannose
PG1 Galactan, 0.03%, 60 min, less than 3 kDa 28.7 95.2 4.8 0 0 0 0
PG2  Galactan, 0.03%, 60 min, between 3 and 10 kDa 30.2 92.7 6.4 0.9 0 0 0
PG3 Galactan, 0.3%, 15 min, less than 10 kDa 67.1 93.0 5.6 1.4 0 0 0
PG4  Galactan, 0.3%, 15 min, between 10 and 100 kDa 29.0 87.7 8.4 2.5 1.4 0 0
PG5  Galactan, 0.3%, 270 min, less than 3 kDa 42.9 93.1 6.6 0.3 0 0 0
SPPP1  SPPP, 0.3%, 15 min, less than 10 kDa 20.6 92.9 3.6 0 3.2 0.3 0
SPPP2  SPPP, 0.3%, 15 min, more than 10 kDa 65.0 53.9 20.2 3.1 10.8 7.4 4.6
a Samples PG1 and PG2 are from one hydrolysis. The sum of their yields does not give 100.0%, since PG1 is the fraction below 3 kDa and PG2 is the fraction between 3 and
10  kDa and the material above 10 kDa was separated as well. Similarly for samples PG3 and PG4, but in this case only material above 100 kDa was discarded. The galacturonic
acid  is presumed to be in the un-reacted material that did not pass the membrane during ﬁltration. In case of SPPP, the endo-1,4--galactanase from E. nidulans expressed
in  P. pastoris catalyzed the cleavage in the galactan part of the substrate, therefore galacturonic acid was  mainly retained in the SPPP2.
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Fig. 7. HPSEC analysis of E. nidulans endo-1,4--galactanase catalyzed hydrolysis of
SPPP.
a monomer composition (in mol%) of 54% galactose, 20% arabinose,
3% rhamnose, 11% galacturonic acid, in addition to 7% glucose and
5% mannose (Table 2).
3.7. Effects on growth in selected mono-cultures
The potential prebiotic properties of the fractionated oligosac-
charides generated by enzymatic catalysis of galactan and SPPP,
respectively, were evaluated by measuring their growth promot-
ing activity on selected pure cultures using a Bioscreen microtiter
system. The growth performance expressed as area under the
growth curve [22] was assessed for ﬁve different bacteria compris-
ing three probiotic strains, L. acidophilus,  B. longum, and B. lactis, one
pathogenic strain of Cl. perfringens, and one commensal E. coli strain.
Fructooligosaccharides were used as a control due to their prebiotic
properties on biﬁdobacteria and lactobacilli and their presumed
ability to decrease growth of clostridia [31].
The growth of each individual test bacterium was  affected differ-
ently by the different compounds. In addition, the different bacteria
also responded differently to the same substrate (Fig. 8).
The PG5 fraction (PG5 is hydrolyzed galactan <3 kDa, 270 min,
E/S 0.3%) stimulated the growth of L. acidophilus and B. longum sig-
niﬁcantly better than any of the other hydrolysates; the stimulation
of the L. acidophilus growth was at the same level as that achieved
with FOS but signiﬁcantly better (p < 0.05) than that obtained with
pure galactose and unhydrolyzed galactan. The stimulation of B.
Fig. 8. Differential growth of bacterial strains on E. nidulans endo-1,4--galactanase
catalyzed hydrolysis products from potato galactan and SPPP (please see text for
details); galactose and fructo-oligosaccharides (FOS) were used as controls; growth
responses for all the 9 substrates is shown for a substrate concentration 10 g/L for
all  bacterial strains. Data are given as average values of 3–6 growth assay replicates
and  shown ± S.D. (for the one-way ANOVA of the bacterial growth the pooled S.D.s
were: L. acidophilus: 74.6; B. longum 51.7; B. lactis 17.2; E. coli: 31.3; Cl. perfringens:
41.3; for the total ANOVA (level: 45) the pooled S.D. was: 50.1).
longum was  more than 6-fold better than that of FOS and signif-
icantly better (p < 0.05) than that achieved with galactose or the
unhydrolyzed galactan (Fig. 8). The PG1 fraction (<3 kDa, 60 min,
E/S 0.03%) and the SPPP1 substrate (<10 kDa fraction generated by
digestion of SPPP for 15 min, E/S 0.3%) also stimulated the growth
of both L. acidophilus and B. longum to a signiﬁcant extent – for
B. longum the growth stimulation by PG1 and SPPP1 as well as
by PG4 was  signiﬁcantly better than that obtained with either
FOS, galactose or the original galactan (p < 0.05) (Fig. 8). The sam-
ples PG1, PG3, PG5, and SPPP1 all contained low molecular weight
oligomers and some galactose (data not shown), which might
explain some of the growth stimulation of L. acidophilus and B.
longum promoted by these substrates. It is important to note, how-
ever, that the growth of B. longum was better on all these fractions
(PG1, PG4, PG5, SPPP1) than on neat galactose (Fig. 8); this result
might indicate that each of these hydrolysates contained particular
galactan or arabino-galactan structures, of relatively low molecular
weight, which were particularly effective to stimulate the growth
of B. longum. These structures could be either small linear -1,4
galacto-oligosaccharides or certain low molecular weight branched
structures that were liberated from the galactan (and SPPP) as the
enzymatic hydrolysis of the -1,4-galactan progressed. The high
molecular weight fraction SPPP2 was  tested only at 0.5% (w/v)
due to its low solubility and high viscosity in the solution at this
dosage level. It did not support the growth of any of the inves-
tigated microorganisms to a high extent (data not shown). The
data also showed that the growth of both E. coli and Cl. perfrin-
gens was not supported by these particular low molecular weight
hydrolysates (p < 0.05) (and signiﬁcantly more decreased than the
corresponding growth on galactose and FOS) as it was  low on galac-
tan – the only exception being the growth on PG5 which for the
E. coli was  the same as that obtained on galactose, but which for
Cl. perfringens was  lower than that on galactose, but higher than
on FOS (Fig. 8). Whether PG5 is as promising a prebiotic agent as
some of the other produced fractions requires further investiga-
tion, e.g. by incubation with mixed microbiota and assessment of
whether competition and/or cross-feeding phenomena inﬂuence
the growth of the pathogen. Galactan, as well as, samples PG2
and PG3 (3 kDa < PG2 < 10 kDa, 60 min, E/S 0.03%; and PG3 < 10 kDa,
15 min, E/S 0.3%) did not appear to support the growth of Cl. per-
fringens. Neither did of these substrates support the growth of very
high levels of any of the three “probiotic” strains, and the growth
of E. coli was  also much lower than that achieved with galactose.
Even though the growth stimulation of E. coli by these substrates
was higher or at least the same level as that obtained with FOS
(Fig. 8) further investigation concerning the structural traits of the
compounds present in these endo--1,4-galactanase hydrolyzed
fractions and identiﬁcation of the presumed key potentially pre-
biotic compounds is warranted. An additional point is that the
presence of galactose would most likely not be important in vivo
since the human organism would absorb the galactose before it
reaches the colon. Although the detailed data analysis revealed
that unhydrolyzed galactan stimulated the growth of B. lactis to
the same extent as neat galactose, hardly any growth of B. lactis
was obtained with any of the substrates, except with FOS (Fig. 8).
In summary, contemplation of the bioscreen data showed that
among the tested samples the lower molecular weight fractions
exhibited more and various potentially prebiotic features.
Whether the observed low or no growth supporting effects on Cl.
perfringens have any signiﬁcance in the genuine competition among
the bacteria in the mixed microbiota in the gut deserve further
investigation.
An evaluation of the enzymes annotated for the sequenced
genomes for different species within Biﬁdobacterium avail-
able via the CAZy database [25] shows that biﬁdobacteria are
generally capable of expressing -galactosidase (EC 3.2.1.23),
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-galactosidase (EC 3.2.1.22), endo--1,6-galactanase (EC
3.2.1.164), exo--1,3-galactosidase (EC 3.2.1.145), -1,3-
galactosidase (EC 3.2.1.-) and endo--1,4-galactanase (EC 3.2.1.89)
[31]. Endo--1,4-galactanase (GH53) can be expressed by B.
dentium (Bd1), B. longum (DJO10A and NCC2705), B. longum subsp.
infantis (157F and JCM1222), B. longum subsp. longum (F8, BBMN68,
JDM301 and JCM1217) and Lactobacillus reuteri (DSM20016 and
JCM1112) but a gene sequence for this enzyme activity has not
been identiﬁed in any of the other genome sequenced Biﬁdobac-
terium and Lactobacillus species. Exo--1,3-galactosidase (GH43)
has been annotated for more than 15 different biﬁdobacteria but
only in four lactobacilli. Endo--1,6-galactanase (GH5 and GH30)
were annotated for several biﬁdobacteria (>12) but only in two
lactobacilli. Lastly, -1,3-galactosidase (GH110) was  annotated for
B. biﬁdum (PRL2010 and S17) but not found in lactobacilli. Different
species of Bacteroidetes and Firmicutes were also reported to be
able to express some of these enzymes [25], but gene stretches
encoding all the enzyme activities were not present in all the
available genomes. The data suggest that especially B. longum may
express particularly high activities of some of these enzymes and
this could give a selective advantage in utilizing the -1,4-linked
galactans and -1,4-linked-oligomers.
The present work was conducted using single cultures, but
the results obtained are in good accord with the amply reported
prebiotic effects of galacto-oligosaccharides [32,33]. The data
also agree with recent data from a human study (a double-
blind, crossover, placebo-controlled intervention study with 59
human volunteers), which have shown that certain enzymati-
cally synthesized -galacto-oligosaccharides, consumed at levels
of 7 g/day, signiﬁcantly increase the biﬁdobacteria ratio com-
pared with a commercial galacto-oligosaccharide (p < 0.05) [34].
It has also been shown that these enzymatically synthesized -
galacto-oligosaccharides have potential in alleviating symptoms
of irritable bowel syndrome and in preventing the incidence
and symptoms of travellers’ diarrhea [35,36]. The latter biﬁ-
dogenic -galacto-oligosaccharides were synthesized by use of
-galactosidase enzymes originating from B. biﬁdum NCIMB 41171
[34–36].  The data clearly suggest that -galacto-oligosaccharides
whether obtained via enzyme catalyzed hydrolysis of longer chain
-galactan structures or via -galactosidase catalyzed synthesis
possess promising beneﬁcial properties in relation to gut health.
The available data also suggest that different sub-structures of
these -galactosides, e.g. certain molecular sizes and/or branch-
ing patterns, exhibit differential prebiotic effects. At present, there
is a severe lack of knowledge about the speciﬁc carbohydrate struc-
tural effects and about the interactions among different “probiotic”
and pathogenic strains in vivo; it can be speculated that the dif-
ferent human gut bacteria respond differently to compounds and
metabolites produced by other bacteria and thus interact highly
differently to cross-feeding phenomena. Any data on this would
provide a signiﬁcantly improved foundation for tailoring of carbo-
hydrate structures for gut health.
3.8. Conclusions
A very active endo-1,4--galactanase from E. nidulans expressed
in P. pastoris has successfully been produced in a 5 L scale fermen-
tation and puriﬁed with a high yield (1.6 g/L). The enzyme was
used to design oligosaccharides from high molecular weight -1,4-
galactan-rich potato ﬁbers (SPPP) as well as from potato galactan
in membrane reactors. A range of these products were demon-
strated to have signiﬁcant prebiotic potential on single cell cultures
of gut microbes. The results of this present work have provided an
additional positive foundation for biocatalytic design of -galacto-
oligosaccharides with putative health effects. The work has also
shown a direction for potential valorization of the potato pulp
byproduct stream.
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A novel Emericella nidulans endo--1,4-galactanase (EnGAL) demonstrates a
strong capacity to generate high levels of very potent prebiotic oligosaccharides
from potato pulp, a by-product of the agricultural potato-starch industry.
EnGAL belongs to glycoside hydrolase family 53 and shows high (72.5%)
sequence identity to an endo--1,4-galactanase from Aspergillus aculeatus.
Diffraction data extending to 2.0 A˚ resolution were collected from a crystal
of EnGAL grown from conditions containing 0.2M zinc acetate. The crystal
structure showed a high similarity between EnGAL and other endo--1,4-
galactanases belonging to GH53. It also revealed 15 zinc ions bound to the
protein, one of which is located in the active site, where it is coordinated by
residues Glu136 and Glu246 which comprise the catalytic machinery. The
majority of the zinc ions are located on the surface of the enzyme, in some cases
with side chains from two different molecules as ligands, thus explaining why the
presence of zinc ions was essential for crystallization.
1. Introduction
Enzymatically solubilized polysaccharides from potato pulp have
been demonstrated to exert potentially beneﬁcial properties as
dietary ﬁbre and prebiotics in both in vitro (human faecal fermen-
tations) and in vivo (rat and human) studies (Thomassen, Vigsnaes et
al., 2011). Recently, high yields of pectinaceous polysaccharides with
high molecular weights have been released by a one-step enzymatic
process using the enzymes pectin lyase and polygalacturonase from
Emericella nidulans (a sexual anamorph of Aspergillus nidulans;
Thomassen, Larsen et al., 2011). The soluble, high-molecular-weight
potato-pulp polysaccharides showed very promising prebiotic
properties. Further hydrolysis of these high-molecular-weight poly-
saccharides with E. nidulans endo--1,4 galactanase expressed in
Pichia pastoris showed that the high-molecular-weight potato
-1,4-galactan could be further enzymatically degraded. The resulting
product, a lower and narrower molecular-weight galactan, exhibits
even more potent prebiotic effects on human gut microbiota. EnGAL
shows optimal activity at 322 K and pH 5.0. Its half-life is 57 min
at 313 K, 27 min at 322 K and 10.5 min at 333 K. On the addition of
divalent metal ions (Ca2+, Mn2+ and Zn2+) a minor increase in activity
was observed (Michalak et al., 2012).
Sequence comparison showed that this endo--galactanase
(EnGAL) belongs to CAZy family GH53 (Cantarel et al., 2009) and
is part of the largest glycoside hydrolase clan (clan A; Supplementary
Table S11). It acts with retention of the conﬁguration at the anomeric
position in a double-displacement mechanism (Jenkins et al., 1995;
Henrissat et al., 1995). EnGAL shows 72.5% sequence identity to the
endo--1,4-galactanase from A. aculeatus (AAGAL), the structure of
which has been determined at two temperatures: 293 and 100 K (PDB
entries 1fhl and 1fob; Ryttersgaard et al., 2002). Le Nours et al. (2003)
determined the structures of two other fungal endo--1,4-galacta-
nases with higher temperature optima, one from Humicola insolens
(HIGAL; PDB entry 1hjq) and the other from Myceliophthora
thermophilia (MTGAL; PDB entries 1hjs and 1hju). The structure is
also known of an endo--1,4-galactanase from Bacillus licheniformis
# 2013 International Union of Crystallography
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(BLGAL) both in the apo form and as oligosaccharide complexes
(PDB entries 1r8l, 1ur0, 1ur4, 2ccr, 2gft and 2j74; Ryttersgaard et al.,
2004; Le Nours et al., 2009). In order to provide a structural back-
ground for the functional analysis of EnGAL in relation to the other
enzymes from family GH53, structure determination of EnGAL was
initiated.
2. Materials and methods
2.1. Macromolecule production
The endo--1,4-galactanase gene AN5727.2 (GenBank
ABF50874.1; UniProtKB/SwissProt Q5B153) was obtained from
the Fungal Genetics Stock Center (http://www.fgsc.net). It had been
cloned earlier as the gene construct shown in Table 1 (Bauer et al.,
2006). The expression in P. pastoris, characterization and puriﬁcation
of EnGAL have been described in detail elsewhere (Silva et al., 2011;
Michalak et al., 2012). The gene construct included a C-terminal
6His tag. A His-tag IMAC column was used for puriﬁcation using
a binding buffer consisting of 0.04M EPPS pH 8.0, 0.5M NaCl and
subsequent elution with 0.04M EPPS, 0.5M NaCl, 0.5M imidazole.
The imidazole was removed by gel ﬁltration (PD10 column; GE
Healthcare Life Sciences) with 0.04M EPPS pH 8.0, 0.5M NaCl. The
protein was stored at 253 K with 25%(v/v) glycerol added.
2.2. Crystallization
The EnGAL solution was concentrated to 23.9 mg ml1 on a
cellulose membrane and was subsequently spun for 10 min at
10 000 rev min1 to remove higher molecular-weight aggregates. The
supernatant was used to set up MRC 2 Well sitting-drop trays with an
Oryx 8 Crystallization Robot (Douglas Instruments Ltd). Crystal-
lization trials were carried out with the Index HT, JCSG+ and PACT
screens at room temperature using the same protein buffer (0.04M
EPPS pH 8.0, 0.5M NaCl) for all experiments. The volume of the 1:1
ratio drops was 300 nl and the volume of the reservoir was 100 ml. A
box-shaped single crystal with approximate dimensions of 50  50 
150 mm appeared after ﬁve months in a condition consisting of 0.2M
zinc acetate, 0.1M imidazole pH 8.0, 20%(w/v) PEG 3000. None
of the other screening conditions gave any crystalline material. The
crystal was cryoprotected with mother liquor and cryoprotectant
solution (16% glycerol, 16% ethylene glycol, 18% sucrose, 4%
glucose) in a 1:1 ratio and ﬂash-cooled in liquid nitrogen.
2.3. Data collection and processing
X-ray diffraction data were collected on ESRF beamline ID23-2
(Flot et al., 2010) from the crystal cooled to 100 K. The strategy
devised by EDNA (Incardona et al., 2009) was used in the data
collection, which was performed with radiation of wavelength
0.8726 A˚. The crystal diffracted to 2.0 A˚ resolution. Processing of the
180 images with XDS (Kabsch, 2010) showed that the crystal
belonged to the orthorhombic space group P212121. The intensities
were scaled with XSCALE (Kabsch, 2010). Details of the data
collection and data processing are presented in Table 2.
2.4. Structure solution and refinement
The structure of EnGAL was determined by the molecular-
replacement method using A. aculeatus endo--1,4-galactanase
(AAGAL; PDB entry 1fob; Ryttersgaard et al., 2002) as a search
model. Employing PHENIX (Adams et al., 2010), phenix.automr
gave convincing Z-scores (RFZ 29.6, TFZ 42.2) and a positive log-
likelihood gain for a solution with one molecule per asymmetric unit,
corresponding to a solvent content of 60%. The molecular-replace-
ment solution was adapted to the correct sequence, covering amino
structural communications
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Table 1
EnGAL gene construct and enzyme production.
Source organism A. nidulans FGSC A4 (E. nidulans)
DNA source Chromosomal DNA
Forward primer GAAAGCACGTGATATGATTCTCTCCTCCCTCTTA
Reverse primer TACAGTCTAGAAGATCACCAAAAACACTTATACTT
Cloning and expression
vector
pPICZC
Expression host P. pastoris
Complete amino-acid
sequence of the
construct produced
MILSSLLPLSLVTLTSAALTYRGADISSLLIEEDSGVAYK-
NLNGETQAFELILANNGVNSIRQRIWVNPSDGSYNL-
EYNLELAKRVQDAGMSVYLDLHLSDTWADPGDQA-
TPSGWSTTDIDTLAWQVYNYTLDVCNTFAENNVAV-
EIVSIGNEIRNGLLHPLGSTDHYDNIARLLHSGAWG-
VKDSSLSTTPKILFHLDNGWDWDAQKYFYDTVLAT-
GTLLSTDFDLIGVSYYPFYNADATLSSLKTSLTNLKS-
NYGKNVLVVETDWPVQCSSPEYAFPSDLSSIPFSADG-
QETFLGRLADTLEDVGGVGIYYWEPGWVDNAGLG-
SSCEDNLMVDWRDRTVRESISVFGDLHHHHHH
Table 2
Data-collection and processing statistics.
Values in parentheses are for the highest resolution shell.
Diffraction source ID23-2 beamline, ESRF
Wavelength (A˚) 0.8726
Temperature (K) 100
Detector 225 mm MAR Mosaic
Crystal-to-detector distance (mm) 196.36
Rotation range per image () 1
Total rotation range () 180
Exposure time per image (s) 3
Space group P212121
Unit-cell parameters (A˚) a = 62.90, b = 72.37, c = 98.38
Mosaicity () 0.2
Resolution range (A˚) 47–2.0 (2.12–2.00)
Total No. of reﬂections 226112 (34730)
No. of unique reﬂections 58261 (9139)
Completeness (%) 99.4 (96.5)
Multiplicity 3.9 (3.8)
hI/(I)i 9.3 (2.0)
Rr.i.m. (%) 14.4 (76.8)
Overall B factor from Wilson plot (A˚2) 20.9
Table 3
Structure-reﬁnement statistics for EnGAL.
Resolution range (A˚) 47–2.0 (2.11–2.00)
Completeness (%) 99.5
No. of reﬂections, working set 58202
No. of reﬂections, test set 2912
Final Rcryst 0.159
Final Rfree 0.194
Cruickshank DPI 0.1
No. of non-H atoms 5357
Protein 5092
Glycosylation 14
Cations 15
Ligands (acetate, imidazole, glycerol) 55
Water molecules 181
R.m.s. deviations
Bonds (A˚) 0.012
Angles () 1.312
Average B factors (A˚2)
Protein 22.3
Cations 29.9
Ligands 43.4
Water molecules 31.7
Ramachandran plot
Favoured regions (%) 96.4
Additionally allowed (%) 2.7
Outliers (%) 0.6
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acids 18–352, by phenix.autobuild and manual building. The differ-
ence map showed 15 peaks close to negatively charged side chains,
which were consistent with bound metal ions. In native AAGAL and
BLGAL (Ryttersgaard et al., 2002, 2004) crystallized in the presence
of calcium ions, only one calcium ion could be located in each
structure. In the present case the crystallization conditions contained
0.2M zinc acetate, which made zinc ions the most likely candidate. At
the wavelength used for data collection f 0 0 for calcium is signiﬁcantly
smaller (less than 25%) than f 0 0 for zinc. The anomalous difference
map revealed fairly large peaks at all proposed metal sites, which
veriﬁed them as zinc ions that could be reﬁned at full occupancy. The
difference density revealed N-acetylglucosamine (GluNAc) bound to
Asn112. The ﬁnal model also includes two residues from the His tag,
which were modelled as Ala. Structure reﬁnement was carried out
with phenix.reﬁne (see Table 3 for statistics). The Ramachandran plot
was generated with MolProbity (Chen et al., 2010).
3. Results and discussion
3.1. Overall structure
The overall fold of EnGAL is essentially identical to the previously
observed (/)8 barrel of the other three fungal galactanases
belonging to GH53. This fold is highly conserved and EnGAL has
an all-atom r.m.s.d. of 0.374 A˚ to its closest relative AAGAL. The
cysteine bridge between Cys253 and Cys310 is conserved in the fungal
enzymes. Among the four structurally characterized -1,4-galacta-
nases, BLGAL is the enzyme that deviates most from the fungal
galactanases, with an additional loop at the N-terminus, exhibiting an
r.m.s.d. of 0.972 A˚ to EnGAL. Fig. 1 shows an overlay of EnGAL
with the closest (AAGAL) and the least similar (BLGAL) endo-
galactanase structures. The sequence differences between EnGAL
and the other fungal galactanases are predominantly found in the
regions involved in ion binding (see below) and in residues 318–334
structural communications
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Figure 1
Overlay of endo--1,4-galactanases from family GH53: EnGAL (in green) superimposed on the closest relative AAGAL (PDB entry 1fob; blue; r.m.s.d. 0.374 A˚) and the
least similar BLGAL (PDB entry 1r8l; violet; r.m.s.d. 0.972 A˚). The zinc ions bound to EnGAL are illustrated as green spheres. The violet sphere is the calcium ion in
BLGAL. All ﬁgures were generated with PyMOL (DeLano, 2002).
Figure 2
Illustration of selected zinc sites in EnGAL, with the anomalous difference map in yellow contoured at the 5 level. (a) Zinc ion 402 coordinated by three amino acids from
two molecules; (b) zinc ion 405 coordinated by two side chains from two molecules and two water molecules; (c) His150 bridging zinc ions 404 and 414.
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of the C-terminus, where BLGAL possesses an additional -helix
(Fig. 1 and Supplementary Table S1). The GluNAc N-glycosylation at
Asn112, analogous to Asn111 in MTGAL and HIGAL, is consistent
with previous observations for proteins expressed in P. pastoris (Zou
et al., 2013). The active site of EnGAL with the conserved catalytic
machinery comprised of Glu136 and Glu246 contains a zinc ion
(Supplementary Fig. S3).
3.2. Zinc-binding sites
The anomalous difference map and analysis of the surroundings of
the peaks identiﬁed 15 zinc ions bound to EnGAL. The coordination
of the ions is in accordance with the results obtained previously by
Harding (2004) for protein-bound zinc ions. Although the coordi-
nation geometry of the zinc ions (Supplementary Table S2) is
predominantly tetrahedral, there are also ions with octahedral and
trigonal bipyramidal coordination. Only Zn407 is found in the
interior of the protein, coordinated by the two catalytic residues
Glu136 and Glu246 (Supplementary Fig. S3). The surface-bound
zinc ions in the crystal structure of EnGAL display variety in their
coordination environment, as illustrated by a few examples. Fig. 2(a)
shows the tetrahedral coordination of Zn402 by four carboxylate
groups: Asp317 and Asp320 from its parent protein, Asp149 from
a symmetry-related molecule and an acetate group. Fig. 2(b) shows
how Zn405 is coordinated by two water molecules and the side chains
of Glu60 and Lys166, again from two different molecules in the unit
cell. The side chain of Lys166 is neutral owing to the high pH for
crystallization and to the proximity to the zinc ion. A similar role of
bridging symmetry-related molecules is found for ﬁve of the other
zinc ions (Zn401, Zn408, Zn409, Zn410 and Zn412). Finally, Fig. 2(c)
depicts how the His150 side chain links two zinc-ion sites (Zn404 and
Zn414) from the same molecule.
3.3. The role of the zinc ions
It is noteworthy that it was only possible to obtain crystals of
EnGAL at a high pH in the presence of 0.2M zinc acetate. The
structure analysis showed that about half of the bound zinc ions
bridge the molecules in the unit cell (Supplementary Fig. S4), which
explains why the presence of zinc ions was imperative for the crys-
tallization of EnGAL. A search of the PDB revealed several similar
examples of proteins with metal ions from the crystallization condi-
tions bound to the surface (Zn in PDB entry 1aol, Fass et al., 1997; Cu
in PDB entry 3zud, Quinlan et al., 2011). Recently, Cha et al. (2012)
conducted a thorough study of zinc-ion binding to proteins and
showed how an apparently nonspeciﬁc binding to the surface of
proteins could be used to provide experimental phases. Crystal-
lization of a protein at high pH in the presence of 0.003–0.3M zinc
ions can facilitate crystal formation by stabilizing intermolecular
interactions, and the anomalous scattering from the zinc can aid the
structure determination.
An interesting question remains: why does EnGAL bind zinc ions
to an extent not seen for the other fungal galactanases? The calcu-
lated pI values for the fungal galactanases span from 4.0 (AAGAL)
to 6.0 (BLGAL, MTGAL, HIGAL) and is 4.2 for EnGAL, the pI of
which has been experimentally determined to be below 3.5. Although
the overall negative charge does not differ greatly from the charge of
AAGAL, a depiction of the surface charge of EnGAL reveals several
negatively charged patches suitable for possible metal-ion binding
(Fig. 3). Furthermore, the 15 zinc ions compensate the 29 negative
structural communications
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Figure 3
Relative surface charges plotted at neutral pH for AAGAL and EnGAL without the contribution from the bound metal ions (shown as black spheres).
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charges of the galactanase polyanion, which favours crystallization in
addition to bridging different molecules in the unit cell. The non-
covalent cross-linking of molecules by zinc ions facilitates crystal-
lization and acts similarly to glutaraldehyde-linking (Wine et al., 2007)
and protein-engineering approaches (Derewenda & Vekilov, 2006).
EnGAL shows increased activity in the presence of divalent metal
ions (Michalak et al., 2012). The structure did not suggest any cata-
lytic role for the zinc ions, so the likely explanation for the increased
activity is that the bound zinc ions exert a stabilizing effect on the
structure and neutralize the surface charge, which could favour
interactions with the neutral substrate.
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